STRUCTURAL AND FUNCTIONAL CHARACTERISATION OF MUCUS ADHESION PROTEINS OF LACTOBACILLUS REUTERI by Etzold, Sabrina
1 
 
 
STRUCTURAL AND FUNCTIONAL 
CHARACTERISATION OF MUCUS ADHESION 
PROTEINS OF LACTOBACILLUS REUTERI 
 
Sabrina Etzold, M.Sc. 
 
Thesis submitted for the degree of Doctor of Philosophy 
To 
The University of East Anglia 
 
Institute of Food Research 
School of Biology  
(University of East Anglia) 
 
 
September 2013 
 
© This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with the author and that use of any information 
derived there from must be in accordance with current UK Copyright Law. In addition, any 
quotation or extract must include full attribution.  
2 
 
ABSTRACT 
Mucus is the first point of contact between the gut microbiota and the host. Mucus 
adhesins are thought to be key mediators in the mucus adhesion of commensal 
Lactobacillus species. However, knowledge on the structural or functional basis of 
adhesin interaction with mucin glycoproteins, the main component of mucus, is limited. 
This work describes the biochemical and structural properties of two cell-surface 
proteins from Lactobacillus reuteri, the mucus-binding protein (MUB) and the Lar0958 
protein, and their mucin binding ability.  
MUB from L. reuteri ATCC 53608 consists of 14 Mub repeats, six type 1 and eight type 
2. Single and tandem Mub repeats were heterologously expressed and purified for 
structural and functional studies. The three-dimensional structure of the Mub type 1 
MubRV was determined by X-ray crystallography and revealed two structural domains, 
B1 and B2. Furthermore, structural homology between MubRV and fibre-like adhesins 
of Gram-positive pathogens was identified. Small angle X-ray scattering experiments of 
single and tandem Mub repeats suggested an elongated structure of MUB in 
a ‘beads on a string’ arrangement. Functional studies of recombinant Mub repeats and 
the full-length native MUB isolated from Lactobacillus spent culture media, 
demonstrated binding to different mucins in vitro. Sugar inhibition experiments and 
glycan arrays suggested the involvement of sugar recognition in MUB protein binding 
to mucins. 
Lar0958 is a modular protein of six Lar0958 repeats present on the cell-surface of 
L. reuteri DSM 20016T. The crystal structure of a single recombinant Lar0958 repeat 
was solved at 1.5 Å, demonstrating a similar protein fold to Mub repeats. In addition, 
the Lar0958 repeat shows structural similarity to internalin proteins of the pathogen 
Listeria monocytogenes. 
Taken together these results provide new insights into the structural organisation of 
lactobacilli mucus adhesins and their interaction with mucins, highlighting similarities 
with Gram-positive adhesins of pathogenic bacteria. 
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FITC Fluorescein isothiocyanate 
FPLC Fast protein liquid chromatography 
Fuc Fucose 
GAG Glycosaminoglycans 
Gal Galactose 
GalNAc N-acetylgalactosamine 
Glc Glucose 
GlcNAc N-acetylglucosamine 
GI Gastrointestinal 
IBD Inflammatory bowel disease 
IEF Isoelectric focusing 
Ig Immunoglobulin 
IMAC Immobilised metal ion affinity chromatography 
IPTG Isopropyl-β-D-1-thiogalactopyranoside 
ITC Isothermal titration calorimetry 
Lac Lactose 
LacNAc N-acetyllactosamine 
LPS Lipopolysaccharides 
LTA Lipoteichoic acid 
Man Mannose 
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MME Monomethylether 
MES 2-(N-morpholino)ethanesulfonic acid 
MR Molecular replacement 
MS Mass spectrometry 
Msa Mannose specific adhesin 
MSCRAMM Microbial surface components recognising adhesive 
matrix molecules 
Mub Mucus binding  
MUC Human mucin 
muc Non-human mucin 
MW Molecular weight 
MWCO Molecular weight cut off 
NeuAc N-acetylneuraminic acid  
O/N Over night 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline with Tween-20 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
PGM Porcine gasric mucin 
pPGM Purified procine gastric mucin 
pI Isoelectric point 
PSIM Porcine small intestinal mucus 
PTS domain Proline/ threonine/ serine rich domain 
PVDF Polyvinylidine fluoride 
RCA Ricinus communis agglutinin 
RT Room temperature 
SAXS Small angle X-ray scattering 
SEA sea-urchin sperm protein, enterokinase and agrin 
SDP Sortase-dependant protein 
SDS Sodium dodecylsulphate  
SDS-PAGE Sodiumdodecylsulphate-polyacrylamide gel 
electrophoresis SEC Size exclusion chromatography 
SI Small intestine 
SNA Sambus nigra agglutinin  
SOC Super optimal broth with catabolite repression 
SPR Surface plasmon resonance 
TAE Tris-acetate-EDTA 
TCA Trichloroacetic acid 
TE Tris-EDTA 
TEMED N,N,N,N’-tetramethylethylenediamine 
TMB 3,3’,5,5’-Tetramethylbenzidine 
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Tris 2-Amino-2-hydroxymenthyl-propane-1,3-diol 
UEA Ulex europaeus agglutinin 
UC Ulcerative colitis 
UV Ultra-violet 
VNTR Variable number of tandem repeats 
WGA Wheat germ agglutinin 
WHO World Health Organisation  
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CHAPTER 1 INTRODUCTION 
1.1 The gastrointestinal (GI) tract 
1.1.1 Physiology of the mammalian GI tract 
The gastrointestinal (GI) tract is a large organ with a surface area of more than 300 cm2 
and 7 metres long in human adults [1]. Its main function is the supply of nutrients and 
energy via conversion and adsorption of food components and water. The mammalian 
GI tract can generally be divided into three major compartments: stomach, small 
intestine and large intestine. The small intestine is comprised of duodenum, jejunum 
and ileum, while the large intestine can be further subdivided into appendix, cecum, 
colon (ascending, transverse, descending and sigmoid) and rectum (Figure 1.1).  
 
 
Figure 1.1 Schematic representation of the human (mammalian) gut with its subdivisions 
(taken and adapted from www.medtronic-gastro-uro.com.au) 
 
The esophagus, stomach and parts of the duodenum are anatomically known as the 
foregut. The midgut reaches from the duodenum to the transverse colon and the 
hindgut is comprised of descending colon and rectum [2]. 
Ileum 
Jejunum 
Stomach 
Duodenum 
Transverse colon 
Ascending colon 
Descending colon 
Sigmoid colon 
Rectum 
Appendix 
Anus 
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The distinct sections of the GI tract differ with regard to physiological environment and 
structural composition offering biological niches for various microbial ecosytems. For 
example, a difference in pH can be observed along the gut, where the pH rises 
significantly from a highly acidic pH of about 1.0 to 2.5 in the stomach to pH 6.6 in the 
proximal small intestine (jejunum) reaching a neutral pH of 7.3 to 7.6 in the distal small 
intestine (ileum) [3-4]. The mean pH in the colon is pH 6.3. Additionally, transient times 
vary between different parts of the GI tract due to peristaltic movements from 1 h in the 
stomach, about 10 h in the small intestine and up to 17 h in the colon [4-6]. 
Furthermore, the microbial biomass differs between distinct regions of the GI tract with 
the lowest bacterial cell density (102-3 cells/mL) in the stomach. A significant increase in 
bacterial cell density can be observed in the jejunum and ileum with 104-5 and 
108 cells/mL, while the bacterial density is highest in the colon with 1010 cells/mL [7].  
 
 
 
Figure 1.2 Schematic representation of the human colonic mucosa 
The luminal exposed surface of the gut, the mucosa, consists of muscularis mucosae, 
lamina propria, extracellular matrix (ECM), epithelium, glycocalyx and the mucus layer 
(taken and adapted from [8]). 
The luminal surface of the GI tract is called the mucosa, which forms a physical barrier 
between the luminal content and the host, prevents microbial invasion and mantains 
a healthy state (Figure 1.2). Its most important structural elements are the extracellular 
matrix (ECM), the epithelial cell layer, the glycocalyx and the mucus layer [8].  
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1.1.2 The GI mucus layer 
The mucus layer forms a dynamic, viscous and physical barrier, which separates the 
underlying GI epithelium from the luminal content, i.e. bacteria and food components, 
serves as a lubricant to aid passage, and provides a habitat for the diverse microbial 
community termed the gut microbiota [9]. The intestinal epithelium is comprised of 
4 different epithelial cell lineages, enterocytes, enteroendocrine cells, Paneth cells, and 
goblet cells. They are derived from intestinal epithelial stem cells located at the base of 
epithelial invaginations named crypts [10]. Goblet cells are the main source of mucus 
production and release with fast renewal rates of several hours as demonstrated for 
colonic mucus by in vivo labelling [11-12]. In humans up to 10 L of small intestinal and 
colonic mucus are secreted per day [12]. Continuous secretion is necessary due to 
microbial enzymatic degradation and mechanical shear forces [13-15]. The mucosal 
release is a constitutive exocytose process and enhanced mucus secretion is induced 
by certain secretagogues, i.e. physical disruption or intestinal microbes [16-21].  
 
 
Figure 1.3 Representation of mucus thickness and organisation in rats  
(taken and adapted from [22]) 
 
The mucus layer covers the epithelial surface from the stomach to the colon varying in 
thickness, composition and biophysical properties (Figure 1.3) [23-24]. In the stomach 
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and the colon, mucus is composed of two structurally distinct layers, whereas latest 
studies identified only a single layer in the small intestine [24]. The outer luminal layer 
of gastric and colonic mucus is loosely adherent, can easily be removed and is the 
habitat for the commensal gut flora especially in the colon [25]. In contrast, the 
underlying colonic mucus layer is firmly attached, of stratified, ordered appearance and 
mainly devoid of bacteria [25]. However, the inner adherent mucus layer in the stomach 
and the single small intestinal mucus layer are likely to be penetrable by bacteria [24]. 
The relative contribution of each layer to the overall thickness of the mucus gel, which 
is highest in the colon, varies throughout the GI tract (Figure 1.3). Mucus 
measurements in rat, mice and human showed an increased thickness of the loosely 
adherent outer mucus layer of 7-, 3- and 2 to 3-fold, respectively, in comparison to the 
firm mucus blanket in direct contact to the underlying epithelial cells [23, 25-26]. In total 
the colonic mucus extends about 800 μm in rat, 150 μm in mice and 134 μm in human 
above the epithelial surface.  
The main structural component of the colonic loose and firm mucus, as revealed via 
a proteomic approach, is the secreted-gel forming mucin 2 (Muc2, mouse or MUC2, 
human), a highly glycosylated protein of the secreted mucin protein family (see 1.2) 
[27]. These observations suggest the formation of the loose outer mucus layer from the 
firm inner presumably via proteolytic cleavage [24, 28]. Due to its intrinsic domain 
properties, Muc2/ MUC2 is able to form net-like polymers making up a hydrated mucus 
mesh with certain pore-size. It functions as a physical filter for the GI bacteria keeping 
them away from the mucosal epithelium (see 1.2.1) (Figure 1.4) [29]. The absence of 
the Muc2 mucus layer allows bacteria to come into direct contact with the epithelial cell 
surface causing severe inflammation and eventually colon carcinoma in Muc2-/- mice 
[25, 30].  
Besides Muc2, the mucus layer contains a high number of other proteins forming 
a fairly consistent core proteome in different sections of the murine GI tract from 
stomach to colon [28]. One example is the Fc-gamma binding-protein, which is strongly 
associated with colonic Muc2. It was found to bind immunoglobulin (Ig) G but may have 
additional roles as a Muc2 cross-linker [27, 31]. 
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Figure 1.4 Defence mechanisms at the GI mucosal surface  
Direct epithelial contact and penetration of gut microbes prevented by the mucus layer, 
acting as a physical barrier, antimicrobial proteins secreted by Paneth cells and secretory 
IgA produced by plasma cells (taken from [32]). 
Furthermore, the mucus gel contains high levels of secretory IgA, whose production is 
stimulated by the intestinal microbiota (Figure 1.4) [33-34]. IgA is produced by plasma 
cells and dimeric IgA is transported across the epithelium via a polymeric-
immunolgobulin receptor (pIgR) on columnar epithelial cells [33, 35]. Secreted IgA 
mediates the neutralisation of viruses and bacterial toxins, and prevents mucus 
penetration by GI microbes [36-37]. Additionally, large amounts of antimicrobial 
proteins, such as α-defensins, lyzosyme and RegIIIγ, are secreted into the mucus layer 
mainly by Paneth cells as part of the innate immunity (Figure 1.4) [38-43]. They restrict 
numbers of intestinal microbes in proximity to the GI epithelium by inducing cell lysis 
[44-46]. While α-defensins are fairly abundant, and show constitutive as well inducible 
expression, RegIIIγ production is niche-specific and activated upon bacterial stimuli 
[47-48]. RegIIIγ seems to preferentially target Gram-positive bacteria by recognition of 
their cell wall component peptidoglycan (see 1.3.3) [49]. 
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1.2 Mucins in the GI tract 
Mucins are highly glycosylated proteins constituting the major component of all 
mucosal surfaces of the respiratory, digestive and urogenital tract, where they build 
a protective barrier against the external environment. To date 20 members of the mucin 
family have been identified, which are characterised by a highly-regulated, 
tissue-specific and overlapping expression [50].  
 
 
Figure 1.5 Schematic representation of the domain architecture of secreted and 
membrane-bound mucins (taken from [51]) 
 
Apomucins vary in size from about 30 to over 1000 kDa, i.e. the human MUC2 gene 
product is more than 5100 amino acids in size giving a 540 kDa apoprotein [52-53]. 
Due to difference in location and molecular organisation mucins can be divided into 
three subfamilies: secreted gel forming (MUC2, MUC5AC, MUC5B, MUC6 and 
MUC19), secreted non-gel forming (MUC7, MUC8 and MUC9) and membrane-bound 
mucins (MUC1, -3A, -3B, -4,-11, -12, -13, -15, -16, -17,-18, -20, -21) (Figure 1.5). In the 
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GI tract, 15 different mucins are expressed including the main gel-forming mucins 
MUC2 (small intestine, colon), MUC6 (stomach) and MUC5AC (stomach), and for 
example the cell surface mucins: MUC1 (stomach, small intestine), MUC3A/B (small 
intestine, colon), MUC4 (colon, stomach), MUC12 (colon, small intestine), MUC13 
(colon, small intestine) and MUC17 [54-60]. Gel-forming mucins are the main 
constituent of the hydrated mucus gel, whereas membrane-bound mucins on mucosal 
epithelial cells constitute the glycocalyx.  
Membrane-bound mucins possess a C-terminal cytoplasmic domain for signal 
transduction and share common extracellular domains such as the epidermal growth 
factor-like (EGF) domain or Sea urchin sperm protein Enterokinase, and Agrin (SEA) 
domain [61-64]. The SEA domain, close to the cell surface, undergoes proteolytic 
cleavage facilitating mucin shedding into the mucosal environment [65-66]. 
Secreted-gel forming mucins are characterised by cysteine-knot (CK) domains 
mediating C-terminal dimerisation and the N-terminal D domains allow further 
oligormerisation [67]. D domains are designated as van Willebrand (VW) domains due 
to sequence and structural similarities to the VW factor, a disulphide-bridged multimeric 
glycoprotein [68-69]. 
All mucins possess one or more regions with variable numbers of tandem repeat 
(VNTR) sequences called PTS domains, which are rich in the amino acids proline (P), 
threonine (T) and serine (S). Thr and Ser residues of the P-T/S motif are potential 
O-glycosylation sites allowing the decoration of the apomucin with a diverse array of 
O-glycans, giving it its filamentous ‘bottle-brush’ appearance of several hundred 
nanometers in length [70]. Mucin O-glycosylation is initiated in the Golgi-apparatus by 
an N-acetylgalactosamine (GalNAc)-transferase attaching GalNAc to the hydroxyl 
group of Ser or Thr. The initital GalNAc-Ser/Thr precursor, termed Tn-antigen, is then 
further modified by glycosyltransferases generating mainly 4 most common O-glycan 
core types (core 1 to 4) along the GI tract (Figure 1.6) [71].  
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Figure 1.6 Mucin type O-glycan core structures 
Core 1 to 4 O-glycan structures with Gal (Galactose) (yellow sphere), GalNAc 
(N-acetylgalactosamine) (yellow square) and GlacNAc (N-acetylglucosamine) (blue square) 
attached to Ser/Thr of the polypeptide chain (taken and adapted from www.sigma-
aldrich.com). 
For further elongation, Gal and GlcNAc molecules are attached to these core 
structures. The O-glycan chains are further modified by differentially linked Fuc, 
Neu5Ac and GalNAc residues and different terminal structures are formed, such as 
blood group antigens, resulting in an enormous complexity of mucin associated 
O-glycans [57]. Additionally, mucin glycans often carry sulphate groups adding another 
level of diversity. The mucin glycosylation pattern depends on genetic background, is 
tissue-specific and altered in disease, for example inflammatory bowel disease (IBD), 
ulcerative colitis (UC), or cancer due to the differential expression or presence of 
certain glycosyltransferase genes [72-79].  
 
 
 
 
Gal(β1-3)GalNAcα1-ol 
Gal(β1-3)[GlcNAc(β1-6)]GalNAcα1-ol 
GlcNAc(β1-3)GalNAcα1-ol 
GlcNAc(β1-3)[GlcNAc(β1-6)]GalNAcα1-ol 
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Figure 1.7 Common core building block of N-glycans 
Man (green sphere) and GlcNAc (blue square) residues attached to the polypeptide chain 
via asparagine (Asn) (taken from www.sigma-aldrich.com). 
Besides the predominant O-glycans, mucins additionally carry a small number of 
N-glycans where a GlcNAc residue is attached to asparagine (Asn, N) within the 
consensus sequences NXS/T, which is located outside of the PTS domains 
(Figure 1.7) [80-81]. In contrast to O-glcyans, N-glycans contain Man as part of their 
common core building block (Man3GlcNAc2). Mucin N-glycosylation has a role in the 
correct dimerisation of mucin molecules [82-84].  
1.2.1 The membrane-bound mucin MUC1/Muc1 
MUC1 is the major cell-surface mucin of the GI tract and constitutent of the glycocalyx, 
the carbohydrate-rich and final protective coating of mucosal epithelial cells [85]. 
It contains a PTS domain, the site for O-glycosylation (as described above), with 20 
amino acid tandem-repeats, an extracellular SEA domain, a hydrophobic membrane 
spanning region and a cytoplasmic domain (Figure 1.8) [86-87]. The latter contains 
phosphorylated tyrosine (Tyr) residues, which are thought to mediate signal 
transduction [62, 88-89]. MUC1, as present at the cell-surface, contains two 
non-covalently linked subunits. Autoproteolysis during mucin biosynthesis and 
subsequent reassociation of the two subunits is mediated via the SEA domain [90-91]. 
Although MUC1 is mainly associated with the cell membrane, it is also present in 
soluble form as a splice variant lacking the cytoplasmic tail or as a proteolytic cleavage 
product [92-94]. 
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Figure 1.8 Schematic representation of the membrane-bound mucin MUC1 
Cell membrane (blue) MUC1 presented with its cytoplasmic domain, and extracellular SEA 
(green) and PTS (black) domains with attached O-glycans (grey). 
MUC1 O-glycans, which account for up to 80% of the protein mass in colonic epithelia 
cells, share common features with other mucin glycans, including the expression of 
poly-LacNAc chains, and show tissue-specific glycosylation patterns (see 1.2) [57, 92, 
95]. Aberrant and under-glycosylated MUC1 is found in gastric, colonic, breast or 
ovarian carcinoma, and often characterised by the reduction of O-glycans chains to the 
core type level and increased levels of sialylation [96-99]. For example, certain glycan 
eptiopes, such as the sialyl-Tn (Neu5Acɑ2-6GalNAcɑ) and the core 2 TF-antigen (Galβ
1-3GalNAcɑ), sialyl-Lex but not the core 1 Tn-antigen (GalNAcɑ), show elevated 
expression in colon carcinoma [100-101]. 
1.2.2 The gel-forming mucin MUC2/ Muc2 
The human MUC2 and its homologue Muc2 expressed in mice, rats and pigs are the 
major gel-forming mucins in the small intestine and colon [54, 78, 102-103]. MUC2 
contains several domains: three complete (D1-3) and one incomplete (D’) cysteine 
(Cys)-rich von Willebrand (VW) D domains in N-terminal, two CysD domains, one 
adjacent to and one interspersed between the two central PTS domains, two complete 
VW D-domains (D3-4) in C-terminal, and Cys-knot (CK) domain (Figure 1.9) [104].  
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Figure 1.9 Schematic representation of the human MUC2 domain organisation 
MUC2 with 4 complete van Willebrand (VW) D domains (D1-4) (blue), two CysD domains 
(red), two PTS domains (black) with glycan residues represented as grey lines and 
a CK-domain (black). 
The C-terminal CK domain facilitates dimerisation of MUC2 in the endoplasmic 
reticulum (ER) and further trimerisation occurs via the N-terminal D domains in the 
Golgi-apparatus (Figure 1.10 A) [82, 105]. The CysD domain which separates the 
central PTS domains, has recently been reported to mediate non-covalent crosslinking 
of MUC2, thereby contributing to the net-like appearance, particularly of the inner 
mucus layer, and determining the pore size of the mucus mesh (Figure 1.10 B and C) 
[106]. Ambort and co-workers demonstrated the storage of MUC2 in goblet cell 
granules as hollow mucin tubules around a concatenated, hexameric ring [107].  
  
 
Figure 1.10 Representation of the MUC2 net formation 
(A) MUC2 dimerisation via the C-terminal CK domains (black) and trimerisation via the 
N-terminal D-domains (blue). (B) Model for a net-like polymeric MUC2 sheet with 
concatenated, hexameric ring structures. (C) Crosslinking of two MUC2 sheets via 
non-covalent dimerisation of CysD domains (taken from [29]). 
Storage, release and expansion of the mucus-net may be regulated by Ca2+- and 
pH-dependant interactions of structural mucin domains, mainly of the VW D domains, 
as observed for the VW factor [108-110]. The two central PTS domains of MUC2 
contain about 100 tandem repeat sequences of 23 amino acids with a high frequency 
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of Thr O-glycosylation sites. O-glycans account for up to 80% of the molecular weight 
of MUC2 forming a mucin monomer of over 2.5 MDa in mass [52, 111-112]. 
1.2.3 MUC2 O-glycosylation  
The MUC2 O-glycans present in different regions of the normal human gut reveal 
a tremendous structural complexity and diversity, while only limited variability was 
observed between individuals [113-114]. More than 100 different, both linear and 
branched, glycan structures with up to 12 monosaccharide residues, have been 
identified in human MUC2 [113-114]. An increasing gradient of sialic acid (NeuAc) and 
sulphate residues was found along the human GI tract from the ileum to the rectum, 
while the abundance of Fuc decreases [115].  
 
Composition of oligosaccharide alditols and terminal epitopes 
LacNAc Gal(β1-3)GlcNAc (type 1) 
 
 Gal(β1-4)GlcNAc (type 2) 
Core 3 based Gal(β1-3/4)GlcNAc(β1-3)[NeuAc(α2-6)]GalNAc-ol 
Tn GalNAc-ol 
Sialyl-Tn  NeuAc(α2-6)GalNAc-ol 
Terminal NeuAc  NeuAc(α2-3)Galβ 
Blood group H [Fuc(α1-2)]Gal(β1-3)GlcNAcβ 
Blood group A GalNAc(α1-3)[Fuc(α1-2)]Galβ 
Sda/Cad  GalNAc(β1-4)[NeuAc(α2-3)]Galβ 
Lea Gal(β1-3)[Fuc(α1-4)]GlcNAcβ 
Leb [Fuc(α1-2)]Gal(β1-3)[Fuc(α1-4)]GlcNAcβ 
Lex Gal(β1-4)[Fuc(α1-3)]GlcNAcβ 
Sulphated structures Gal-3[SO3-Gal-GlcNAc-6)]GalNAc-ol 
 Gal-3[SO3-Gal-(Fuc)GlcNAc-6)]GalNAc-ol 
 Fuc-Gal-3[SO3-Gal-(Fuc)GlcNAc-6)]GalNAc-ol 
Table 1.1 Predominant oligosaccharide structures in human MUC2 
NeuAc (N-acetylneuraminic acid or sialic acid) and Fuc (Fucose) 
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The core 3 structure is the main building block of nearly all human colonic MUC2 
O-glycans, whereas in mice core 2 and core 1 structures are more abundant [113-114, 
116-117]. It is modified with N-acetyllactosamine-units (LacNAc), β1-3 or β1-4 linked 
Gal and GlcNAc forming type 1 or type 2 LacNAc, respectively, and terminated by 
Neu5Ac, Fuc and SO3- (Table 1.1) [113-114, 118-120]. A few structures in the distal 
colon are built around the core type 2 and are mostly sulphated, while core 4 O-glycans 
found in the ileum possess a high Fuc content (α1-4 or α1-2 linked) [113-114]. The 
tetrasaccharide Gal(β1-3/4)GlcNAc(β1-3)[NeuAc(α2-6)]GalNAc-ol or the sialyl 
Tn-antigen (NeuAcα2-6GalNAc-ol), both based on the core 3 structure, were detected 
in the majority of carbohydrate chains [113]. A high degree of sialylation and sulphation 
often coexisting was observed on MUC2 oligosaccharides (Table 1.1). Sulphation 
occurs at position C3 of Gal and C6 of GlcNAc. NeuAc was typically found α2-6 linked 
to GlcNAc and α2-3 linked to Gal often forming a α2-6 sialylated core type 3 (NeuAc(α
2-6)GlcNAc-ol) or a terminal NeuAc epitope. Several terminal ABO blood group 
determinants including blood group H and A epitopes as well as Lea, Leb and Lex 
structures can be identified in the intestine (Table 1.1). Modified blood group 
Sda/Cad-determinants are also present in colonic mucins [114, 118]. 
MUC2 O-glycosylation is an important intrinsic mucus property, facilitating for example 
the hydration of the mucus gel after release due to its acidic nature. Additionally, a high 
content of sialic acid and sulphate groups in the colon of humans is beneficial to 
prevent degradation via bacterial or host glycosidases [121-123]. Numerous members 
of the residential gut microflora produce glycosidases providing them with the ability to 
utilise mucin as a carbon source [124-128]. Moreover, Muc2 O-glycans are critical to 
maintain the mucus barrier properties. Studies in mice showed that the aberration of 
certain core-derived O-glycans results in increased mucus permeability. This allows 
greater translocation of bacteria into mucosal tissues, which leads to inflammation or 
colitis [129-130]. In addition, mucin glycans are believed to serve as attachments sites 
for the gut bacteria, which have adapted to the mucosal environment by expressing 
complementary adhesins [22, 131]. Hence, a correlation between bacterial 
colonisation, and mucin expression and glycosylation can be deduced. 
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1.3 Mechanisms of host-microbe interaction in the GI tract 
The mucosal surface of the GI tract is in constant contact with an enormous resident 
microbiota, which offers physiological advantages for the host including degradation of 
indigestible nutrients, development of the immune system and enhancement of the 
mucosal barrier facilitating pathogen colonisation resistance [14, 132-135]. Dysbiosis of 
the gut microbiota has been associated with a growing number of gut-related diseases, 
for example UC, Crohn’s disease (CD) and obesity, indicating the importance of 
maintaining a homeostatic relationship with the resident gut bacteria [136-140]. Mucus 
is the first point of contact of GI bacteria with the host and mucus-microbe interactions 
are critical to maintain a healthy interplay and for the selection of a beneficial microbial 
community in the GI tract [141]. 
1.3.1 The gastrointestinal microbiota composition 
The colonisation of the gut starts at birth and the composition of the intestinal bacterial 
community changes over time establishing a fairly stable gut microbiota in adults [142-
145] with an estimated number of 1013 to 1018 microbes, which outnumber our own 
body cells by a factor of 10 [14]. In the established microflora, an increase in bacterial 
population density and diversity can be observed from the stomach to the colon [146-
148]. Despite the enormous number of colonic bacteria they only represent 8 phyla 
(division), namely Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, 
Fusobacteria, Verruomicrobia, Cyanobacteria and Spirochaetes, but vary highly at 
species (subdivision) level (Figure 1.11) [14, 149]. The majority of the resident 
commensal microflora belongs to the phyla Bacteroidetes followed by Firmicutes, as 
several genomic based approaches mainly focussing on bacterial populations in faeces 
have shown over the last years [149-150]. From these studies only about 400 species 
were found to be culturable but a total of several thousand species can be estimated in 
the colon, of which at least 160 are present in one individual, according to the latest 
reports using 16S ribosomal RNA sequencing techniques [149, 151-152].  
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Figure 1.11 Phylogenetic tree of GI microbiota 
Phylogenetic analysis of the bacterial flora in human mucosal sites and faeces via 16S 
rRNA analysis (taken from [153]).  
Despite variations in the microbial population between individuals, even between twins, 
there is evidence for a common phylogenetic core [154-155]. Representatives of the 
Bacteroidetes and Firmicutes, mainly from Clostridium clusters, were found to be 
predominant inhabitants of mucus [156-157]. Furthermore, mucosa-associated 
lactobacilli have been identified in human intestinal tissue (stomach, small intestine and 
colon) and faeces samples including L. rhamnosus, L. plantarum and L. reuteri strains 
[158-160]. 
Some beneficial bacteria associated with the human gut are termed probiotics among 
them 17 identified Lactobacillus species as well as Bifidobacteria and some benificial 
Streptococcus strains [161-162]. Probiotics are defined by the FAO/WHO as “live 
microorganisms that when administered in adequate amounts confer a health benefit 
on the host”, when fulfilling certain criteria including a demonstrated health benefit, lack 
of adverse side effects, and prolonged residency and survival in the GI tract [163]. For 
example, Bifidobacterium and Lactobacillus strains, which possess mucus-binding 
ability, are capable of strain dependant inhibition of adhesion via direct competition or 
upregulation of MUC gene expression, as well as displacement of different pathogens 
[19-20, 164-168]. A therapeutic effect of probiotics, including lactobacilli species, in 
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intestinal diarrhoea and gastroenteritis as well as prevention of traveller’s diarrhoea has 
been reported in humans [169-170]. Generally, probiotic actions of Lactobacillus strains 
comprise pathogen inhibition, enhancement of the epithelial barrier function and 
immunonomodulation [171]. 
Several Lactobacillus species, including L. reuteri, L. gasseri, L. crispatus, L. salivarius 
and L. ruminis, are autochthonous residents of the vertebrate gut, which form stable 
populations and occupy a biological niche albeit at low bacterial numbers in humans 
[137, 162, 172-175]. In contrast, other allochthonous species such as L. plantarum, 
L. rhamnosus, L. johnsonii or L. adicophilus, have not been proven to stably inhabit the 
GI tract, but are often found in food produces [162]. 
 
 
Figure 1.12 Phylogenetic analysis of L. reuteri isolated from different vertebrate hosts 
Genotyping of L. reuteri strains originating from rodents, pig, human and poultry (colour 
coded) and clustering into L. reuteri populations (taken from [175-176]). 
In particular, the gut symbiont L. reuteri shows association with different vertebrate 
hosts as diverse as humans, pigs, rats, mice and some bird species, as well as close 
host co-evolution and specialisation (Figure 1.12) [175, 177]. Hence, L. reuteri is 
a good model gut inhabitant to study the mechanisms that mediate lactobacilli 
persistence in the GI tract. Indeed, oral administration of an autochthonous human 
L. reuteri isolate strain to human subjects showed high levels of bacterial colonisation 
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and persistence [178]. Probiotic effector molecules of L. reuteri, which mediate 
bacterial adherence and aggregation, are for example collagen-binding proteins 
(CnbP/MapA), a mucus-binding protein (Mub), a large surface protein (Lsp) and 
glycoxyltransferases (GtfA/Inu) [175].  
1.3.2 Bacterial interaction at the mucosal surface 
Intestinal bacterial communities show adaptation to various ecological niches impacted 
by physiological conditions, i.e. pH, mucin glycosylation, nutrient requirements and 
metabolism [125, 179-182]. Gut bacteria express a repertoire of metabolic genes for 
hydrolysis, uptake and degradation of dietary carbohydrates depending on location in 
the gut and host diet [183-187]. Additionally, Bacteroides, Akkermansia and 
Ruminococcus species produce mucin-degrading enzymes allowing them to utilise 
mucin-glycans, abundant and constitutively expressed in GI mucus (see 1.2.2), as 
a nutrient source [126, 128, 186, 188-189]. Efficient nutrient metabolism allows 
commensal inhabitants of the gut to outcompete pathogenic bacteria and directly inhibit 
pathogen growth or virulence by production of metabolites such as short chain fatty 
acids (SCFA) [190-194].  
Mucin O-glycans are not only a substrate for intestinal bacteria, but are also considered 
important for the selection of the bacterial gut flora by providing attachment sites for GI 
bacteria that have adapted to the mucosal environment by expressing the right 
complement adhesins [22]. Variations in the mucin glycosylation pattern along the GI 
tract, including core type structures, fucosylation, sialylation and sulphation as well as 
the expression of certain glycan epitopes, such as the Sda/Cad antigen or ABO blood 
group antigens (see 1.2.2), coincide with and directly influence variations in bacterial 
composition among different parts of the gut [148, 195-198]. Alterations in mucin 
expression and glycosyation have been reported in intestinal inflammation, whether 
this is a cause or consequence of changes in the microbial flora remains elusive [79, 
199-202]. Lactobacilli can induce MUC2 or MUC3 expression [19-20] and Bacteroides 
thetaiotaomicron has been reported to enhance the expression of terminal 
Fuc residues on mucin glycans, which the bacterium can then harvest and use as 
a carbon source [186, 203]. The expression of gel-forming and membrane-bound 
mucins, including Muc2 and Muc1, is also altered by pathogenic bacteria such as 
Listeria monocytogenes, Pseudomonas aeruginosa or Citrobacter rodentium, which is 
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used as a surrogate for Escherichia coli in in vivo infection studies of human 
gastroenteritis, and is considered as a host defence mechanism against pathogenic 
infection [204-206]. In addition, membrane-bound mucins such as MUC1 are shed into 
the mucus layer, where they act as soluble decoy receptors facilitating pathogen 
exclusion [207]. However, GI pathogens such as Helicobacter pylori and 
Entamoeba histolytica have developed strategies allowing them to penetrate the mucus 
layer, for example via local pH changes or MUC2 proteolysis [208-209]. In contrast, 
potential probiotic Lactobacillus and Bifidobacterium species do not disrupt the mucus 
due to a lack of secretion of MUC2 proteases, stressing their role as commensal 
inhabitants of mucus [210]. 
1.4 Bacterial adhesins  
Bacterial adhesion to the host is an important first step to promote colonisation and 
persistence, penetration of the host cell barrier or induction of signalling pathways [211-
216]. The initial adhesion of bacterial cells to solid surfaces is mainly driven by 
hydrophobic properties of the microbial surface (van der Waals interaction) and 
additionally influenced by cell-cell or cell-surface electrostatic interactions (Figure 1.13) 
[217-220]. While the majority of bacteria, regardless of whether they are Gram-positive 
or Gram-negative, possess a negative surface charge such as the surfaces they 
adhere to, adhesive positively charged organism have been identified as well [221-
223].  
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Figure 1.13 Schematic representation of bacterial-surface interactions 
(A) Initital adhesion of bacteria (grey) with mostly negative or positive surface charge to a 
negatively charged surface via hydropobic and electrostatic interactions. (B) Bacteria close 
to the surface engaging in ligand-receptor interactions via bacterial cell-surface molecules.  
These initial mechanisms of contact between bacteria and cell surfaces allow a more 
specific and closer host-bacteria interaction mediated by host receptors and bacterial 
cell-surface molecules [224]. The latter include adhesion proteins such as pili (also 
known as fimbriae), flagella or other cell components like lipopolysaccharides (LPS) of 
Gram-negative, and exopolysaccharides (EPS) or lipoteichoic acid (LTA) of 
Gram-positive bacteria (Figure 1.14) [141].  
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Figure 1.14 Cell wall architecture and surface molecules of Gram-positive and 
Gram-negative bacteria 
Structural components of the bacterial cell wall of (a) Gram-positive and (b) Gram-negative 
bacteria including fimbriae (pili) and flagella (found in both bacterial groups), cell-surface 
proteins (including adhesins), CPS (cell-wall associated polysaccharides), and WTA (wall 
teichoic acid) or LTA (lipoteichoic acid) of Gram-positive and LPS (lipopolysaccharides) of 
Gram-negative bacteria (taken from [141]). 
Several cell surface molecules of both pathogenic and commensal species have been 
suggested to be involved in the specific interaction with host receptors, including 
mucins, mucin-like glycans or ECM proteins. These adhesins include flagella and pili, 
extended cell-surfaces appendages found in Gram-positive and Gram-negative 
bacteria, MSCRAMM (microbial surface components recognising adhesive matrix 
molecules), sugar recognising proteins (i.e. lectins), Serine (Ser) rich proteins or other 
often modular domain surface proteins [225-227].  
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1.4.1 Mucus adhesins in pathogenic bacteria 
Most of the current knowledge on microbe-mucus interaction and the specific adhesins 
and ligands involved are limited to enteric pathogens (Table 1.2), but information on the 
biochemical and structural basis of interaction is often rudimentary.  
 
Pathogen  Adhesin Ligand Reference 
Clostridium 
difficile 
FliC and FliD 
(Flagella) 
Mouse mucus [228] 
Pseudomonas 
aeruginosa 
FliD (flagellum) Respiratory mucins 
(Muc1) 
[229-230] 
Escherichia coli 
O126:H6 
Flagellum Bovine mucus, mucins 
and ECM proteins 
[231] 
E. coli O157:H7 Flagellum Bovine mucus, mucins 
and ECM proteins 
[231] 
E. coli O157:H7 Pili (type 1) Intestinal mucin (via 
mannose) 
[232-233] 
E. coli  FimH (pili) mannose [234-236] 
E. coli F17-G (pili) Intestinal mucin (via 
GlcNAc) 
[237-238]  
Streptococcus 
pneumoniae 
Spr1345  PGM, bovine submaxillary 
mucin, polysaccharides 
[239-240]  
Helicobacter 
pylori 
BabA 
 
SasA 
Leb (on MUC5AC and 
MUC1) 
sialyl-Lex (on glycolipids) 
[241-244]  
Vibrio cholerae GbpA Instestinal mucin (via 
GlcNAc) 
[245]  
Entamoeba 
histolytica 
Ga/GalNAc lectin Human and rat colonic 
mucins (via GalNAc and 
Gal) 
 [246-248]  
Listeria 
monocytogenes 
Internalins Human MUC2 [249] 
Table 1.2 Adhesins and potential host receptors of selected pathogens 
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Flagella are flexible cell appendages important for bacterial motility, chemotaxis and 
virulence in pathogens [250-251]. The binding of flagella to bovine mucus and mucins 
for the enteropathogenic and enterohemorrhagic E. coli (EPEC and EHEC) strains of 
E. coli O157:H7 and E. coli O126:H6 was demonstrated [231]. In addition, the flagellum 
of E. coli O126:H6 also showed binding to ECM proteins. The FliD flagellum protein of 
P. aeruginosa is involved in the bacterial adhesion to human respiratory mucins and 
rodent Muc1 [229-230]. Furthermore, the FliC and FliD flagella proteins, both 
recombinant and native, of Clostridium difficile bind to mouse mucus but not to porcine 
stomach mucus [228]. However, whether mucin glycans are involved in the 
mucin/mucus binding of the described flagella has not been addressed.  
Pili are important virulence factors in pathogenic bacteria relevant for host tissue 
colonisation, and their binding ability to host ligands is especially well described in 
Gram-negative species [227]. The E. coli F17-G pili protein demonstrated binding to 
GlcNAc as well as GlcNAcβ1-3/β1-6Galβ1- in intestinal mucin O-glycans [238]. In fact, 
the binding of the F17-G adhesin to several sugar molecules including GlcNAc 
saccharides has been characterised by surface plasmon resonance (SPR) experiments 
and the GlcNAc binding site identified via X-ray crystallography [237]. Another 
extensively studied type 1 pili adhesin is FimH present in E. coli and 
Salmonella enterica, which binds specifically to mannose demonstrated [234-236]. 
Several mannose containing glycan receptors of FimH on urinary epithelial cells have 
been suggested including ECM proteins, but no interaction with mucins has been 
reported yet [236, 252-253]. Additionally, the FimH has been structurally described and 
the mannose binding site identified by X-ray crystallography [235, 254]. Another 
example for a fimbrial adhesin is Std of S. enterica which mediates binding to intestinal 
epithelial cells in vitro [255]. Inhibition studies using the intestinal epithelial cell line 
Caco-2, which expresses mucin glycans, demonstrated reduced binding of Std positive 
bacterial cells in the presence of the blood group epitope H2 (Fucα1-2Galβ1-4GlcNAc), 
while LacNAc (Galβ1-4GlcNAc) did not have an effect [256-257]. In addition, binding of 
isolated Std pili proteins to mouse intestinal mucus was competitively inhibited in the 
presence of the Fucα1-2 specific agglutinin from Ulex europaeus (UEA). Gram-positive 
pili have mainly been studied for species commonly encountered in the respiratory tract 
where they bind to epithelial cells, the place of respiratory mucin production [227, 258-
259]. However the cell receptors for pili proteins such as Spa of Corynebacterium 
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diphtheriae or GBS52 of Streptococcus agalactiae have not yet been identified [260-
263].  
The Spr1345 cell-surface protein from Strept. pneumoniae contains a mucin-binding 
protein (MucBP) domain (Pfam database PF06458), which is often found in lactobacilli 
proteins (see 1.4.2). Recombinant MucBP, for which the crystal structure has been 
determind by X-ray crystallography, binds to porcine gastric mucin (PGM) and bovine 
submaxillary gland mucin as well as sulphated and non-sulphated glycosaminoglycans 
(GAGs), long unbranched polysaccharides [239-240].  
The interaction of H. pylori to gastric mucins, which is mediated via the recognition of 
ABO blood group antigens by two adhesins, BabA (blood group antigen-binding 
adhesin) and SasA (sialic acid-binding adhesin), has been extensively studied [264]. 
BabA binds to Lea (Galβ1-3[Fucα1-4]GlcANc) on MUC5AC or MUC1, while SasA 
recognises sialylated Lewis antigens, sLex (NeuAcα2-3Galβ1-4[Fucα1-3]GlcNAc) and 
sLea (NeuAcα2-3Galβ1-3[Fucα1-4]GlcNAc) [50, 241-242]. These epitopes are found on 
glycolipids and their expression is upregulated during gastritis [244, 265]. 
A Gal/GalNAc lectin of the enteric parasite E. histolytica has been identified and 
isolated via Gal affinity chromatography [266]. E. histolytica binds to rat and human 
intestinal mucosa and adherence can be inhibited by GalNAc [248]. Additionally, the 
binding of the parasite to Chinese hamster ovary cells can be inhibited by rat and 
human colonic mucins as well as Gal [246]. 
Vibrio cholerae colonises the host intestine via adherence to mucosal surfaces, which 
is mediated by different cell-surface molecules including the chitin-binding protein 
GbpA [245, 267-268]. Recombinant GbpA showed binding to mouse mucus and 
isolated mucin in microtitre plate assays and mucin binding was abolished in the 
presence of GlcNAc [245].  
Members of the internalin (Inl) protein family of Listeria monocytogenes have been 
demonstrated to facilitate entry into host cells, including intestinal epithelial cells, via 
interaction with different receptors [269-270]. Furthermore, a study suggested binding 
of human intestinal MUC2 to InlJ, InlB and InlC, but no further characterisation of the 
binding has been performed [249]. 
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1.4.2 Mucus adhesins of Lactobacillus species  
In contrast to the often well characterised pathogenic adhesins and their specific host 
receptors, information on commensal adhesion molecules and host ligand structures, 
especially mucosal surface components, is rudimentary. The majority of studies on 
commensal adhesins have been carried out in Lactobacillus species due to their 
postulated probiotic effects [161, 168, 271]. Indeed, the ability of lactobacilli to adhere 
to intestinal mucus is regarded as a probiotic factor and the varying mucus adhesion 
capability has been demonstrated for a variety of Lactobacillus strains [272-274]. 
Immobilised mucus/ mucin, intestinal epithelial cell culture and whole tissues are 
frequently used in vitro adhesion models to study mucosal adhesion [275]. Recently, 
more sensitive techniques to study bacterial mucin binding have emerged including 
surface plasmone resonance (SPR), atomic force microscopy (AFM) and flow 
cytometry (FCM) [276-278]. 
The identification of putative cell-surface adhesion molecules mediating the binding of 
bacteria to intestinal mucosal surfaces, benefitted greatly from genome sequencing of 
Lactobacillus species (Table 1.3) [181, 279-281]. 
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Commensal  Adhesin Ligand Reference 
L. reuteri ATCC 53608 MUB Porcine and chicken 
mucus, porcine gastric 
mucin, Igs  
[282-283] 
L. reuteri 104R MapA Small intestinal mucus, 
porcine gastric mucin 
[284-285] 
[L. reuteri NCIB 11951 CnBP Collagen [286-287] 
L. rhamnosus GG Spa C and F 
(Spa B) 
Human colonic mucus [288-289] 
 MBF Human colonic mucus [290] 
Lactococcus. lactis 
TIL448 
YhgE2 Human intestinal cells [291] 
L. acidophilus NCFM Mub 
SlpA 
FbpA 
Human intestinal cell  [292] 
L. plantarum WCFS1 Msa Mannose [293]  
L. plantarum LA 318 GAPDH Human colonic mucin, 
ABO blood antigens 
[294] 
L. mucosae ME-340 Lam29 ABO blood group antigens 
H3 protein (in human 
colonic mucus) 
[295-296] 
L. johnsonii La1 NCC 
533 
EF-Tu 
GroEL 
Human intestinal cells, 
mucus 
[297-298] 
L. salivarius UCC118 LspA Human intestinal cells  [299] 
L. fermentum BCS87 32-Mmubp Porcine mucus and mucin [300] 
Table 1.3 Commensal adhesins of Lactobacillus involved in host surface interaction 
 
Many Lactobacillus adhesins, which have been implicated in mucus or intestinal 
surface binding, belong to a class of sortase-dependant proteins (SDP) [8, 280]. They 
are characterised by an N-terminal signal sequence (YSIRK) for transport to the cell 
wall and a C-terminal LPXTG-motif recognised by an enzyme called sortase, which 
facilitates covalent cell-wall anchoring via a Thr residue to a peptidoglycan amino group 
[225, 301]. 
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The canonical sortase-dependent mucus-binding protein (MUB) (353 kDa) of L. reuteri 
ATCC 53608 has been initially functionally characterised by Roos and Jonsson [283]. It 
is composed of 14 tandemly arranged repeats of two types, Mub type1 and Mub type 2, 
present in 6 (RI to RVI) and 8 (R1 to R8) copies, respectively, of about 183 to 206 
residues (Figure 1.15). 
 
 
Figure 1.15 Schematic representation of MUB of L. reuteri 53608 
Mub type 1 (blue) and type 2 (green) labelled with Roman and Arabic numbers, 
respectively. N-terminal domain (Nterm) coloured grey and the LPXTG-motif presented as 
black line. 
L. reuteri ATCC 53608 binds to porcine, chicken and mouse mucus, which is mainly 
mediated by the presence of MUB on the bacterial cell surface [283, 302]. Fusion 
proteins of selected Mub type 1 and Mub type 2 repeats with a mannose-binding 
protein (MBP) showed adhesion to porcine and chicken mucus, as well as porcine 
gastric mucin [283]. Mub-MBP binding was inhibited by mucin and glycoproteins, fetuin 
and asialofetuin, suggesting interaction of MUB with a glycan receptor. A synthetic 
peptide (MUB70), comprising the first 70 residues of MubR5, showed binding to Muc2 in 
colonic mucus tissue sections [303]. In addition, recombinant type 1 and type 2 Mub 
repeats bind human secretory IgA, IgG and the IgGFab fragment in vitro [282]. 
A comparative protein database search identified 48 Mub domain-containing proteins in 
lactic acid bacteria (LAB) of which 30 contained more than 3 or 4 copies of the Mub 
domain [304]. The majority of those were identified in Lactobacillus species, while 
4 Mub domain-containing proteins are present in Lactococcus and Pedicoccus. A more 
recent in silico analysis identified 47 mucus-binding proteins in the extracellular 
proteomes of six Lactobacillus genomes [280]. The Mub domain appears to be 
abundant in LAB, in fact a recent database search by John Walshaw (Institute of Food 
Research, Norwich, UK) identified a total of 147 Mub domains in Lactobacillus species 
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of the GI tract alone, and 28 Mub domains were present only in L. reuteri ATCC 53608 
[305]. 
Mub domains contain a distinct shorter sequence domain termed mucin-binding protein 
(MucBP) domain as found in the Pfam database (PF06458) (http://pfam.sanger.ac.uk/), 
which, in Mub repeats of L. reuteri ATCC 53608, is located at the C-terminal end and 
folds as a structurally distinct domain (see 1.6) [282].  
Another Mub domain protein that was suggested to be involved in bacterial binding to 
intestinal cells is Mub of L. acidophilus NCFM, which contains 15 Mub domains [292, 
304]. Additionally, two other adhesion proteins were identified in the same strain, the 
S-layer protein SlpA and the fibronectin-binding protein FbpA, which contribute to the 
overall binding to intestinal epithelial cells. The surface (S)-layer is the crystalline 
proteinaceous and outermost layer of the Gram-positive cell wall and found in some 
lactobacilli [306]. 
LPXTG-like pili structures have so far only been identified in L. johnsonii, L. ruminis, 
L. rhamnosus and recently in Lactococcus lactis [288, 291, 307-308]. The pili, present 
on the cell-surface of L. lactis TIL448, is responsible for bacterial adhesion to human 
intestinal cells, while the adhesive phenotype is nearly absent in a mutant strain with 
disruptions in the pili genes [291]. L. rhamnosus GG encodes two different pilin fibres, 
SpaCBA and SpaFED, which show a typical pili architecture of Gram-positive bacteria 
with different pilin subunits [309]. SpaCBA and SpaFED are comprised of major 
backbone pilin subunits, SpaA and SpaD, minor pilins, (SpaB, SpaC and SpaE, SpaF) 
[288]. SpaC of the SpaCBA pili has been demonstrated to mediate the bacterial binding 
to human intestinal mucus [288]. SpaB and SpaF of the SpaFED pili also showed 
binding to colonic mucus, although the mucus binding ability of SpaB may be due to 
electrostatic interactions [289]. Another mucus-adhesin, present on the cell surface of 
L. rhamnosus GG, is the mucus-binding factor (MBF), which contains 4 MucBP 
domains and an anchoring motif [290]. Recombinant MBF has been demonstrated to 
bind to human colonic mucus and mucus adhesion of bacterial cells was reduced with 
an anti-MBF antiserum [290]. 
The sortase-dependant protein MapA of L. reuteri 104R (formerly known as 
L. fermentum 104R), was identified by its ability to bind porcine small intestinal mucus 
and gastric mucin via dot-blot assay after mucin-affinity chromatography [285]. It has 
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also been demonstrated to be involved in bacterial binding to mucin-expressing human 
intestinal cells and recombinant MapA has been localised on intestinal cells by 
immunofluorescence microscopy [284]. LspA of L. salivarius UCC118 contains 
7 repeats similar to Mub domains of L. reuteri ATCC 53608 and has been implicated in 
bacterial adhesion to colonic epithelial cells [299]. The cell-surface protein Lam29 of 
L. mucosae ME-380 binds to ABO blood group antigens A (GalNAcα1-3[Fucα1-2]Gal ) 
and B (Galα1-3[Fucα1-2]Gal) as well as the human histone 3 (H3) protein from colonic 
mucus, as observed in SPR and microtitre plate assays [295-296]. A mucus-adhesin 
(32-Mmubp) has been identified in L. fermentum BCS87 via its ability to bind porcine 
mucus and mucin [300].  
Additionally, a few normally cytoplasmic proteins show surface association and have 
been demonstrated to possess mucin-binding ability. The elongation factor Tu (EF-Tu) 
and the heat shock protein GroEL of L. johnsonii NCC533 bind to intestinal epithelial 
cells and human colonic mucin. In addition, binding of the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) of L. plantarum LA 318 to human colonic mucin and ABO 
blood group antigens A, and H (Fucα1-2Gal) was characterised in SPR experiments 
[294, 310].  
The mannose-dependent binding of a few L. plantarum strains to human colonic cells 
has been observed [311] and a mannose-specific adhesin (Msa) has been identified in 
L. plantarum WCFS1 by mannsoe-dependent yeast agglutination assays as well as 
several other L. plantarum strains [293, 312]. Msa proteins encompass domains similar 
to Mub domains found in L. reuteri ATCC 53608 and a ConA-like lectin domain of 
Staph. aureus generally responsible for mannose-recognition [293]. 
The collagen binding protein CnaB of L. reuteri NCIB 11951 binds to an alternative cell 
surface receptor, the ECM component collagen [286-287].  
Generally, for many of the identified adhesins described above there is a lack of direct 
evidence for their binding ability to mucus or mucin. For the majority of these adhesion 
molecules no further functional characterisation on the nature of the interaction with 
intestinal cells, mucus or mucins has been performed. Additionally, there is only 
a limited amount of structural information available on commensal adhesins, which 
could support their functional characterisation. 
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1.5 Structural basis of bacterial mucus adhesins  
The MUB protein of L. reuteri ATCC 53608 is the first commensal mucus adhesin 
which was structurally characterised. The structure of the Mub type 2 repeat MubR5 
(PDB entry 3I57) was determined at 1.8 Å via X-ray crystallography in our lab [282]. 
MubR5 folds like an elongated distorted cylinder 110 Å long and 25 Å in diameter 
revealing two distinct domains, an N-terminal B1 (2-75 residues) and a C-terminal B2 
domain (76-184 residues) with an inter domain region (IR domain) forming a 3 stranded 
β-sheet (Figure 1.16).  
 
 
 
 
 
Figure 1.16 Presentation of the Mub type 2 MubR5 X-ray crystal structure 
Protein fold of MubR5 with α-helix (red) and β-sheets (yellow). N- and C-termini and 
structural elements are labelled. Ca2+-ion presented as grey sphere. Structural domains are 
labelled with B1, B2 an IR (inter domain region).  
The B1 domain has an ubiquitin-like β-grasp fold most similar to that found in the 
Ig-superfamily [313]. This fold contains of two pairs of antiparallel β-strands (β1-β2 and 
β3 and β4) in a 4-stranded sheet which are connected by an α-helix. A Ca2+-ion is 
coordinated by residues of the loop connecting strands β3 and β4 and two water 
molecules complete the coordination sphere stabilising the loop. Calcium binding is 
characteristic for calcium-dependant lectins (C-type lectins) recognising carbohydrate 
ligands, however MubR5 does not structurally resemble a lectin fold [314-315]. High 
structural similarity of the B1 has been observed to the Ig-binding protein L (PpL) from 
Peptostreptoccocus magnus (PDB entry 1HEZ) [316]. The B1 domain is also 
structurally similar to the B2 domain, which has a modified ubiquitin-like β-grasp fold, 
where the two antiparallel β-strands in the β-sheet are connected by a β-strand instead 
of an α-helix as in the B1 domain.  
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Figure 1.17 MUB, MucBP or related crystal structures of bacterial cell-surface proteins 
(A) Mub-R5 of L. reuteri ATCC 53608 with B1 and MucBP containing B2 domain (PDB entry 
3I57). (B) Functionally characterised MucBP domain Spr1375 of Strept. pneumoniae (PDB 
entry 3NZ3). Annotated MucBP domains (C) LBA1460 of L. acidophilus (PDB entry 3Q69), 
PEPE_0118 of Pedicoccus pentosaceus (PDB entry 3LYY) (E) and Imo0835 of 
L. monocytogenes (PDB entry 2KVZ). (D) MucBP domain of an adhesion exoprotein from 
P. pentosaceus (PDB entry 2KYW). (G) Structurally related InlB B-repeat of 
L. monocytogenes (PDB entry 2K5B). Structures superimposed on common framework. 
(taken from [22]). 
The B2 domain, exclusive of the IR domain, coincides with the MucBP domain as 
defined in the Pfam database (PF06458), which, as evident from the MubR5 crystal 
structure, describes a structurally distinct protein domain (see 1.5). The functionally 
characterised MucBP domain of the Spr1345 protein (PDB entry 3NZ3) from 
Strep. pneumoniae, which exhibits mucin and polysaccharide binding ability, is 
structurally similar to the B2 domain of MubR5 (Figure 1.17 B) [240]. Other 3D 
structures annotated as MubBP have been predicted as cell-surface adhesins including 
PEPE_0118 of Pediococcus pentosaceus (PDB entry 3LYY) and LBA1460 of 
L. acidophilus. Furthermore, structural similarity for B2 of MubR5 was observed to the 
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B-repeat of the cell-surface adhesion protein InlB from L. monocytogenes, which has 
an ubiquitin-like β-grasp fold most similar to small ubiquitin-like modifiers (SUMOs) 
(see 1.4.1) [317]. 
 
 
Figure 1.18 Presentation of the crystal structures of the E. coli adhesins F17-G and FimH  
(A) Ribbon diagram of F17-G (PDB entry 1O9W) with the β-sheets of the Ig-like lectin 
domain shown in yellow (back sheet) and blue (front sheet) and minor β-strands shown in 
grey. Bound GlcNAc presented in light blue, and β-strands, N- and C-termini labelled. 
Residues 22 to 27 are missing in structure file (present residues labelled). (B) Electrostatic 
surface representation of F17-G in complex with GlcNAc with negative and positive charged 
surface area presented in red and blue, respectively. (C) Ribbon diagram of the N-terminal 
receptor-binding domain of FimH (PDB entry 1KLF) in complex with mannose with β-strands 
in yellow. β-strands, N- and C-termini labelled. (D) Surface representation of the FimH 
receptor-binding domain in complex with mannose with negatively and positively charged 
surface area presented in red and blue, respectively. 
Pathogenic adhesins are generally better functionally and structurally characterised, 
especially cell-surface adhesion molecules of pathogenic E. coli [318-319]. The 
structure of the F17-G adhesin (PDB entry 1O9W) has been solved in the presence of 
a GlcNAc molecule allowing the identification of the receptor binding pocket located at 
the N-terminal end of the protein (Figure 1.18 A and B) [237]. The interaction of amino 
acid residues of the sugar binding site via their carbonyl groups, side chains or 
nitrogens with GlcNAc is mediated by 11 hydrogen bonds, four of which involving water 
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molecules [237]. The F17-G adhesin fold is a variant of the Ig-like fold, which is 
characterised by a β-sandwich of 7 β-strands arranged in two β-sheets of 4 and 3 
β-strands. [320]. The β-sandwich present in F17-G consists of a 5-stranded sheet (A2, 
G, F, C and D2) and a 4-stranded sheet (A1, B, E and D1) (Figure 1.18 A). Additional 
minor β-strands (A’, F’ and G’) extend those of the β-sandwich. The mannose-binding 
adhesin FimH (PDB entry 1KLF) of E. coli contains two domains, an N-terminal 
receptor-binding domain and a C-terminal pilin domain. While the latter has an Ig-like 
fold, the receptor-binding domain is an 11-stranded β-barrel (Figure 1.18 C) [235]. The 
mannose molecule is located in the negatively charged binding pocket at the 
N-terminal end of the FimH receptor-binding domain (Figure 1.18 D) and ligand 
interaction is mediated by hydrogen bonding and hydrophobic interactions. 
 
 
 
 
 
 
 
 
Figure 1.19 Examples of internalins with Ig-like fold domains 
(A) Domain organisation of L. monocytogenes internalins with signal sequence (SS), cap 
domain (green), characteristic LRR (Leucin rich repeat) (red), interrepeat-region (IR) (blue), 
B-repeat (BR), C-repeat (CR), cell-wll spanning region (Cws) and membrane anchor (MA) 
(orange). (B) X-ray crystal structures of InlB and InlH with Ig-like fold IR domains (blue), 
LRR (red) and cap (green) domains with the N-terminal β-strand of the IR domain coloured 
magenta (adapted from [321]). 
Additionally, several Inl proteins of the invasive pathogen L. monocytogenes contain 
protein domain adjacent to their main Leucine rich (LRR) effector domain known as 
inter repeat (IR) domains (Figure 1.19 A). They describe an Ig-like fold dominated by 
a 4-stranded β-sheet, where the N-terminal strand is an extension of the C-terminal 
A B 
InlA 
InlB 
InlC 
InlH 
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strand of the LRR domain (Figure 1.19 B) [321]. While the receptors recognised by the 
LRR domains of the two major invasive Inls, Inl A and B, are known, no functional 
information is available for the Ig-like IR domains (see 1.4.1) [212, 322-323].  
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1.6 Aims and objectives of this research project 
 
The overall aim of this research project is to gain structural insight into mucus adhesins 
of Lactobacillus reuteri, to investigate their adhesive properties to intestinal mucus and 
mucins, and to functionally characterise their mechanism of adhesin binding to 
structural mucus/ mucin components. 
 
The specific objectives of this project are: 
 to purify and characterise mucus adhesins from L. reuteri ATCC 53608 and 
L. reuteri DMS 20016T 
 
 to obtain structural information on protein domains of mucus adhesins using 
X-ray crystallography and to investigate their domain organisation by small 
angle X-ray scattering (SAXS) 
 
 to determine the binding ability of L. reuteri adhesins to intestinal mucus, 
mucins and mucin glycans in vitro using binding assays, isothermal titration 
calorimetry (ITC) and X-ray crystallography 
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CHAPTER 2 MATERIAL AND METHODS 
2.1 Materials 
2.1.1 Standard buffers 
Deionised ultrapure water was used to a resistance of 18.0 MΩ/cm (Barnstead 
Nanopure Diamond, Barnstead Thermolyne Corporation, New Hampshire, USA). All 
used chemicals were supplied by Sigma-Aldrich (Poole, UK) unless otherwise stated.  
Standard buffers used in this study were phosphate buffered saline (PBS) (8.1 mM 
Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4), PBST (PBS with 
0.05% Tween-20), sodium phosphate buffer (10 mM Na2HPO4, 10 mM NaH2PO4, 
pH 7.5) and Tris-HCl (10 mM Tris base (Formedium, Hunstanton, UK), pH 7.5).  
Pierce Protein-Free (PBS) blocking buffer (Thermo Scientific, Hemel, UK) was used as 
a blocking agent, if not otherwise stated. 
2.1.2 Sugars and mucins 
The sugars used in this study for crystallisation (see 2.4.1.2) or binding experiments 
(see 2.3.6) were Fucose (Fuc), Mannose (Man), Galactose (Gal), 
N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and 
N-acetylneuraminic acid (Neu5Ac) (all supplied by Sigma-Aldrich, Poole, UK), 
N-acetyllactosamine (LacNAc) (Dextra Laboratories, Reading, UK) and 6’-Sialyllactose 
(6’SL) (Glycom, Kgs. Lyngby, Denmark). Mannose-α1-6-mannose (Manα1-6man) and 
Mannose-α1-3(Mannoseα1-6)mannose (Man(Manα1-6)man) used for isothermal 
titration calorimetry (ITC) (see 2.4.1) experiments were supplied by (Dextra 
Laboratories, Reading, UK). 
Porcine small intestinal mucus (PSIM) [324] and porcine gastric mucin type III (PGM) 
(Sigma-Aldrich, Poole, UK) (further purified by ethanol-precipitation (pPGM)), were 
used in membrane, slot-blot and microtitre plate binding studies (see 2.3.6). 
Human MUC2, purified from urine samples of patients with artificial bladder derived 
from intestinal tissues [325-326], was kindly provided by Michael McGuckin (Mater 
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Medical Research Institute, South Brisbane, Australia) and used in microtitre plate 
assays (see 2.3.6.4). 
Human MUC2 from biopsy samples for membrane binding assays (see 2.3.6.1) and 
MUC1-glycopeptides (with a mouse immunoglobulin G (IgG) Fc fusion tag) carrying the 
specific glycan antigens Tn (GalNAcα), sialyl-Tn (Siaα2-6GalNAcα), TF (Galβ
1-3GalNAcα) or sialyl-TF (Siaα2-3Galβ1-3GalNAcα) [327-328], used in membrane 
binding assays (see 2.3.6.1), were kindly provided by Gunnar Hansson (University of 
Gothenburg, Sweden). 
2.1.3 Lectins and antibodies  
All lectins (Ricinis communis agglutinin I (RCA), Wheat germ agglutinin (WGA), 
Sambucus nigra agglutinin (SNA) and Ulex europaeus agglutinin (UEA)) used in this 
study were supplied by Vector Labs (Peterborough, UK) as fluorescein (f-) labelled or 
biotin (b-) conjugated proteins.  
Primary antibodies and secondary antibody-conjugates used in this study for protein 
detection on membrane or in microtitre plate assays are listed below (Table 2.1). 
Polyclonal rabbit antibodies were raised against recombinant Mub type proteins MubR5 
and MubRI, and Lar0958, and were produced by Bio Genes (Berlin, Germany) at a titre 
of > 200,000 (MubR5 and MubRI) or > 100,000 (Lar0958). 
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Antibody  Target raised in Supplier 
Anti-MubR5 Recombinant Mub type 2 
repeat RI 
rabbit BioGenes  
(Berlin, Germany) 
Anti-MubRI Recombinant Mub type 2 
repeat RI 
rabbit BioGenes  
(Berlin, Germany) 
Anti-Lar0958 Recombinant Lar_0958 
repeat 
rabbit BioGenes  
(Berlin, Germany) 
Anti-His5 Five consecutive 
histidine residues 
mouse Merck KGaA  
(Darmstadt, Germany) 
Anti-MUC2C3 C-terminal human MUC2 
peptide 
PHYVTFDGLYYSYGNCa 
rabbit Provided by Gunnar 
Hansson (University of 
Gothenburg, Sweden) 
Anti-Muc2.3 murine Muc2 peptide 
CPEDRPIYDEDLKK  
rabbit Provided by Michael 
McGuckin (Mater Medical 
Research Institute, South 
Brisbane, Australia) 
Anti-rabbit-HRPb rabbit IgG donkey Amersham Bioscience, 
GE Healthcare  
(Little Chalfont, UK) 
Anti-mouse-
HRPb 
mouse IgG goat Invitrogen, Life 
technologies Ltd (Paisely, 
UK) 
Anti-rabbit-APc rabbit IgG goat Sigma-Aldrich (Poole, UK)  
Anti-mouse-AP mouse IgG horse Vector Lab  
(Peterborough, UK) 
Anti-rabbit-
AlexaFluor®555 
rabbit IgG donkey Abcam (Cambridge, UK) 
Table 2.1 Used primary and secondary antibodies 
 a[25], bHorseradish peroxidase (HRP) and cAlkaline phosphatase (AP) 
 
2.1.4 Bacterial strains, media composition and culture conditions 
Bacterial strains used in this study were Lactobacillus reuteri ATCC 53608 for MUB 
protein isolation, L. reuteri DSM 20016T, Escherichia coli DH5α (Novagen, Merck 
KGaA, Darmstadt, Germany) for transformation and plasmid amplification, and E. coli 
Tuner(DE3)pLacI2 (Novagen, Merck KGaA, Darmstadt, Germany), E. coli BL21 (DE3) 
(Novagen, Merck KGaA, Darmstadt, Germany) and E.coli BL21StarTM (DE3) (Novagen, 
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Merck KGaA, Darmstadt, Germany) for recombinant protein expression. The 
Tuner(DE3)pLacI2 strain is a lacZY deletion mutant of E. coli BL21 and carries 
a chloramphenicol resistance gene. E. coli BL21StarTM (DE3) strains harbouring the 
pET101-InJ or pET101-InlJ-LRR-IR plasmids, were kindly provided by Pascale Cossart 
(Institute Pasteur, Bacteria-cell interactions Unit, Paris, France). 
Bacterial culture media used in this study were modified standard Luria broth (LB), 
‘de Man, Rogosa and Sharpe’ (MRS), and Lactobacillus defined media (LDMII) (see 
Appendix I). For E. coli bacterial cell growth, LB media or LB agar was used containing 
10 mg/mL Bacto tryptone, 5 mg/mL Bacto yeast extract and 10 mg/ml sodium chloride, 
or additionally 15 g/L agar, and the pH was adjusted to pH 7.5. L. reuteri cultures were 
grown in MRS broth containing 10 mg/mL peptone, 8 mg/mL ’Lab-Lemco’, 4 mg/mL 
yeast extract, 20 mg/ml glucose, 2 mg/ml di-potassium hydrogen phosphate, 5 mg/mL 
sodium acetate 3H2O, 2 mg/ml tri-ammonium citrate, 0.2 mg/mL magnesium sulphate 
7H2O, 0.05 mg /mL manganese sulphate 4H2O and 1 mL sorbitan mono-oleate. Super 
Optimal broth with Catabolite repression (SOC) medium (20 mg/mL Bacto tryptone, 
5 mg/mL Bacto yeast extract, 10 mM NaCl, 2.5 mM potassium chloride, 10 mM 
magnesium chloride, 10 mM magnesium sulphate, 20 mM glucose) was used for cell 
regeneration after bacterial transformation (see 2.2.5). 
Long term stocks of L. reuteri in MRS with 20% (v/v) glycerol and of E. coli in LB 
medium with 50% (v/v) glycerol were stored at -80°C. L. reuteri ATCC 53608 cells were 
grown to stationary phase from long term stocks at 37°C for 20 h in a static incubator. 
For native MUB protein isolation, cells were sub-cultured at 0.1% (v/v) into LDMII 
medium (see Appendix I) at 37°C for 24 h in a static incubator. E. coli strains were 
cultured from long term stocks at 37°C for 16 h in a shaker incubator in LB broth with 
1% (w/v) glucose or on LB agar supplemented with antibiotics, carbenicillin at             
50 μg/mL, chloramphenicol at 34 μg/mL or kanamycin at 30 μg/mL, as needed. 
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2.2 Molecular biology 
2.2.1 Polymerase chain reaction (PCR) 
Amplification of target gene fragments (mubRV, mubRVI, mubR8-V, mubRV-VI, Nterm, 
NtermmubRI and lar0958) for vector cloning was achieved by polymerase chain 
reaction (PCR) with whole bacterial cells as a template. L. reuteri ATCC 53608 and 
DSM 20016T cells were grown in MRS broth to stationary phase (see 2.1.4), cells 
pelleted by centrifugation (1342g, 5 min, 15°C), washed twice in ultrapure water and 
re-suspended at OD600 5.5 in ultrapure water. For whole cell PCR, 10 μL cell 
suspension and 10 pmol gene specific forward and reverse primers (see Appendix II) 
were added to the HotStarTaq Master Mix with 125 U HotStarTaq DNA polymerase 
(Qiagen, Crawley, UK) and the reactions carried out in a Biometra® T gradient 
thermocycler (Biometra, Goettingen, Germany) with the following reaction profile: initial 
polymerase activation for 5 min at 95°C; 35 cycles of denaturation for 30 sec at 94°C, 
annealing for 30 sec at 56°C (Nterm and mubRVI), 50°C (NtermmubRI), 49°C (mubRV 
and mubRV-VI) or 51°C (mubR8-V), and extension 180 sec (mubNterm and 
mubNtermRI), 45 sec (mubRV and mubRVI) and 75 sec for (mubR8-V and mubRV-VI) 
at 72°C; and a final extension for 10 min at 72°C.  
Amplified DNA was separated and analysed by agarose gel electrophoresis (see 2.2.3) 
and purified using a QIAquick® PCR purification kit (Qiagen, Hilden, Germany). 
Alternatively, DNA fragments were excised from gel and purified using a QIAquick® gel 
extraction kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.  
2.2.2 Plasmid DNA purification  
Plasmid DNA was purified from E. coli cells grown in LB broth for 16 h (see 2.1.1) using 
a QIAprep® Spin Miniprep Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions, and purified DNA was eluted with sterile ultrapure water for 
use in sequencing or restriction analysis, or by a TENS buffer DNA precipitation 
method (40 mM Tris base, 1 mM ethylenediaminetetraacetic acid (Na2EDTA), 0.1 N 
sodium hydroxide and 0.5% sodium dodecyl sulphate). For this, E. coli cells were 
separated from culture media by centrifugation at 16.200g for 10 sec and the 
supernatant decanted. TENS buffer (300 μL) and 3 M sodium acetate (pH 5.2) (150 μL) 
were then added for cell lysis, and cell debris and chromosomal DNA separated by 
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centrifugation at 16,200g and 4°C for 3 min. The supernatant was transferred to 
a clean tube, plasmid DNA was precipitated with ice-cold absolute ethanol and pelleted 
by centrifugation at 16.200g for 5 min (4°C). The DNA pellet was rinsed with 
70% (v/v) ethanol (3 min, 16.200g, 4°C), dried at RT and re-suspended in Tris 
ethylenediaminetetraacetic acid (EDTA) (TE) buffer (40 mM Tris base, 1 mM 
Na2 EDTA, pH 7.7-8.0) with 2.5-5 U RNase ONETM Ribonuclease (Promega, Madison, 
USA).  
2.2.3 DNA agarose gel electrophoresis 
Agarose gel electrophoresis was used for DNA separation after PCR (see 2.2.1), 
plasmid purification (see 2.2.2) or restriction digest (see 2.2.6) with 1% (w/v) agarose 
gels. DNA samples were prepared by adding Orange G loading buffer (50 mM EDTA 
Na2, pH 7.5; 70% (w/v) sucrose; 0.1 % (w/v) Orange G dye) at 60% (v/v) before loading 
onto the gels. Gels were run in Tris acetate EDTA (TAE) buffer (40 mM Tris, 2 mM 
sodium acetate 1 mM Na2 EDTA, pH 7.7-8.0) for 30 min at 100 V and stained with 
ethidiumbromide (EtBr) for up to 30 min, rinsed with water and DNA was detected 
under UV light. The Gibco 1kb DNA ladder and the Gibco 100 bp ladder (Invitrogen, 
Life Technologies Ltd., Paisley, UK) were used as DNA standards.  
2.2.4 DNA cloning in expression vectors 
Cloning of PCR amplified mubRV, mubRVI, mubR8-V, mubRV-VI and lar0958 DNA 
fragments (see 2.2.1) into pETBlue-1 AccepTorTM (Novagen, Merck KGaA, Darmstadt, 
Germany) was achieved by direct ligation of linearised vector DNA with single 
3’-dU overhangs and PCR products with single 3’-dA overhangs produced by PCR 
using Taq DNA polymerase (see 2.2.1). For ligation, insert and vector DNA were 
combined in a 5:1 or 10:1 molar ratio and added to a ClonablesTM 2 ligation premix 
(Novagen, Merck KGaA, Darmstadt, Germany) and the ligation reaction incubated at 
16°C for 2 h. The In-FusionTM PCR cloning kit (Clontech, Mountain View, California, 
USA) was used for cloning of nterm and ntermmubRI DNA into the pOPINF vector by 
ligation-independent fusion of vector and gene insert (see Appendix III) [329]. PCR 
primers (see Appendix II) for amplification of nterm and ntermmubRI were designed to 
incorporate 15 bp sequence-extensions with homology to the pOPINF vector to 
facilitate DNA insertion via homologous recombination using an In-FusionTM enzyme 
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and linearised vector DNA (Clontech, Mountain View, California, USA) according to the 
manufacturer’s instructions. The pOPINF was linearised in a single restriction digest 
with the restriction endonucleases HindIII (Roche, Mannheim, Germany) and KpnI 
(Roche, Mannheim, Germany) (see 2.2.6).  
The pETBlue-1 AccepTorTM and the pOPINF vectors allow high level protein expression 
under the control of a T7lacpromotor upon induction with IPTG, when cloned into the 
expression strains E. coli Tuner (DE3)pLacI2 and E. coli BL21(DE3), respectively. The 
pOPINF vector facilitates the expression of target proteins with an N-terminal fusion tag 
of six consecutive histidine (His) residues cleavable by 3C peptidase. Both vectors 
encode an ampicillin resistance gene facilitating bacterial growth in the presence of 
carbenicilin (E. coli BL21(DE3) pOPINF) or carbenicilin and chloramphenicol (E. coli 
Tuner(DE3)pLacI2 pETBlue-1 AccepTorTM) (see 2.1.4).  
2.2.5 Bacterial transformation 
For heat shock transformation of E. coli DH5α, E. coli Tuner(DE3)pLacI2 and E. coli 
BL21(DE3) (see 2.1.4), cells were thawed on ice and 45 µL of the cell suspension were 
mixed with vector DNA (see 2.2.4) (2.5 µL In-Fusion reaction or 1 µL plasmid ligation 
product), and incubated on ice for 5 min. The heat shock was performed in a 42°C 
water bath for 30 sec, followed by 2 min incubation on ice. For cell regeneration, 
250 µL SOC medium (see 2.1.4) were added to the transformation reaction and the cell 
suspension was incubated at 37°C for 1 h. Cells were then plated on LB-agar (see 
2.1.4) with antibiotics and incubated O/N at 37°C. 
2.2.6 Recombinant DNA analysis 
Clones were tested for the presence of the target genes by whole cell PCR using 
bacterial colony scrapes as a template (see 2.2.1) and by restriction analysis of 
plasmid DNA. For restriction digest, plasmid DNA were purified as described earlier 
(see 2.2.2) and incubated with HindIII (Roche, Mannheim, Germany) and KpnI (Roche, 
Mannheim, Germany) at 37°C for 6 h in restriction buffer A (pOPINF) or with XbaI 
(Roche, Mannheim, Germany) and EcoRI (Roche, Mannheim, Germany) at 37°C for 
2 h in restriction buffer H (pETBlue-1 AccepTor). The integrity of the cloned sequences 
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was verified by automated DNA sequencing (Genome Enterprise Ltd. BBSRC Genome 
Analysis Centre, Norwich, UK; or Eurofins MWG operon, Ebersberg, Germany).  
2.2.7 Estimation of DNA concentration  
DNA concentrations were estimated using ND-1000 spectrophotometer (Thermo 
Scientific, Waltham, USA), where an absorbance of 1 at 260 nm equalled 100 ng/μL, or 
after agarose gel electrophoresis, when compared to DNA standard. 
2.3 Biochemistry 
2.3.1 Recombinant protein production  
2.3.1.1 Protein expression 
For protein expression, cells were sub-cultured at 3% (v/v) from an O/N starter culture 
(see 2.1.4) into fresh LB media (500 mL in 2 L flasks with chicanes) and grown to an 
OD600 of 0.6-0.8 and recombinant proteins expressed in E. coli strains 
Tuner(DE3)pLacI2, BL21(DE3) or BL21StarTM (DE3) after induction with 1 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) at 37°C for 3-5 h or at 30°C overnight (MubR8-V). 
Bacterial cells were harvested by centrifugation at 12,250g and cells stored at -20°C 
until further use. 
2.3.1.2 Protein extraction 
Recombinant proteins were extracted using a freeze-thaw method (10 min freezing and 
20 min thawing) (MubR5, -RI, RV, -RV-VI and -R8-V, Lar0958), using BugBuster® HT 
Protein Extraction Reagent (Novagen, Merck KGaA, Darmstadt, Germany) (Nterm, 
NtermMubRI) for cell lysis according to the manufacturer’s instructions or via 
ultrasonication for cell disruption (Mub-RI-II-III, InlJ, InlJ-LRR-IR). For this, bacterial cell 
suspensions were ultrasonicated using a Status 70 MS72 homogeniser (Philip Harris 
Scientific; Ashby-de-la-Zouch, UK) at 50% power for 3 30 sec bursts with 60 sec 
incubation on ice in between bursts or a Soniprep 150 homogeniser (MSE; Sanyo, 
London, UK) set at 6 µm amplitude for 8 15 sec bursts with 30 sec cooling on ice. 
Protein extracts were clarified at 13,500g for 20 min at 4°C before further purification. 
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2.3.1.3 Protein purification 
Non-tagged Mub-repeat proteins and Lar0958 protein extracts were loaded onto an ion 
exchange chromatography (IEC) column (Mono Q HR 10/10) (GE Healthcare, Little 
Chalfont, UK) equilibrated with 10 mM sodium phosphate buffer and proteins were 
eluted with a linear gradient of 10 mM sodium phosphate buffer containing 1 M NaCl 
using a AKTA Fast Protein Liquid Chromatography (FPLC) system (GE Healthcare, 
New Jersey, USA).  
His-tagged fusion proteins (Nterm, NtermMubRI, InlJ and InlJ-LRR-IR) were purified by 
immobilised metal affinity chromatography (IMAC) with an AKTA FPLC system using 
a HisTrapHP column (GE healthcare, Uppsala, Sweden) (NtermMubRI, Nterm) or by 
gravity flow using a HisBind resin column (Novagen, Madison, USA) (InlJ and 
InlJ-LRR-IR) according to the manufacturer’s instructions. Protein extracts were loaded 
onto a HisTrapHP column pre-equilibrated with 20 mM sodium phosphate wash buffer 
(20 mM Na2HPO4, 20 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole; pH 7.5) and bound 
proteins were eluted step-wise with 20 mM sodium phosphate elution buffer (20 mM 
Na2HPO4, 20 mM NaH2PO4, 0.5 M NaCl, 500 mM imidazole; pH 7.5). HisBind 
purification was performed according to the manufacturer’s instruction with the 
exception of a sequential column wash with two different wash buffers (20 mM 
Tris-HCl, 500 mM NaCl; pH. 7.9) containing 20 mM or 40 mM imidazole. Bound 
proteins were eluted with elution buffer (20 mM Tris-HCl, 500 mM NaCl, 1 M imidazole: 
pH. 7.9). 
When needed, pooled protein fractions were further purified via size exclusion 
chromatography (SEC) on a Superdex 75 16/60 prep grade or a Superdex 200 16/60 
prep grade (GE Healthcare, Little Chalfont, UK) (only MubRI-II-III, InlJ and InlJ-LRR-IR) 
with PBS or 10 mM Tris-HCl containing 150 mM NaCl (pH 7.5) at a flow rate of 
1 ml/min. For calibration of SEC columns proteins from standard high and low 
molecular weight (LMW and HMW) gel filtration calibration kits (Amersham Pharmacia 
Biotech, Little Chalfont, UK), namely Ribonuclease A (13.7 kDa), Chymotrypsinogen A 
(25 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa), Albumin (67 kDa), 
Alcolhol dehydrogenase (150 kDa) or Aldolase (158 kDa), were used. For use in X-ray 
crystallisation studies (see 2.5.1) or small angle X-ay scattering experiments 
(see 2.5.2), proteins were dialysed twice in 10 mM sodium phosphate buffer or 10 mM 
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Tris-HCl at 4°C for a minimum of 4 h using a 3,500 molecular weight cut-off (MWCO) 
Spectra/Por dialysis tube (Spectrum, Breda, The Netherlands). Proteins were then 
concentrated to at least 10 mg/ml using centrifugal filter units (10,000 or 3,000 
MWCO), immediately frozen in liquid nitrogen and stored at -80°C till further use. 
2.3.2 MUB purification 
The full-length native MUB was purified from spent media of a L. reuteri ATCC 53608 
culture. Briefly, bacterial cells were grown till stationary phase in LDMII and separated 
from spent medium at 7,500g for 15 min at 4°C. Medium solution was further clarified 
by vacuum-filtration using 0.45 μm and 0.2 μm filters consecutively and then 
concentrated by tangential flow filtration using Vivaflow 200 cassettes (100,000 MWCO 
PES) (Vivascience AG, Hannover, Germany). The concentrated extract was dialysed 
twice in 4 L PBS at 4°C for at least 4 h using a 3,500 MWCO Spectra/Por membrane 
(Spectrum, Breda, The Netherlands), filtered using 0.45 μm Ultrafree-Cl spin columns 
(Millipore, Merck KGaA, Darmstadt, Germany) and concentrated in 100,000 MWCO 
spin concentrators (Sartorius, Surrey, UK). The MUB protein solution was purified by 
size exclusion chromatography (SEC) using a Superose 6 prep grade resin column 
(GE Healthcare, Little Chalfont, UK) equilibrated with PBS at a flow rate of 0.4 mL/min 
using an AKTA Fast Protein Liquid Chromatography (FPLC) system (GE Healthcare, 
New Jersey, USA). 
2.3.3 Estimation of protein concentration 
Protein concentrations were estimated by measuring the absorbance (Abs) of 1 to 2 μL 
sample at 280 nm in a NanoDrop 2000 or ND-1000 spectrophotometer (Thermo 
Scientific, Waltham, USA) according to the Beer-Lambert’s law [A280=ɛ･l･c･MW; with 
ɛ= extinction coefficient, c=molar concentration in mol/L, MW=molecular weight in 
g/mol, and l=optical path length in cm). The protein extinction coefficient and the 
Abs 0.1%, absorbance value, where the protein concentration equals 1 mg/mL, were 
calculated from amino acid sequence using the ExPasy protein parameter tool 
(http://web.expasy.org/protparam/). 
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2.3.4 Protein gel electrophoresis 
All electrophoresis gels, running buffers, sample buffers and Western transfer buffer 
were supplied by Invitrogen, Life Technologies Ltd. (Paisley, UK) unless otherwise 
stated.  
2.3.4.1 Polyacrylamide gel electrophoresis (PAGE) 
For reducing denaturing sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) of recombinant protein samples, NuPAGE® 4-12% Bis Tris gels (12 well, 
1.0 mm) or RunBlue 12% (Expedeon, Harston, UK) (17 wells, 1.0 mm) were used with 
2-(N-morpholino)ethanesulfonic acid (MES) (35 min at 200 V) or 
3-(N-morpholino)propanesulfonic acid (MOPS) SDS running buffer (55 min at 200 V) 
for proteins with molecular weights (MW) of ≤50 kDa or >50 kDa, respectively. For the 
MUB protein, NuPAGE® 4-8% Tris-acetate gels (15 well, 1.0 mm) gels (55 min at 
150 V) were used with Tris-Acetate SDS running buffer. Samples were prepared with 
lithium dodecyl sulphate sample buffer and 10 mM dithiothreitol (DTT) as a reducing 
agent, and incubated for 10 min at 70°C before loading onto the gels. The Broad 
Range Protein Molecular Weight Marker (10-225 kDa) (Promega, Southhampton, UK), 
Broad Range Prestained Protein Standard (7-175 kDa) (New England Biolabs, Ipswich, 
UK) and HiMarkTM Unstained High Molecular Weight Protein Standard (30-460 kDa) 
(Invitrogen, Life Technologies Ltd., Paisley, UK) were used as MW standards. 
For non-denaturing PAGE of MUB, NuPAGE® 4-16% Tris-acetate native gels (12 well, 
1.0 mm) were used with Tris-glycine running buffer and samples separated at 150 V for 
2 h after adding Tris-glycine sample buffer. The Native MarkTM Protein Standard was 
used as a MW standard. 
2.3.4.2 Agarose-polyacrylamide composite gel electrophoresis (AgPAGE) 
For Agarose-polyacrylamide composite gel electrophoresis (AgPAGE) of high 
molecular weight mucus and mucin samples, agarose-polyacrylamide gels were 
prepared by mixing two heated solutions A (1% agarose, 0.375 M Tris-HCl (pH 8.1), 
15% acrylamide/bis-acrylamide with (w/w) ratio of 19:1, 10% (v/v) glycerol) and B 
(0.5 g agarose, 0.375 M Tris-HCl (pH 8.1)). The gels with gradients of 0.5-1% agarose, 
polyacrylamide 0-6% and 0-10% glycerol were cast at 60°C using a gradient mixer 
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after adding 3 μL APS and TEMED. Gels were left to dry for 3 h at RT and stored at 4°
C in a humidified environment for up to a week. 
Samples were reduced and alkylated with 2 sample loading buffer (0.75 M Tris-HCl 
(pH 8.1), 60% glycerol, 0.01% bromphenyl blue and 12% SDS) and DTT at a final 
concentration of 200 mM for 2 h at 37°C, and stored at -20°C till further use. Prior to 
loading onto gels, samples were boiled at 90°C for 5 min and AgPAGE performed with 
composite running buffer (192 mM boric acid, 1 mM EDTA, 0.1% SDS; pH 7.6 adjusted 
with 2 M Tris base) at 4°C and 30 mA per gel for 6.5 h or 12 mA per gel for 16 h. Gels 
were fixed (see 2.3.4.4) and stained using the Colloidal Blue staining kit according to 
the manufacturer’s instructions or with alcian blue (see 2.3.4.4). 
2.3.4.3 Isoelectric focusing (IEF)  
For the determination of the isoelectric point (pI) of proteins, Novex® pH 3-7 IEF gels 
were run in Novex® Cathode pH 3-7 and Novex® Anode buffer (Invitrogen, Life 
Technologies Ltd., Paisley, UK) at run conditions of 100 V for 1h, 200 V for 1h and 
400 V for 30 min. Samples were prepared with Novex® IEF Sample buffer and the IEF 
Markers pH 3-10 SERVA liquid mix (Invitrogen, Carlsbad, USA) used as a standard for 
pI determination of analysed protein samples. Gels were fixed in 12% trichloroacetic 
acid (TCA) (v/v) for 30 min and stained with Colloidal Blue staining kit (see 2.2.7.2). 
2.3.4.4 Staining of gels 
For staining of SDS-PAGE gels, the Colloidal Blue staining kit (Invitrogen, Life 
Technologies Ltd., Paisley, UK) or the GelCode Blue Stain Reagent (Thermo Scientific, 
Hemel Hempstead, UK) were used according to the manufacturer’s instructions. For 
Colloidal Blue staining, gels were fixed with 50% (v/v) methanol or ethanol and 10% 
(v/v) acetic acid for 10 min.  
For alcian blue staining of AgPAGE gels, gels were first fixed with 50% (v/v) methanol 
and 1% (v/v) acetic acid for 1h and then equilibrated in 25% (v/v) ethanol and 10% (v/v) 
acetic acid (2  15 min). Gels were incubated in 0.125% alcian blue solution (25% 
(v/v) ethanol and 10% (v/v) acetic acid) until sufficiently stained. After Western blotting 
of AgPAGE onto PVDF membranes, membranes were briefly rinsed with methanol 
(absolute) and stained with alcian blue solution for 10 min after. Membranes were 
destained in methanol for 5 2 min. 
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Native gels were stained with Gelcode Blue Stain Reagent and not destained before 
Western blotting. 
A GS-800 calibrated densitometer (Bio-Rad, Hertfordshire, UK) or an AlphaImager 
FluorChemE (Protein Simple, Santa Clara, USA) were used for scanning or imaging 
gels. 
Before Western blotting, gels were destained in 50% (v/v) ethanol and 10% (v/v) acetic 
acid for several hours. Destained SDS-PAGE gels were then incubated in SDS running 
buffer containing 1% (w/v) SDS for 1 h, Native PAGE gels in 0.1% (w/v) SDS for 1 min 
and composite gels in 10 mM Tris-HCl (pH 7.6) containing 1% (w/v) SDS for 1 h.  
2.3.4.5 Western blotting 
For Western electroblotting, recombinant purified proteins were transferred onto 
Pplyvinylidene fluoride (PVDF) ImmobilonTM-P membrane (Millipore, Watford, UK) of 
0.45 μm pore size, native MUB onto nitrocellulose HybondTM-C extra membrane 
(Amersham Bioscience, GE Healthcare, Little Chalfont, UK) of 0.45 μm pore size, using 
an XCellTM Blot Module (Invitrogen, Life Technologies Ltd., Paisley, UK) and Western 
blot transfer buffer (SDS-PAGE gels) or 25 mM Tris-glycine buffer (25 mM Glycine, 
pH 9.2) (non-denaturing PAGE gels) according to the manufacturer’s instructions.  
After AgPAGE (see 2.3.4.2), samples were transferred onto PVDF Immobilon PSQ 
membrane (Millipore, Watford, UK) (0.2 μm pore size) with composite blotting buffer 
(25 mM Tris-HCl, 0.192 M glycine, 0.04% (w/v) SDS and 20% (v/v) methanol) for 5 h at 
4°C and 150 V (40 W). 
2.3.5 Protein detection via antibodies and lectins 
After transfer of proteins to a membrane by Western blotting (see 2.3.4.6) or 
slot-blotting (see 2.3.4.3), membranes were incubated in blocking buffer for at least 1 h, 
washed three times with PBST and once with PBS and proteins were detected via 
primary and secondary antibodies or fluorescein labelled lectins (see 2.1.3).  
For detection via specific antibodies, membranes were incubated with primary anti-His5 
(1:1,000), anti-MubR5 (1:20,000), anti-MubRI (1:20,000), or a mix of anti-MubR5 and 
anti-MubRI (1:20,000 each), followed by secondary antibodies conjugated with alkaline 
phosphatase (AP) (1:25,000) or horse reddish peroxidase (HRP) (1:25,000) 
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(Table 2.1). Nitroblue tetrazolium (100 μg/mL), 5-bromo-4-chloro-3-indolyl 
phosphate-toluidine (50 μg/mL) in 100 mM Tris-HCl (pH 9.6) with 4 mM MgCl2 were 
used as an AP substrate and incubated on membranes until signals showed. 
Immobilon™ Western Chemiluminescent HRP Substrate (Millipore, Merck KGaA, 
Darmstadt, Germany) was added to the membranes and incubated for 5 min before 
imaging with the AlphaImager FluorChemE (Protein Simple, Santa Clara, USA). All 
incubation steps were performed at RT for at least 1 h followed by washing steps with 
PBST (3 5 min) and PBS (1 5 min).  
For protein detection via lectins, membranes were incubated with fluorescein labelled 
lectins (1:500 in PBS) for 1 h and washed three times with PBST and once with PBS 
before measuring the fluorescence signal using a Pharos-FX Plus Molecular Imager 
(BioRad, Hemel Hempstead, UK). 
2.3.6 Protein binding assays 
2.3.6.1 Membrane protein binding assays after electrophoresis 
To investigate the binding of purified MUB (see section 2.3.2) to MUC1-glycopeptides 
(see 2.1.3), glycoproteins were transferred onto a nitrocellulose membrane via Western 
blotting (see 2.3.4.5) after SDS-PAGE (see 2.3.4.1). Membranes were incubated in 
Blocking buffer (see 2.1.1) for at least 1 h and then probed with MUB at 15 μg/mL for 
16 h at RT. Bound proteins were detected via primary anti-MubRI and anti-MubR5, and 
secondary anti-rabbit-HRP as described before (see 2.3.5).  
To remove all bound proteins, the membrane was incubated twice for 10 min with 
stripping buffer (15 g/L Glycine, 1 g/L SDS, 10 mL/L Tween-20; pH 2.2), followed by 
PBS (2 10 min) and PBST (2 5 min), and MUC1-glycopeptides were detected via 
f-WGA and f-RCA (see 2.3.5). 
In order to investigate the binding of MUB and recombinant adhesion proteins 
(MubRI-II-III and MubR5) to human MUC2, mucins were separated by AgPAGE and 
transferred onto PVDV membrane (see 2.3.4.2 and 2.3.4.5). After blocking with 5% 
dried milk powder in PBST for 2 h at RT and washing with PBST (3 5 min), the 
membrane was incubated with MUB (10 μg/mL) and MubR5 (50 or 70 μg/mL) for 2 h. 
Bound proteins were detected via primary anti-MubR5, anti-MubRI (1:5,000 in PBS) for 
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16 h at RT (see 2.7), followed by incubation with anti-rabbit-HRP (Pierce, Thermo 
Scientific, Hemel, UK) (1:2,000 in PBS) for 2 h at RT (see 2.3.5). 
2.3.6.2  Glycan array 
A nitrocellulose glycan array was kindly provided by William Willats (University of 
Copenhagen, Denmark), where polysaccharides and BSA-conjugated 
oligosaccharides, mainly plant cell wall components and their building blocks, were 
printed on nitrocellulose in duplicate at 1 mg/mL, 0.2 mg/mL and 0.04 mg/mL for non 
BSA-conjugated structures and 2 mg/mL, 0.4 mg/mL and 0.08 mg/mL for 
BSA-conjugates. After incubation with Blocking buffer for 1 h, the array was probed 
with MubRI (0.3 mg/mL), MubR5 (0.3 mg/mL), NtermMubRI (0.45 mg/mL) and MUB 
(60 μg/mL) for 4 h. Specific detection of bound proteins was achieved by primary 
anti-MubRI (1:5,000), anti-MubR5 (1:5,000) and anti-His5 (1:1,000), followed by 
secondary alkaline phosphatase antibody conjugates (see 2.3.5). 
To investigate binding to mammalian glycans, MUB proteins and Lar0958 were tested 
on mammalian printed arrays of the Consortium for Functional Glycomics (CFG). 
2.3.6.3 Mass Spectrometry glycan array  
The binding of recombinant MUB proteins and native MUB to sugar molecules (Fuc, 
Gal, Man, GlcNAc, Lac, 6’SL and 3’sialyllactose (3’SL)) was investigated using 
functionalised Gold(Au)-surfaces and detection by mass spectrometry (MS) in 
collaboration with Sabine Flitsch (and Mirja Hartmann) (Manchester Institute of 
Biotechnology, University of Manchester, UK). 
2.3.6.3.1 Functionalisation of Au-surfaces 
Self-assembled monolayers (SAM) were formed on Au-chips by mixing linker 
(0.476 mM) and spacer (0.328 mM) molecules in a 1:4 ratio O/N at RT. Au-plates were 
washed between incubation steps with pure ethanol and dried in a nitrogen flow. For 
functionalisation of SAM, an activation mixture of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (35 mg/mL in DMF) and pentafluorophenol 
(PEP) (32 mg/mL in DMF) was incubated on Au-surfaces for 2 h at RT, followed by 
incubation with amino-functionlised glycosides (Fuc, Gal, Man, GlcNAc and Lac) 
(50 mM in PBS) O/N at RT. Sialylated Lac sugars, 6’SL and 3’SL, were formed on gold 
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chips by enzymatic synthesis with sialyl-transferase (with 1 mM CMP-Neu5Ac in 
100mM Tris-HCl (pH 8.0)) and trans-sialidase from Trypanosoma cruzi (with 4.3 mg/mL 
fetuin in 100 mM sodium phosphate buffer (pH 7)) at 25°C and 37°C O/N. Successful 
assembly and functionalisation of Au-surfaces was confirmed by MALDI-ToF mass 
spectrometry (Ultraflex MALDI TOF/TOF Mass spectrometer, Bruker Daltonics) in 
linear positive mode using a 2’,4’,6’-trihydroxyacetophenone monohydrate (THAP) 
matrix (10 mg/mL in acetone). 
2.3.6.3.2 Protein binding on functionalised Au-glycan chips 
After functionalisation (see 2.3.6.3.1), MubRI-II-III (300 μg/mL), MubR8-V (450 μg/mL), 
MubRV-VI (2.8 mg/mL), MubRV (1.0 mg/mL), MubR5 (1.0 mg/mL), Nterm (230 μg/mL) 
and MUB (25 μg/mL) were added in duplicate to functionalised glycan arrays and 
incubated in PBS for 4 h at 37°C. In addition, incubation of protein on Au-surfaces or 
on non-functionalised SAM was performed to obtain a MS protein profile and as a 
negative binding control. Au-chips were washed with PBS and left to dry, before matrix 
solution (sinapinic acid (20 mg/mL) in acetonitrile and 0.1 % trifluoroacetic acid, ratio 
70:30) was applied. Mass spectra were collected in a mass-to-charge-ratio range of 
6,000 to 160,000 m/z by MALDI-ToF mass spectrometry (Ultraflex MALDI TOF/TOF 
Mass spectrometer, Bruker Daltonics) in linear positive mode with a matric containing 
sinapinic acid (stock concentration 20 mg/mL) in acetonitrile with 0.1% trifluoroacetic 
acid (TFA) (70:30 ratio). Data were analysed using the open source mass spectrometry 
tool mMass (version 5.4.1) (http://www.mmass.org/). 
2.3.6.4 Slot-blot assay 
Purified MUB proteins were slot-blotted onto a nitrocellulose membrane by loading 
200 μL protein solutions in serial dilution into the slots of a PR600 24-slot-blot 
apparatus (Hoefer, Holliston, USA) with a vacuum of 350 mBar using the mini vacuum 
pump (Biometra, Goettingen, Germany). Slots were washed twice by adding 1 mL PBS 
and the vacuum increased to about 700 mBar. In order to achieve a better blotting 
efficiency, the vacuum was applied for another 2 min, the membrane then removed and 
incubated in blocking buffer for at least 1 h. For analysis of MUB (0-8 μg), Mub repeats 
(0-64 μg) and Nterm (0-32 μg) binding to mucin, membranes were incubated with PSIM 
(0.5 mg/mL) and pPGM (1 mg/mL) for 16 h and bound mucin detected by f-RCA 
(see 2.3.5). The membrane was then incubated with stripping buffer to remove any 
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bound protein and MUB proteins detected via primary anti-MubRI, anti-MubR5 or 
anti-His5 and secondary HRP antibody conjugate (see 2.3.5).  
In order to investigate the potential glycosylation of MUB, membranes were incubated 
with f-RCA, f-WGA, f-UEA and f-SNA as described in section 2.3.5. 
As a control for MUB binding studies with MUC1-glycopeptides (see 2.3.6.1), 
slot-blotted MUB was incubated with an mouse IgG Fc fragment (Pierce, Thermo 
Scientific, Rockford, USA) (1 μg/mL) at an equal molar concentration as present in 
MUC1-glycopeptides for 16 h at RT. Bound IgGFc was detected via anti-mouse-HRP 
(see 2.3.5). 
2.3.6.5 Microtitre plate assays 
For binding of MUB proteins to surface immobilised mucin samples, Microlon 600 
polystyrene microtitre plates (Greiner Bio-One Ltd., Stonehouse, UK) were incubated 
with 200 μL PSIM (0.1 mg/mL) and pPGM (1 mg/mL) in PBS at 4°C for 16 h. 
To remove any free protein, the plate was washed three times with 200 μL PBST and 
blocked with Blocking Buffer for 5 h. All incubation steps were performed in PBS at RT 
followed by a PBST wash step as described above. Native MUB and recombinant 
Mub-repeat proteins were added to the wells in a concentration range of                      
0-10 μg/mL and 0-200 μg/mL (100 μL per well), respectively, and plates incubated for 
16 h. To detect bound MUB proteins, primary anti-MubRI, anti-MubR5 or a combination 
of both were added to the wells (100 μL at 1:20,000) and incubated for 2 h, followed by 
incubation with secondary anti-rabbit-AP (100 μL at 1:20,000) for 2 h. 
Then, SIGMAFAST p-nitrophenol phosphate (pNPP) AP substrate (100 μL of 1 mg/mL 
pNPP in 0.2 M Tris with 5 mM MgCl2, pH 9.6-10.5; Sigma) was added to the wells and 
the absorbance measured at 405 nm after 1 h incubation in the dark. Assays were 
performed in triplicate with coated BSA as a control (1 mg/mL) (Sigma-Aldrich, Poole, 
Dorset, UK). 
Inhibition assays were performed as described above, but after incubation with MUB 
proteins, 100 μL inhibitor solutions containing 6’SL, Neu5Ac and Lac (see 2.1.2) at 
concentrations of 25, 50, 75 and 200 mM were added to the wells and incubated 
for 2 h. 
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A modified microtitre plate binding assay was used to analyse the binding of MUB, 
Lar0958 and Internalin J proteins to human MUC2, pPGM and PSIM, where purified 
adhesion proteins (see 2.3.1 and 2.3.2) were coated onto Microlon 600 polystyrene 
microtitre plates (Greiner Bio-One Ltd., Stonehouse, UK) at 0.4 μg (Lar0958 and 
internalins) or 0.6 μg (MUB) per well in PBS at 4°C for 16 h. Excess protein was 
removed by washing three times with 200 μL PBST and wells blocked with 1% (w/v) 
BSA in PBS for 1 h. All incubation steps were performed in PBS at RT followed by a 
PBST wash step as described above. PSIM (100 μL of 16 μg/ml), pPGM (100 μL of 
4 ng/mL) or human MUC2 (100 μL of 6 μg/mL) were added to the wells and incubated 
for 2 h. Bound PSIM components and mucin were either detected via b-WGA (1:500) 
followed by incubation with ExtrAvidin-peroxidase (1:1,000) (Sigma-Aldrich, Poole, UK) 
or by anti-Muc2.3 (1:1,000) for PSIM and pPGM, and anti-MUC2C3 (1:1,000) for 
MUC2, and anti-rabbit-HRP (1:10,000). For detection, 100 μL 
3,3’,5,5’-Tetramethylbenzidine (TMB) peroxidase substrate was added to the wells and 
the absorbance measured at 640 nm every 10 min for 1 h in a Benchmark PlusTM 
microplate spectrophotometer (Bio-Rad, Hercules, USA). 
2.4 Biophysics 
2.4.1 Isothermal titration calorimetry (ITC) 
To assess the binding of Mub proteins to sugar ligands, isothermal titration calorimetry 
(ITC) experiments were conducted in collaboration with David Bolam (Institute for Cell 
and Molecular Biosciences, Newcastle University, UK). Briefly, Man, Manα1-6Man and 
Manα1-3(Manα1-6)Man (10 mM) were titrated into MubR5 in 10 mM sodium phosphate 
buffer at 95 μM or in matching buffer control (25 injections at 25°C). 
2.4.2 Circular dichroism (CD) 
Circular dichroism (CD) experiments were carried out in a JASCO J-710 
spectropolarimeter (Great Dunmow, Cambs, UK) using a 0.1 mm split-cuvette. Purified 
proteins were transferred into ultrapure water and concentrated to 1 mg/mL and 4 or 10 
UV CD spectra per sample were accumulated and averaged over a scan range of 
180-260 nm at a scan speed of 20 nm/min with a band width of 1.0 nm and a response 
time of 4 sec. Data were manipulated including subtraction of blank spectra (ultrapure 
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water) using the JASCO Spectra Manager 32 v1.40.00a software (Easton, MD, USA) 
and the DichroWeb online tool (http://dichroweb.cryst.bbk.ac.uk) and CONTIN analysis 
program [330]. 
2.4.3 Analytical ultracentrifugation (AUC) 
Analytical ultracentrifugation experiments were performed using a Beckman XL-I 
analytical ultracentrifuge (Beckman Coulter, High Wycombe, UK) equipped with 
scanning absorbance and interference optics and an An50Ti rotor. Native MUB was 
freeze-dried directly after purification (see section 2.3.2), stored at -80°C and 
re-suspended in PBS, 0.1 M carbonate buffer (pH 9.8, 150 mM NaCl) and 10 mM 
citrate buffer (pH 4.6, 150 mM NaCl) at a final concentration of 0.1 mg/mL immediately 
prior sedimentation equilibrium experiments or in PBS for sedimentation velocity 
experiment. For sedimentation equilibrium experiments, five scans where recorded 
every four hours at 7,000 rpm and 20°C, and concentration profiles measured using 
absorbance optics at 280 nm. Sedimentation velocity experiments were recorded at 
35,000 rpm using interference optics.  
The partial specific volume of MUB was calculated from amino acid sequence using the 
program SEDNTERP [331] as 0.72 mL/g. Buffer densities were 1.0053 g/mL for PBS 
and 1.0055 g/mL for carbonate buffer. The program UltraScan [332] was used for AUC 
data analysis and fit. Sedimentation velocity data were analysed by a radial derivative 
(dC/dr) method to calculation of S(20,w) value. Sedimentation equilibrium profiles of 
MUB in carbonate buffer and PBS were fitted to a single component or an independent 
two component system, respectively. 
2.4.4 Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) experiments were performed in the temperature 
controlled DynaPro Protein Solutions DLS device (Wyatt Technology, Santa Barbara, 
USA) controlled by the DYNAMICS V5 software (Protein Solutions Inc., Charlottesville, 
USA) to investigate presence of aggregation in purified protein samples. Scattering 
data of MubR5, -RV, -RV-VI and MUB in PBS and Tris-HCl buffer and MubRI-II-III in 
PBS, 10 mM sodium phosphate buffer, 10 mM Tris-HCl, 10 mM Tris-HCl with 150 mM 
NaCl, 0.1 M carbonate buffer (pH 9.8, 150 mM NaCl) and 10 mM citrate buffer (pH 4.6, 
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150 mM NaCl) were collected at 100% laser intensity with an acquisition time of 10 sec 
and acquisition number of 10 at 25°C or 4°C. Data were analysed using the 
DYNAMICS V5 software package. 
2.5 Structural biology 
2.5.1 X-ray crystallography 
Protein crystallisation was performed via hanging or sitting drop vapour diffusion in 
24 or 96 well crystallisation trays (Molecular Dimensions, Newmarket, UK). Purified 
protein solutions in sodium phosphate or Tris-HCl buffer at 10 mg/mL (or 19 mg/mL for 
MubRI) (see 2.3.1), snap-frozen in liquid nitrogen and stored at -80°C, were thawed on 
ice immediately before crystallisation experiments, which were set-up using an 
Oryxnano crystallisation robot (Douglas Instruments, East Garston, Hungerford, UK) 
with a 1:1 ratio of protein to precipitant solution and a drop size of 0.5 μL. Three 
different crystallisation screens of 96 conditions were used in this study: Structure 
Screens 1 and 2, JCSG-plus Screens 1 and 2 (all Molecular Dimensions, Newmarket, 
UK), and PEG/Ion Screens 1 and 2 (Hampton Research, Aliso Viejo, USA) (see 
Appendix V). Crystallisation trays were incubated at at 16°C and 4°C and crystal 
growth was monitored using an Olympus SZX9 light microscope (2 or 1.5 objective 
lens) with a Highlight 2100 Olympus Europe light source (Southend-on-Sea, UK). 
Crystals were harvested and stored in liquid nitrogen until crystal diffraction data sets 
were collected at Diamond Light Source (Didcot, UK). 
2.5.1.1 Protein crystallisation 
MubRV was crystallised at a protein concentration of 10 mg/mL with a precipitant 
solution of 0.2 M ammonium acetate and 24% (w/v) PEG 3,350 at 16°C. Crystals were 
cryo-protected by adding 25% (v/v) DMSO to the reservoir solution. MubRI crystals 
were grown at a concentration of 18 mg/mL in 0.1 M HEPES (pH 7.5), 10% (v/v) 
2-propanol/ 20% (w/v) PEG (polyethylene glycol) 4,000 at 4°C, and crystals soaked in 
10 mM ytterbium or mercury chloride solution with 25% (v/v) ethylene glycol as 
cryoprotectant for multi-anomalous dispersion (MAD) data set collection. Lar0958 was 
crystallised at 12 mg/mL in 0.2 M ammonium sulphate, 0.1 M sodium acetate (pH 4.5) 
with 25% (w/v) PEG 4,000 or 30% (v/v) PEG 2,000 MME (monomethylether) at 4°C. 
Crystals were soaked with 0.5 M potassium bromide for single anomalous dispersion 
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(SAD) phasing, and soaked and native crystals cryo-protected with 20% (v/v) ethylene 
glycol.  
2.5.1.2 Crystal soaking and co-crystallisation studies 
Crystal soaking and co-crystallisation studies of MubR5 with fucose (Fuc), mannose 
(Man), galactose (Gal), N-aceytlgalactosamine (GalNAc), N-acetylglucosamine 
(GlcNAc), N-acetylneuraminic acid (Neu5Ac) and the disaccharide N-acetyllactosamine 
(LacNAc) were performed at a protein concentration of 8 mg/mL. For crystal soaking 
studies, single protein crystals were grown in 20% to 30% (w/v) PEG 3350 and 
0.2   Gal, GalNAc, GlcNAc, Neu5Ac and LacNAc solutions with 25% to 30% (w/v) PEG 
3350 as cryoprotectant and incubated for several minutes at sugar concentrations of 
1 mM to 500 mM dependening on the crystal stability in sugar solution. For 
co-crystallisation experiments, crystal structure screens were performed with LacNAc, 
Neu5Ac and Man at different sugar concentrations of 10 mM, 50 mM, 100 mM and 
200 mM and single crystals grown in 25% PEG 4000, 0.2 M magnesium chloride, 
0.1 M Tris (pH 8.5). 
2.5.1.3 X-ray data set analysis 
Integration and reduction of X-ray diffraction data from single crystals of MubR5, 
MubRI, MubRV and native Lar0958 was achieved using either a comination of 
MOSFLM [333] and SCALA [334] or by means of the Xia2 automated data reduction 
system [335]. Crystal diffraction data were analysed using the CCP4i [336] and 
PHENIX program suits [337].  
Model building was performed with the σ-weighted 2mFobs-DFcalc and mFobs-DFcalc 
Fourier electron density maps [338]. For structural validation, a Ramachandran 
analysis was performed to assess favoured, allowed or disallowed orientation of amino 
acids. The amino acid geometry was improved if possible according to the limits of the 
electron density maps. The solvent content of crystals was estimated according to 
Matthews, indicating the number of protein molecules in the asymmetric unit (ASU) 
[339]. 
Molecular replacement with MubR5 complexes, MubRI and MubRV data sets was 
performed with MOLREP [340] and PHASER [341] using the MubR5 structure as 
a serach model or a search model based on the MubR5 structure[340-341]. Alignment 
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models for MubRI or MubRV were generated after amino acid alignment with MubR5 
for MubRI and MubRV or with PEPE_0118 (PDB entry 3LYY) for MubRV using 
CHAINSAW via pruning of non-conserved residues [342]. For ligand identification in 
MubR5 data sets of crystal soaking or co-crystallisation, the COOT tool ‘unmodelled 
blobs’ [343] was used after initial refinement using REFMAC [344]. Model refinement 
and alternating manual model building was performed using RESOLVE and COOT 
[343, 345]. 
For space group validation of the MubRV data set, the programs LABELIT and 
ZANUDA were used [346]. 
Lar0958 data for crystals derivatised with KBr was integrated, reduced and intensities 
scaled using DENSO and SCALEPACK as part of HKL2000 [347]. Bromide atoms 
were located via AutoSol and initial SAD phasing performed by PHASER [341, 348]. 
A first molecular model was built by AUTOBUILD [348]. Manual model building in the 
molecular graphics program COOT [343] alternated with refinement using PHENIX 
[348].  
2.5.2 Small angle X-ray scattering (SAXS) studies 
2.5.2.1 SAXS data collection 
The scattering curves of MubR5, MubRV, MubRI, MubR8-V, MubRV-VI, and 
MubRI-II-III in Tris-HCl were recorded in a concentration range of ~0.6-9 mg/mL as 
10 10 sec frames at a wavelength of 0.93 Å and a sample-detector distance of 2.4 m 
covering the momentum transfer range of 0.04<s<0.61 Å-1 (s=4π sin (θ)/λ, where 2θ is 
the scattering angle and λ the wavelength) on the ID14-3 beamline, ESRF, Grenoble, 
France.  
Additionally, scattering curves of MubRI-II-III in sodium phosphate buffer and PBS, 
both supplemented with 2 mM DTT, and Nterm in Tris-HCl were recorded in 
a concentration range of ~0.5-5 mg/mL for MubRI-II-III and 0.6 to 9 mg/mL for Nterm 
as 10 10 sec frames at a wavelength of 0.99 Å and a sample-detector distance of 2.9 
m covering the momentum transfer range of 0.03<s<0.45 Å-1 on the BM29 beamline, 
ESRF, Grenoble, France. 
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2.5.2.2 SAXS data analysis 
The ATSAS (version 2.4) software was used for SAXS data analysis. Data were 
normalised subtracting the buffer scattering, scaled for concentration and data points 
across different concentrations were merged using PRIMUS [349]. The radius of 
gyration (Rg) and scattering at zero angle (I(0)) were calculated by Guinier 
approximation with Rgs ≤ 0.8 for elongated proteins (Mub-repeats) or with Rgs ≤ 1.0 for 
more globular proteins (Nterm), and the distance distribution function (P(r)) was 
generated by GNOM [350] computing the maximum particle diameter (Dmax) and an 
Rg value calculated for the whole scattering range. Ten ab initio shapes were 
reconstructed by GASPOR [351] or by DAMMIF (for MubRI-II-III only) and averaged by 
the DAMAVER program package [352], generating a Χ (Chi) value, a measure for the 
fit of the experimental data to the shape reconstruction, and a normalised spatial 
discrepancy (NSD), a measure for the agreement between computed shape models. 
Manual docking of the high-resolution X-ray structures of MubR5 (PDB entry 3I57) and 
MubRV (PDB entry 4MT5), into low-resolution shape reconstructions was performed 
using SCULPTOR (version 2.1) [353] and SITUS [354]. The refinement of the docking 
solution by SITUS calculated a cross correlation coefficient R, which allows quantitative 
evaluation of volumetric map and docked structure. The solution scattering of MubR5 
and -RV were computed from their atomic structures and fitted to the collected 
experimental scattering curves using CRYSOL [355]. The molecular weight of solutes 
was calculated by scaling against reference solutions of BSA providing information on 
the oligomeric state of the proteins in solution. 
2.6 Bioinformatics 
2.6.1 General data analysis 
For microtitre plate adhesion assays (see 2.3.6.4), pI determination by isoelectric 
focusing (see 2.3.4.3) and molecular weight determination by gel filtration or 
SDS-PAGE, data were analysis in Excel (Microsoft, Washington, USA). 
72 
 
2.6.2 Sequence analysis  
The ExPasy protein parameter tool (http://web.expasy.org/protparam/) was used to 
calculate the theoretical molecular weight, isoelectric point, protein extinction coefficient 
and Abs 0.1%, absorbance value from amino acid sequence of proteins.  
The multiple sequence alignment program ClustalW [356] was used for sequence 
alignment of DNA or protein molecules.  
2.6.3 Protein structure analysis 
Pairwise structural alignment of proteins was achieved using DaliLite [357] and was 
employed for protein structure comparison searching the Protein Data Bank (PDB) 
using the Dali server [358-359].  
The MarkUs function annotation server [360] was used to investigate structural, 
biophysical and functional properties of protein structure models. 
2.6.4 Crystal diffraction and SAXS data analysis 
Crystal diffraction data were analysed using the CCP4i [336] and PHENIX [337] 
program suites (see 2.5.1.3). For SAXS data analysis, the ATSAS (version 2.4) 
software was used (see 2.5.2.2). Final figures were made using the PyMOL Molecular 
Graphics System Version 1.5.0.4 Schrödinger, LLC. 
73 
 
CHAPTER 3 PURIFICATION AND BIOCHEMICAL 
CHARACTERISATION OF MUB PROTEINS AND 
NATIVE MUB 
The cell-surface mucus binding (MUB) protein of L. reuteri ATCC 53608 (also known 
as 1063), consists of 14 tandemly arranged Mub type repeats, Mub type 1 and 2, 
classed based on amino acid sequence. Mub type 1 repeats comprise MubRI, -RII,       
-RIII, -RIV, -RV and -RVI, and Mub type 2 repeats comprise MubR1, -R2, -R3, -R4,       
-R5, -R6, -R7 and -R8 (Figure 3.1) In addition, MUB contains an N-terminal domain 
adjacent to the first Mub repeat RI (see 1.4.2).  
 
 
Figure 3.1 Schematic representation of cell-surface anchored MUB and neighbour joining 
tree for Mub repeat sequences  
(A) Mub type 1 and type 2 repeats are coloured blue and green and numbered in Roman 
and Arabic, respectively. The N-terminal domain is shown in grey named Nterm. 
(B) Phylogeny tree calculated by JALVIEW [361] based on percentage identity of aligned 
Mub repeat sequences (repeats R2, R4, and R6, as well as R3 and R5 are identical). 
The Mub type 2 repeats (184 residues) show high sequence identity between 84 and 
100% (for sequence alignment and alignment scores see Appendix IV). In contrast, the 
Mub type 1 repeats (183-206 residues) are more diverse with sequence identities 
ranging from 29% for RIV and RV to 88% for RI and RII. The lowest similarity (24%) 
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between a type 1 repeat and type 2 repeats was observed for RVI and R5 (R3 and R1 
being identical or nearly identical) (for Mub domain borders see Appendix II). 
In order to obtain structural information on MUB protein domains and to investigate 
their functional role in the adhesion to mucin and mucin glycans, recombinant MUB 
proteins of individual or tandem Mub repeats were cloned, expressed and purified, and 
native MUB isolated and purified from L. reuteri ATCC 53608 culture media.  
3.1 Cloning, heterologous expression and purification of MUB proteins 
3.1.1 Mub type 1 and 2 repeat proteins 
For characterisation studies of different Mub repeat proteins, the single type 2 repeat 
MubR5, the single type 1 repeats MubRI and -RV, the Mub type 1 double repeat 
MubRV-VI, the mixed type double repeat MubR8-V and the type 1 triple repeat 
MubRI-II-III, were cloned and the recombinant proteins heterologously expressed in 
E. coli (Figure 3.2).  
 
 
Figure 3.2 Schematic representation of MUB with recombinant MUB proteins 
Mub type 1 and type 2 repeats are coloured blue and green, and numbered in Roman and 
Arabic, respectively. The N-terminal domain is shown in grey named Nterm. Recombinant 
Mub repeat and Nterm proteins indicated by brackets.  
Vector constructs encoding MubR5, MubRI and MubRI-II-III were already available at 
the beginning of this study and the cloning of the remaining MUB proteins was 
performed following the same approach. Briefly, oligonucleotide primers for the Mub 
repeat genes mubR5, mubRI, mubRV, mubRV-VI, mubR8-V and mubRI-II-III were 
designed to anneal to specific Mub repeat border regions within the mucus-binding 
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protein gene of L. reuteri  ATCC 53608 (American Type Culture Collection). The 
borders of individual Mub repeats were determined by comparative multiple sequence 
alignments of MUB protein domains from different Lactobacillus and Lactococcus 
species [304]. The so defined Mub repeat boundaries are different from those 
described for the GenBank accession number AF120104 (see Appendix II). 
Genes were amplified by PCR (see 2.2.1) from washed bacterial cells, cloned into the 
pETBlue-1 AccepTor vector (see 2.2.4) and sequence integrity verified by automated 
DNA sequencing (see 2.2.6). The recombinant vectors carrying the mub repeat genes 
were used to transform E. coli Tuner(DE3)pLacI2 cells for protein expression. MubR5, 
MubRI, MubRV, MubRV-VI and MubRI-II-III recombinant proteins were produced in 
a soluble form at 37°C and MubR8-V at 30°C after induction with 1 mM 
β-D-1-thiogalactopyranoside (IPTG) (see 2.3.1.1), as demonstrated below by 
SDS-PAGE analysis (Figure 3.3 to 3.8).  
Owing to their small size, the single Mub repeat proteins, MubR5, -RI and –RV, were 
extracted via freeze-thaw method, to avoid cell disruption and reduce the 
contamination by host proteins in the clarified crude extract (see 2.3.1.2). After an initial 
purification step via ion exchange chromatography (IEC), all three single Mub proteins 
showed high sample homogeneity (Figure 3.3 A and B, 3.4 A and B, and 3.5 A and C). 
Two major elution peaks were present in the IEC chromatogram of MubR5 
(Figure 3.3 A). For both peaks only a single distinct protein band with an apparent 
molecular weight (MW) of about 22 kDa was observed on the Coomassie stained 
SDS-PAGE gel (Figure 3.3 B), which is slightly higher than the calculated MW of 
MubR5 of 20.5 kDa (calculated with ExPasy ProtParam tool, see 2.6.2). 
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Figure 3.3 Purification of MubR5 by IEC and SEC 
(A) IEC profile of MubR5 and (B) SDS-PAGE analysis (NuPAGE 4-12% gel) of MubR5 
elution fractions (1-4) (as indicated in A). (D) SEC elution profile and (C) SDS-PAGE 
analysis (RunBlue 12% gel) of MubR5 elution fractions (as indicated in D) (1 sample before 
injection, 2-8 elution fractions).  
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The elution of MubR5 in two distinct peaks is an artefact due to injection of 22 mL 
highly concentrated sample solution onto the IEC column. Nevertheless, both peak 
samples were further examined for their protein properties by circular dichroism (CD) 
and isoelectric focusing (IEF) before use in structural studies (see 3.2). In order to 
investigate potential differences of the two IEC peaks of MubR5, to assess its 
oligomeric state in solution and to reduce the presence of potential protein aggregation, 
MubR5 was further purified by size exclusion chromatography (SEC) (see 2.3.1.3). 
A single elution peak was observed for MubR5 when both IEC peak fractions were 
tested separately or combined at an elution volume of 67.5 mL corresponding to a MW 
of about 28.8 kDa (Figure 3.3 D), suggesting no major difference in protein properties 
between MubR5 of both IEC elution peaks. The SEC column calibration, which was 
performed with standard globular calibration proteins (see 2.3.1.3), indicated 
a considerably higher observed MW for MubR5 compared to its theoretical MW 
(20.5 kDa), which may be explained by the elongated shape of MubR5 as observed in 
the X-ray crystal structure [282].  
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Figure 3.4 Purification of MubRI by IEC and SEC  
(A) IEC profile of MubRI and (B) SDS-PAGE analysis of MubRI peak elution fractions (as 
indicated in A) (1-3). (C) SDS-PAGE analysis of pooled SEC elution fractions (elution profile 
not shown) and (D) Western-blot membrane incubated with primary anti-MubRI and 
secondary anti-rabbit-AP.  
For MubRI and MubRV only single elution peaks were observed by IEC (Figure 3.4 and 
3.5, A) containing a single protein with apparent MW of about 28 and 27 kDa, 
respectivley, as demonstrated by SDS-PAGE analysis (Figure 3.4 and 3.5, B). The 
apparent MW observed for the recombinant proteins were higher compared to the 
calculated MW of 21.3 and 20.3 kDa for MubRI and MubRV, respectively (see 2.6.2). 
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Figure 3.5 Purification of MubRV by IEC and SEC  
(A) IEC profile of MubRV, (B) SDS-PAGE analysis (RunBlue 12% gel) of MubRV peak 
elution fractions as indicated in A) (1 pellet, 2 crude extract, 3-8 peak fractions). (E) SEC 
elution profile, (C) SDS-PAGE analysis of MubRV peak elution fractions (as indicated in E) 
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(1 injection sample, 2-8 peak elution fractions) and (D) Western-blot membrane incubated 
with primary anti-MubRI and anti-MubR5 followed by anti-rabbit-AP. 
Despite high sample homogeneity, MubRI and MubRV were further purified by SEC for 
structural studies (Figure 3.4 C and D, and 3.5 C to E). Both proteins eluted in a single 
peak at an elution volume of 64.0 mL for MubRI (data not shown) and 73.0 mL for 
MubRV (Figure 3.5 E), corresponding to MW of 35.7 kDa and 31.6 kDa, respectively. 
The MubRI and MubRV protein bands showed reactivity with anti-MubRI and 
anti-MubR5 after Western-blotting (Figure 3.4 and 3.5, D). 
The double Mub-repeat proteins, MubR8-V and MubRV-VI, were extracted via 
freeze-thaw method (see 2.3.1.2) and purified via IEC (Figure 3.6 and 3.7, A). 
SDS-PAGE analysis of IEC elution fractions revealed sample heterogeneity (Figure 3.6 
and 3.7, B). The predominant protein bands of MubR8-V and MubRV-VI with apparent 
MW of about 53 and 55 kDa, respectively, showed reactivity with anti-MubRI and 
anti MubRV after Western-blotting (data not shown). As observed before for the single 
Mub repeats, the recombinant proteins showed higher apparent MW compared to the 
calculated MW of MubR8-V and MubRV-VI of 40.6 kDa and 43.1 kDa, respectively 
(see 2.6.2).  
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Figure 3.6 Purification of MubR8-V by IEC and SEC  
(A) IEC profile of MubR8-V and (B) SDS-PAGE analysis (NuPAGE 4-12 % gel) of peak 
elution fractions (as indicated in A) (1 pellet, 2 crude extract, 3-8 elution fractions). (D) SEC 
elution profile and (C) SDS-PAGE analysis (RunBlue 12% gel) of peak elution fractions (as 
indicated in D) (1-3 elution fractions). 
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IEC elution fractions containing high target protein content and least contaminating 
proteins were pooled and the double repeat proteins were further purified by SEC. 
MubR8-V and MubRV-VI showed main elution peaks at an elution volume of 54.3 mL 
corresponding to a MW of about 64.9 kDa, which is higher than their calculated MW 
and in line with observations made for single Mub repeats as described above (Figure 
3.6 and 3.7, D). SEC resulted in sufficient sample homogeneity of MubR8-V and 
MubRV-VI for characterisation and binding studies as demonstrated by SDS-PAGE 
analysis (Figure 3.6 and 3.7, C). 
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Figure 3.7 Purification of MubRV-VI by IEC and SEC 
(A) IEC profile of MubRV-VI and (B) SDS-PAGE analysis of MubRV-VI elution fractions (as 
indicated in A) (1 pellet, 2 crude extract, 3-7 elution fractions). (D) SEC elution profile and 
(C) SDS-PAGE analysis of peak elution fractions (as indicated in D) (1-7 elution fractions). 
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Due to its higher MW, the triple Mub type 1 repeat protein MubRI-II-III was extracted 
from the bacterial cell pellet by ultrasonication (see 2.3.1.2). The triple repeat protein 
was first purified from clarified extract by IEC (Figure 3.8 A) and eluted in heterogenous 
elution fractions as shown by SDS-PAGE (Figure 3.8 B). A predominant protein band 
was observed at an apparent MW of about 77 kDa, which is again higher than the 
theoretical MW of MubRI-II-III of 64 kDa based on amino acid sequence (see 2.6.2). To 
achieve higher purity, MubRI-II-III elution fractions were pooled and applied onto a SEC 
column. Two elution peaks showed with elution volumes of 62.6 mL and 73.8 mL 
corresponding to MW of 162.4 kDa and 71.8 kDa, respectively (Figure 3.8 D). Samples 
of both peaks showed apparent MW of about 77 kDa and 32 kDa, suggesting that the 
triple domain elutes in the first predominant peak probably as a dimer. The 77 kDa 
MubRI-II-III protein showed strong reactivity with the anti-MubRI after Western-blotting, 
but interestingly weak signals were also observed for the lower MW proteins in the 
second elution peak (Figure 3.8 C). Both protein species were further analysed by 
mass spectrometry (MS) (with the help of Fran Mulholland, Institute of Food Research, 
Norwich, UK) after trypsin digest for peptide mass fingerprint analysis, which confirmed 
that the high MW protein contained the three Mub repeats RI, RII and RIII, whereas the 
lower MW protein is a truncated version of the triple domain proteins only comprising 
the first two repeats RI and RII. 
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Figure 3.8 Purification of MubRI-II-III by IEC and SEC 
(A) IEC profile of MubRI-II-III and (B) SDS-PAGE analysis (NuPAGE 4-12 % gel) of peak 
elution fractions (as indicated in A) (1 pellet, 2 crude extract, 2-8 elution fractions. (E) SEC 
elution profile, (C) SDS-PAGE analysis (RunBlue 12 % gel) of main peak elution fractions 
(as indicated in E) (1-5 main peak elution fractions, 6+7 second elution peak fractions) and 
(D) Western-blot membrane incubated with anti-MubRI and anti-rabbit-HRP. 
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To summarise, all Mub-repeat proteins were successfully purified by IEC and SEC to 
homogeneity. For all Mub-repeat proteins an elevated apparent MW was observed 
upon SDS-PAGE and by SEC, possibly due to an elongated, non-globular protein fold. 
Protein yields varied between the different Mub repeats and were calculated as protein 
per wet cell weight with 2.4 mg/g for MubR5, 2.2 mg/g for MubRV, 1.8 mg/g for MubRI, 
3.5 mg/g for MubR8-V, 1.5 mg/g for MubRV-VI and for 0.28 mg/g MubRI-II-III (see 
3.1.2, Table 3.1). 
3.1.2 His6-tagged N-terminal MUB domain constructs 
The N-terminal domain gene (nterm) of MUB is located between the signal sequence, 
which facilitates MUB protein transport to the bacterial cell wall, and the first Mub 
repeat gene mubRI (GenBank accession number AF120104) (Figure 3.2). Primers 
were designed, that shared sequence homology to nterm alone or nterm and mubRI 
(ntermmubRI), as well as to the pOPINF target vector. This allowed homologues 
recombination dependent cloning of targets genes into the pOPINF vector, which 
encodes an N-terminal His6-tag, using the InFusion cloning system (see 2.2.4) [329]. 
The pOPINF vectors coding for nterm and ntermmubRI were successfully cloned into 
E. coli BL21(DE) (see 2.2.4).  
Both His6-tagged proteins, Nterm and NtermMubRI, were expressed in a soluble form 
at 37°C after induction with 1 mM IPTG and extracted from the bacterial cell pellet 
using BugBuster HT (see 2.3.1.1 and 2.3.1.2) (Figure 3.9 and 3.10, B). The clarified 
extracts were loaded directly onto an immobilised metal affinity chromatography 
(IMAC) column and the His6-tag facilitated specific protein purification and elution with 
imidazole (see 2.3.1.3).  
For IMAC elution fractions of Nterm, a predominant band at an apparent MW of about 
84 kDa was observed on SDS-PAGE analysis (Figure 3.9 A and B), which was higher 
than the calculated MW of 56.3 kDa (see 2.6.2). The band showed reactivity with 
anti-His5 after Western-blotting (Figure 3.9 C). The IMAC elution fractions contained 
a high number of host proteins (Figure 3.9 B) and Nterm was therefore further purified 
by SEC to obtain sample of sufficient homogeneity (Figure 3.9 D and E). The Nterm 
protein eluted at an elution volume of 73.3 mL corresponding to a MW of about 
74.2 kDa.  
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Figure 3.9 Purification of Nterm by IMAC and SEC  
(A) IMAC elution profile of Nterm, (B) SDS-PAGE analysis of elution fractions (as indicated 
in A) (1 pellet, 2 crude extract and lanes 3-11 elution fractions) and (C) Western-blot 
membrane incubated with primary anti-His5 and secondary anti-mouse-HRP. (D) SEC 
elution profile and (E) SDS-PAGE analysis of elution fractions (as indicated in D) (1 sample 
before SEC, 2-8 peak elution fractions). 
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NtermMubRI was purified by gravity flow using an IMAC resin column (see 2.3.1.3). 
SDS-PAGE analysis of protein elution fractions showed a predominant protein band at 
an apparent MW of about 109 kDa (Figure 3.10 A), for which reactivity with anti-His5 
was observed (data not shown). The calculated MW for NtermMubRI from amino acid 
sequence including the N-terminal His6-tag is 77.4 kDa and is thus much lower than the 
apparent MW of the recombinant NtermMubRI protein as observed for the recombinant 
Mub repeat proteins and Nterm (see 3.1.1).  
 
 
Figure 3.10 Purification of NtermMubRI by IMAC and SEC 
(A) SDS-PAGE analysis of NtermMubRI elution fractions after IMAC (1 pellet, 2 crude 
extract, 3 flow through, 4 wash and 5-10 elution fractions). (C) SEC elution profile and (B) 
SDS-PAGE analysis of main peak elution fractions (as indiacted in C) (1-5 elution fractions).  
To purify NtermMubRI further, IMAC fractions were pooled, dialysed into gel filtration 
buffer and applied to a SEC column (Figure 3.10 C). One main elution peak was 
obtained corresponding to a MW of about 96 kDa (84 mL elution volume) (Figure 
3.10 C).  
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Mub repeat 
Theoretical MW 
[kDa] 
Apparent MWa 
[kDa] 
Observed MWb 
[kDa] 
Purification 
yield [mg/g] 
MubR5 20.5 22 28.8 2.4 
MubRI 21.3 28 35.7 1.8 
MubRV 20.3 27 31.6 2.2 
MubR8-V  40.6 53 64.9 3.5 
MubRV-VI 43.1 55 64.9 1.5 
MubRI-II-III 64 77 162.4 0.28 
Nterm 56.3 84 74.5 1.1 
NtermRI 77.4 109 95.9 0.5 
Table 3.1 Purification characteristics of MUB proteins 
aapparent MW upon SDS PAGE 
bobserved MW by SEC  
 
The protein yield of NtermMubRI was 0.5 mg protein per g wet cell weight compared to 
1.1 mg/g for Nterm (Table 3.1). Proteolytic degradation of NtermMubRI after storage in 
Tris-HCl (pH 7.5) and PBS (pH 7.4) for 28 days at 4°C was observed by SDS-PAGE 
(data not shown). MS analysis of Nterm and NtermMubRI after trypsin digest confirmed 
the nature of the recombinant proteins and the degradation of NtermMubRI (performed 
in collaboration with Fran Mulholland, Institute of Food Research, Norwich, UK) (data 
not shown). Due to low protein yield and proteolytic degradation, NtermMubRI was not 
used in structural or follow-up functional studies. 
3.2 Structural and biophysical properties of MUB proteins 
In order to verify proper protein folding and to obtain some initial structural information 
on the secondary structural elements of recombinant purified MUB proteins, circular 
dichroism (CD) experiments were performed. In addition, isoelectric point (pI) 
determination was conducted by isoelectric focusing (IEF) to determine the net charge 
of MUB proteins in experimental buffer solutions. 
Structural elements such as β-sheets and α-helices give defined signatures in the CD 
spectrum and help to detect unfolding of protein. Wavelength scans of 180 to 260 nm 
were performed with MubR5 (peak 1 and 2, see 3.1.1), -RV, -RI, -R8-V, -RV-VI,              
-RI-II-III and Nterm (MubRI and –RI-II-III spectra kindly provided by Donald MacKenzie, 
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IFR, Norwich, UK) in ultrapure water (see 2.4.2). After subtraction of water blank, 
recorded spectra were plotted as the molar CD against the wavelength (Figure 3.11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Secondary structure determination of Mub proteins by circular dichroism (CD) 
Far UV CD spectra of purified Mub-repeat proteins (RV light blue, R5 light green, RI red, 
RV-VI dark blue, R8-V dark green, RI-II-III black) and Nterm (black dotted) were collected 
over a scan range of 180-260 nm. Insert: UV spectra of MubR5 IEF elution peak 1 (light 
green) and peak 2 (light green, dotted). 
All tested Mub repeats showed similar far UV CD spectra suggesting a highly similar 
overall protein solution structure (Figure 3.11). In contrast, the UV spectra of the Nterm 
protein differed significantly, indicating a divergent protein shape in solution. The 
spectra for the two IEC elution peaks of MubR5 (see 3.1.1) were nearly identical, 
hence a uniform solution structure can be assumed further suggesting that there is no 
difference between MubR5 of both peaks (Figure 3.11 inset). All sample spectra were 
further analysed via DichroWeb using the CONTIN analysis program with the reference 
data set 3 (see 2.4.2). A similar proportion of secondary structural elements was 
observed for all analysed Mub repeats consisting of 38.7 to 46.4% β-sheets and 21.1 to 
28.5% β-turns (Table 3.2). The percentage of helix was very low with only up to 1.5% 
for MubRI-II-III. In contrast, for Nterm a helix percentage of 6.2% and a total 
percentage of 56.2% β-sheets and -turns were calculated. 
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sample ɑ-helix [%] β-sheets [%] β-turns [%] 
β-sheets and 
β-turns [%] 
unordered 
Nterm 6.2 33.1 23.1 56.2 37.6 
MubR5 0.3 (6.0)a 38.7 (45.9)a 21.1 64.8 34.9 
MubRI 1.0 44.2 22.2 66.4 32.6 
MubRV 1.2 (5.4)a 46.4 (46.7)a 24.4 70.8 28.1 
MubR8-V  0.0 42.5 25.0 67.5 32.5 
MubRV-VI 0.0 39.4 28.5 67.9 32.1 
MubRI-II-III 1.5 42.0 22.4 64.4 34.1 
Table 3.2 Proportion of secondary structural elements in Mub repeats by CD (and after 
X-ray crystal structure determination)a 
 
For further characterisation of Mub repeats, IEF experiments were undertaken by gel 
electrophoresis in a pH range of pH 3 to 7 and a voltage gradient (see 2.3.4.3). The pI 
value of purified MubR5 (peak 1 and 2), -RV, -R8-V and –RV-VI was determined 
compared to an IEF standard (Figure 3.12). Theoretical pI values were calculated from 
amino acid sequence using the ExPASY online tool (Figure 3.12 A and B) (see 2.6.2). 
Both IEC elution peaks of MubR5 showed an identical pI value of 4.43, which was 
similar to its theoretical pI of 4.54, further supporting that there is no difference in 
MubR5 properties of the two elution peaks as also demonstrated by SEC and CD 
analysis (see 3.3.1). For MubRV, -R8-V, -RV-VI and Nterm, pI values were determined 
as 4.53, 4.67, 4.54 and 4.60, and were all in good agreement with theoretical values 
(Figure 3.12 C). 
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sample Theoretical pI Observed pI 
MubR5 4.54 4.43 
MubRV 4.67 4.53 
MubR8-V 4.67 4.67 
MubRV-VI 4.65 4.54 
Nterm 4.83 4.60 
 
Figure 3.12 pI determination of Mub repeats by IEF 
IEF PAGE of (A) MubRV, MubR8-V, MubRV-VI, Nterm (1 and 1+ MubRV; 2 and 2+ 
MubR8-V; 3 and 3+ MubRV-VI; 4 and 4+ Nterm) and (B) MubR5 (two elution peaks) (1 and 
1+ MubR5 peak1; 2 and 2+ MubR5 peak 2). (C) Observed pI values determined in 
comparison to IEF marker by linear regression and theorectical pI values calculated from 
amino acid sequence using the ExPasy online tool (see 2.6.2). 
All tested MUB proteins showed pI values between 4.5 and 4.7 and thus have a net 
negative charge in the standard buffers used in this study (see 2.1.1).  
 
C 
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3.3 Purification and characterisation of native MUB 
In order to obtain biochemical information on the native MUB protein and to study 
interaction of the full-length MUB comprising all 14 Mub repeats and the N-terminal 
domain with potential ligands, we isolated MUB from a L. reuteri ATCC 53608 culture. 
3.3.1 MUB purification 
The full length native MUB protein is generally covalently attached to the bacterial 
cell-wall component peptidoglycan via its LPXTG-motif (with X being Q, see GenBank 
entry AF120104) (see 1.4.2), but under in vitro conditions it is also found in lower 
amounts in the bacterial culture media. The mechanism by which it is released from the 
cell surface remains elusive.  
We developed a method to purify the native mature MUB (353 kDa) from the spent 
media of a L. reuteri ATCC 53608 culture via a multi-step process (see 2.3.2). Briefly, 
after growth of bacteria in LDMII media at 37°C (see 2.1.4), the culture media was 
separated from bacterial cells and extensively filtered. The media extract was 
concentrated and then applied to a SEC for separation of MUB from secreted bacterial 
proteins (see 2.3.2).  
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Figure 3.13 Purification of native MUB by SEC 
(A) SEC purification profile of native MUB protein and (B) SDS-PAGE analysis of MUB 
elution fractions (as indicated in A) (1 bacterial pellet, 2 concentrated media extract, 3-11 
MUB elution fractions). (C) Western-blot membrane incubated with primary anti-MubRI and 
anti-MubR5, and secondary anti-rabbit-HRP (1 bacterial pellet, 2 concentrated media 
extract, 3-11 MUB elution fractions). 
The SEC chromatogram of MUB showed a single, broad elution peak (Figure 3.13 A). 
SDS-PAGE analysis of the peak elution fractions revealed the presence of a single 
high MW protein band with an apparent MW of about 396 kDa in the early elution 
fractions (Figure 3.13 B). The theoretical MW of the mature MUB exclusive of the cell 
wall anchoring motif was determined to be 353 kDa (see 2.6.2). The protein band 
reacted with anti-MubR5 and anti-MubRI as demonstrated after Western blotting 
(Figure 3.13 C). The elution of MUB within the void volume of the column suggests the 
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formation of oligomers or aggregates, which was observed earlier by Roos and 
Johnsson [283]. 
3.3.2 MUB characterisation  
After successful purification of native MUB (see 3.3.1), peptides of pooled elution 
fractions were initially analysed by MS (in collaboration with Fran Mulholland, Insititue 
of Food Research, Norwich, UK). Briefly, MUB was separated by SDS-PAGE and the 
predominant MUB band at about 396 kDa and the fainter protein band above the 
500 kDa protein standard band were treated with trypsin before MS analysis 
(Figure 3.14). 
 
 
Figure 3.14 SDS-PAGE of MUB before trypsin digest and MS analysis 
Separation of purified MUB by SDS-PAGE for trypsin digest and MS analysis of stained 
protein bands 1 and 2.  
For the 396 kDa band of MUB, that showed reactivity with anti-MubRI and anti-MubR5 
(Figure 3.14) (see 3.3.1), nearly exclusively MUB protein peptides, 243 in total of which 
131 were non-duplicates, were identified with a high abundance (score 3176) 
compared to potential contaminants (score 24). The peptides covered 94.5% of the full 
length MUB amino acid sequence including the N-terminal methionine (Met) and the 
MW of MUB was estimated with 358 kDa. No protein peptides were identified for the 
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last 168 residues at the C-terminus of the protein including the LPQTG-anchor motif, 
which may explain its presence in the culture media (see 3.3.1). In addition, MUB 
protein peptides (13 non-duplicates) were present in the second higher MW band in 
low abundance (score 78) amongst peptides from three additional proteins including 
a putative glycosyltransferase.  
3.3.2.1 MUB characterisation by native PAGE and AUC 
Purified MUB showed a higher apparent MW compared to its calculated size and SEC 
suggested the formation of MUB oligomers or aggregates (see 3.3.1). In order to 
address this matter, different MUB purification samples in PBS were analysed by 
non-denaturing native PAGE using Tris-glycine buffer (see 2.3.4.1).  
 
 
Figure 3.15 MUB analysis by native PAGE 
(A) Native PAGE analysis of MUB samples of different purification runs (1-5) (singals in 
black) and (B) Western-blot membrane incubated with primary anti-MubRI and anti-MubR5, 
and secondary anti-rabbit-AP (signals in purple, blue background signal derived from 
Colloidal blue stained native PAGE gel).  
No distinct protein bands could be detected on the stained protein gel (see 2.3.4.4) for 
all tested MUB samples (Figure 3.15 A). In contrast, strongly stained smears were 
observed between the 1048 and 720 kDa marker band and above 242 kDa. 
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Anti-MubR5 and anti-MubRI were used for specific MUB detection after 
Western-blotting and showed only reactivity for protein components above 720 kDa up 
to 1236 kDa (Figure 3.15 B). Hence, MUB seems to be present in different oligomeric 
MW species under the experimental conditions, forming at least a trimer and possibly 
higher oligomers. 
In order to further investigate the association and shape of MUB in solution, analytical 
ultracentrifugation (AUC) experiments were performed in collaboration with Tom Clarke 
(University of East Anglia, Norwich, UK). For sedimentation equilibrium (SE) 
experiments, purified and freeze-dried MUB was resuspended in PBS, carbonate or 
citrate buffer (see 2.4.3). Data scans were recorded for all three conditions, but only 
data for MUB in PBS and carbonate buffer were of sufficient quality for analysis by 
UltraScan [332] (see 2.4.3).  
 
 
Figure 3.16 Sedimentation equilibrium data fits of MUB 
AUC sedimentation equilibrium data of MUB (triangle) in PBS (A) and carbonate buffer (B) 
and data fits (black line) to 2 component and 1 component system, respectively. 
The data of MUB in PBS were fitted to a two component system with protein species of 
160 kDa and 1050 kDa (Figure 3.16 A). In contrast, data for MUB in carbonate buffer 
was fitted to a one component system with a MW of 250 kDa (Figure 3.16 B). The AUC 
observations suggested MUB oligomerisation, which seemed to be condition-
A B 
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dependent and only occurring in standard PBS at pH 7.4 (see 2.1.1). These findings 
are in line with the native PAGE results described above. The size of the lower MW 
components observed in PBS and carbonate buffer was significantly lower than the 
theoretical MW of the 353 kDa MUB, which may indicate protein degradation in these 
buffer systems or after freeze-drying. MS analysis of MUB in PBS however suggested 
a MW coverage of about 358 kDa (94.9%) (see 3.3.2). Sedimentation velocity 
experiments were conducted with MUB in PBS. The radial displacement profiles of 
different scan intervals, where the interference fringes are plotted against the distance 
from the rotor centre, showed elongated tails at higher rotor distance till a plateau was 
reached (see Appendix VI). This AUC profile is characteristic for higher hydrodynamic 
friction caused by an elongated molecule shape. In addition, a smaller sedimentation 
coefficient (S) was observed compared to a globular protein of the same MW. For 
MUB, the sedimentation coefficient, as calculated by a radial derivative (dC/dr) method 
was 5.7S (see Appendix VI). For comparison, Fibrinogen, a 340 kDa plasma protein, 
showing a coiled extended fold of 46 nm after X-ray crystallography [362], presents 
a sedimentation value of 7.9S [363]. 
3.3.2.2 MUB detection by lectins 
Protein glycosylation is a common post-translational modification known in eukarya, 
and has recently been shown to occur in bacteria and archaea [364-365]. Bacterial 
glycosylation has been described for pathogenic bacteria but glycosylated proteins 
have recently been identified in Lactobacillus species [366-368]. However, the 
glycosylation pattern and the functional characterisation of lactobacilli glycoproteins 
remain elusive.  
Glycosylated proteins are characterised by an aberrant migration pattern upon 
SDS-PAGE with a higher observed MW compared to the theoretical value based on 
amino acid sequence. In order to investigate the potential glycosylation pattern of 
native MUB isolated from L. reuteri, lectin detection experiments were performed. 
Briefly, increasing amounts of MUB from two independent purifications were 
slot-blotted onto nitrocellulose and probed with fluorescein isothiocyanate (FITC) 
labelled lectins f-RCA, f-WGA, f-SNA and f-UEA possessing different sugar specificities 
(Table 3.3).  
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Lectin Abbrevation Sugar specificitya 
Ricinis communis agglutinin 
I  
RCA Gal 
Wheat germ agglutinin  WGA GlcNAc, sialylated 
proteins Sambucus nigra agglutinin  SNA α2-6 sial c acid 
Ulex europaeus agglutinin  UEA α-Fuc 
Table 3.3 Sugar specificity of used lectins 
aGalactose (Gal), N-acetylgalactosamine (GalNAc), N-acetlyglucosamine (GlcNAc), 
and Fucose (Fuc) 
 
In a first experiment, positive signals were only detected for MUB probed with f-SNA 
compared to a PBS control (Figure 3.17). Fluorescence signal intensities were 
semi-quantitatively determined from slot blot membranes and demonstrated 
a dose-dependent interaction of MUB with the lectin. SNA binds to α2-6 sialic acid 
attached to terminal Gal, and to a weaker extent to α2-3 sialic acid.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Detection of MUB (purification batch 1) via lectins 
(A) Slot-blot of purified native MUB probed with FITC labelled f-SNA, f-RCA, f-WGA and 
f-UEA (signals in black), or incubated with via anti-MubRI and anti-MubR5 followed by anti-
rabbit-HRP performed as a control (signals in white). (B) Presentation of quantified 
fluorescence signals as an average of 5 counts per concentration with standard deviations 
(blue: f-SNA, blue stripes: f-RCA, blue dots: f-WGA and white: f-UEA).  
f-WGA 
f-UEA 
anti-
MubRI/ R5 
f-SNA  
f-RCA 
MUB 
[μg] 0.25 0.5 8 1 4 0 2 
A B 
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MUB purified from a different L. reuteri ATCC 53608 culture was repeatedly tested for 
its interaction with f-SNA, f-RCA, f-WGA and f-UEA, as described above. MUB showed 
equally strong reactivity with f-SNA and f-WGA, and weaker interaction with f-RCA 
(Figure 3.18) compared to a PBS only negative control. The receptor sugar for WGA is 
GlcNAc, although interaction with sialylated glycoproteins has also been reported. RCA 
binds to terminal Gal residues. 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Detection of MUB (purification batch 2) by lectins 
(A) Slot-blot of purified native MUB probed with FITC labelled f-SNA, f-RCA, f-WGA and 
f-UEA (signals in black), or incubated with anti-MubRI and anti-MubR5 followed by 
anti-rabbit-HRP performed as a control (signals in white). (B) Presentation of quantified 
fluorescence signals as an average of 5 counts per concentration with standard deviations 
(blue: f-SNA, blue stripes: f-RCA, blue dots: f-WGA and white: f-UEA).  
In summary, native MUB showed reactivity with f-SNA, f-WGA and to a lesser extent 
with f-RCA, suggesting the presence of sialic acid, GlcNAc or Gal residues in the 
purified MUB sample. While the reactivity with f-SNA is reproducible for MUB of 
different purifications, the reactivity of f-WGA and f-RCA seemed to be 
batch-dependent. 
  
A 
f-WGA 
f-UEA 
anti- 
MubRI /R5 
f-SNA  
f-RCA 
MUB 
[μg] 0.25 0.5 8 1 4 0 2 
B 
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3.4 Discussion  
Structural information on MUB is restricted to the X-ray crystal structure for the type 2 
MubR5 repeat, providing the first structure of a mucin-binding protein (MucBP) domain 
[282]. We demonstrated the contribution of the cell surface protein MUB of L. reuteri 
ATCC 53068 in the interaction of bacterial cells to the host mucus layer in the GI tract 
[302]. However, the underlying biochemical binding mechanism and the specificity to 
ligands remain elusive.  
In order to obtain further structural information on different MUB proteins, investigate 
the domain organisation of MUB and characterise MUB protein-ligand interaction, we 
successfully cloned, expressed and purified the single type 1 Mub repeats, MubRI and 
MubRV, the type 2 repeat MubR5, the double mixed or type 1 repeat proteins, 
MubR8-V and MubRV-VI, the triple Mub type 1 repeat MubRI-II-III and the N-terminal 
domain proteins, Nterm and NtermMubRI (see 3.1). All recombinant Mub repeat 
proteins showed a higher apparent MW upon SEC compared to their theoretical MW. 
These observations suggest an elongated protein shape and thus a similar protein fold 
of all Mub repeats. CD analysis of MUB proteins demonstrated similar overall 
secondary structure composition of Mub repeats displaying a high β-sheet content and 
a very low α-helix content (see 3.2). MubR5 forms an elongated rod mainly composed 
of β-sheets with a single short helix when crystallised (see 1.5). In contrast, the 
secondary structure analysis of the Nterm protein after CD analysis suggested 
a divergent fold and secondary structural element composition with a higher α-helix 
content (see 3.2).  
Additionally, we developed a purification protocol to isolate the native full-length MUB 
from culture media (see 3.3.1). The surface-associated MUB protein carries an 
LPXTG-motif, which is recognised by an extracellular sortase, a surface peptidase that 
cleaves between threonine and glycine residues and covalently attaches MUB to 
cell-wall peptidoglycan [225]. Besides its surface location, MUB is also released into 
the medium under in vitro culture conditions by a yet unknown mechanism. Surface-
associated proteins possessing a signal peptide but no surface-retention domains are 
found in the external culture media [369-370]. The MS analysis of the MUB protein may 
suggest that the C-terminal protein region containing the anchoring motif is absent in 
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MUB found in the culture media, but this needs to be further investigated by C-terminal 
sequencing (see 3.3.2). 
Biochemical and biophysical characterisation of native MUB by SEC, native PAGE and 
AUC sedimentation equilibrium experiments (see 3.3.1 and 3.3.2) suggested the 
formation of oligomers or soluble aggregates in standard PBS buffer. The S-value of 
MUB was determined by sedimentation velocity AUC, a hydrodynamic technique 
providing some structural analysis of protein shape, as the S-value increases with 
protein mass but decreases with increasing protein asymmetry [363]. MUB showed 
a small S-value compared to its MW, further suggesting an elongated shape in 
solution.  
Lectin staining of MUB revealed reactivity with SNA, WGA and to a lower extent RCA, 
suggesting the presence of sialylated glycans, especially α2-6-linked NeuAc, terminal 
GlcNAc, and Gal or GalNAc structures (see 3.3.2). Putative glycosyltransferases were 
identified in the genome of L. reuteri ATCC 53608 after completion of the whole 
genome sequencing and gene annotation (unpublished data), which may potentially be 
involved in the glycosylation of host proteins. Only a few Lactobacillus glycoproteins 
have been described to date including S-layer proteins, a bacteriocin and the major 
autolysin Acm2 of L. plantarum, and the major secreted protein Msp/p75 of 
L. rhamnosus GG [367-368, 371-372]. Glycosylation of these proteins was identified 
and initially characterised by Periodic-acid Schiff (PAS) stain, lectin detection and MS 
glycopeptide analysis. Lectin recognition assays using succinylated WGA (GlcNAc), 
ConA (Man, Concavalin A), UEA (Fuc) MAA (α2-3 sialic acid, Maackia amurensis 
agglutintin) and SNA (α2-6 sialic acid) indicated the presence of GlcNAc on Acm2 and 
Man residues on Msp/p75. MS analysis provided evidence for the O-glycosylation of 
Acm2 and Msp/p75 presumably via serine residues. O-glycosylation was also observed 
for serine-rich repeat (SRR) proteins, which are present in Gram-positive streptococci, 
staphylococci and lactobacilli. Streptococcal SRR glycoproteins contain O-linked 
GlcNAc and GalNAc residues [373]. The predominant glycan in flagella of the gastric 
pathogens Campylobacter jejuni and Helicobacter pylori is pseudaminic acid, which is 
structurally related to sialic acid. Here we suggest, that the MUB protein of L. reuteri 
ATCC 53608 may be glycosylated, but future work is needed to proof this hypothesis 
including MS glycopeptide analysis and metabolic glycoprotein labeling. 
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CHAPTER 4 STRUCTURAL CHARACTERISATION OF MUB 
AND MUB REPEATS 
The previously reported crystal structure determination of the Mub type 2 repeat 
MubR5 of the cell surface adhesin MUB revealed two structural domains, B1 
(N-terminal) and B2 (C-terminal) (see 1.5) [282]. B1 showed structural similarity to an 
Ig-binding protein and MubR5 was shown to bind to Ig molecules in vitro [282], 
whereas B2 demonstrated structural homology with mucin-binding proteins (MucBP) as 
annotated in the Pfam database (PF06458) [374]. Here, the ability of MubR5 to bind to 
mucin glycans was investigated by crystal soaking and co-crystallisation studies with 
different sugars with the aim to identify potential ligands, reveal the topology of binding 
sites and understand the biochemical basis of protein-sugar interaction. As structural 
information on MUB is so far limited to a Mub type 2 repeat, we additionally aimed to 
determine the X-ray crystal structure of a Mub type 1 repeat. Furthermore, in order to 
obtain additional information on the domain organisation of MUB in solution, small 
angle X-ray scattering (SAXS) experiments of single, tandem and triple Mub repeats as 
well as the N-terminal domain were performed. 
4.1 MubR5 crystal soaking and co-crystallisation studies 
For crystal soaking experiments of MubR5 (183 residues) with potential sugar ligands, 
recombinant MubR5 was purified to homogeneity, dialysed to remove salt and 
concentrated to 8 mg/mL (see 3.1.1). Crystals were grown in 20% to 30% (w/v) PEG 
(polyethylenglycol) 3,350 and 0.2 M magnesium formate as precipitant, which showed 
improved crystal growth when compared to the alternative growth conditions published 
earlier (Figure 4.1) [282]. Crystals were soaked in fucose (Fuc), mannose (Man), 
galactose (Gal), N-acetylgalactosamine (GalNAc), N-acetylglucsoamine (GlcNAc), 
N-acetylneuraminic acid (Neu5Ac) and N-acetyllactosamine (LacNAc) solution 
containing 25% to 30% (w/v) PEG 3350 as a cryoprotectant for several minutes at 
concentrations ranging from 1 mM to 500 mM (see 2.5.1.2). The sugar concentration 
was dependent on crystal stability in the sugar solution used and was particularly low 
(1mM and 5mM) for Neu5Ac and LacNAc. Single wavelength diffraction data sets were 
collected for crystals soaked with 200 mM Fuc, 200 mM Man, 200 mM GalNAc, 500 
mM GlcNAc and 5 mM LacNAc to resolutions of 1.7 to 1.8 Å (see Appendix VII). 
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Figure 4.1 MubR5 crystal soaked with Man  
MubR5 crystal grown in 20% to 30% (w/v) PEG 3350 and 0.2 M magnesium formate and 
soaked with 200 mM Man in harvesting loop flash-cooled to 100 K in a stream of gaseous 
nitrogen before exposure to X-ray beams. 
For co-crystallisation experiments, crystallisation screens were performed with LacNAc, 
Neu5Ac and Man at sugar concentrations of 10 mM, 50 mM, 100 mM and 200 mM 
(only Man) (see 2.5.1.2). Crystal growth was observed for all tested ligands and 
concentrations with 25% (w/v) PEG 4,000, 0.2 M magnesium chloride and 0.1 M Tris 
(pH 8.5). Single wavelength diffraction data sets of sufficient diffraction quality were 
collected for crystals grown in the presence of 10 mM Man, 50 and 100 mM LacNAc, 
and 100 mM Neu5Ac (see Appendix VII). The X-ray diffraction images of all collected 
SAD data sets were indexed and integrated with MOSFLM in the primitive 
orthorhombic space group P212121 and data subsequently reduced using SCALA [333-
334]. The solvent content of the crystals was estimated to be 50% (v/v) with two 
MubR5 molecules in the asymmetric unit (ASU) [339]. The MubR5 structure (PDB entry 
3I57) was used as a model for molecular replacement (MR) using MOLREP and 
PHASER [340-341]. Alternating rounds of model refinement (without water molecules) 
and manual model building were performed using REFMAC and COOT [343-344]. The 
presence of sugar molecules for sufficiently refined protein models of soaked and 
co-crystallised MubR5 crystals was investigated in COOT using the ‘unmodelled blobs’ 
tool in reference to the σ-weighted 2mFobs-DFcalc electron density map. The only 
sugar molecule observed in an electron density map was Man after MubR5 crystal 
soaking. After a single Man molecule was added to the model, the final MubR5 
structure was refined with an Rcryst of 18.9% and an Rfree of 21.9% to a resolution of 1.7 
Å using PHENIX (Table 4.1) [348]. The average temperature factor of Man is 15.1 and 
the residues in the near surrounding have temperature factors between 9.4 and 10.7 
(Figure 4.2 C).  
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MubR5 (Man) 
Data collection  
Beamline Diamond i02 
Space group P 212121 
Cell parameters: a, b , c (Å), (°) 45.4, 45.8, 197.3; α=β=γ=90 
Wavelength (Å) 0.9795 
Resolution (Å) 45.4-1.7 (5.3-1.7) 
Rsym (%) 6.3 (21.5) 
I/σI 17.1 (5.2) 
Unique reflections 47572 (6786) 
Completeness (%) 99.7 (99.4) 
Multiplicity 3.8 (3.8) 
Overall B-factor (Å2) 12.3 
Refinement statistics  
Molecules per AU 2 
Total atoms 3815 
Water molecules 921 
Rcryst (%) 18.9 (24.0) 
Rfree (%) 21.9 (26.8) 
Ramachandran analysis  
Most favoured 99.5 
Outliers 0.0 
r.m.s.d.  
Bonds (Å) 0.007 
Angles (°) 1.023 
Planes (Å2) 0.005 
Mean atomic B-factor (Å2) 12.1 
Table 4.1 MubR5 (Man) data collection and refinement parameters 
 
Man is localised in the inter domain region (IR domain) connecting the B1 and B2 
domain of MubR5 sandwiched between two adjacent protein molecules in the crystal 
lattice (Figure 4.2 A). The amino acid residues in contact with the Man molecule are 
located in the loop connecting βA and β1’ of one MubR5 molecule and in the loop 
between βC and βaC of a second R5 repeat. The main chain carbonyl group of Ser86 
and Thr90 of the first MubR5 forms hydrogen bonds with Man as well as the side chain 
of Lys137 and the main chain carbonyl group of Asn139 of the second MubR5 
molecule (Figure 4.2 B and C). Two water molecules complete the coordination sphere 
of the Man ligand.  
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Figure 4.2 MubR5 structure with mannose (Man) 
(A) Representation of two adjacent MubR5 molecules in contact with a single Man ligand 
(light blue, sticks) with α-helices in red and β-sheets in yellow. (B) Man binding region with 
surrounding residues (sticks) and water molecules (grey spheres) involved in ligand 
interaction (C) and Man overlaid with 2mFobs-DFcalc electron density map contoured at 1.0 σ
level (dark blue). 
The fact that Man was identified as the only ligand in the soaked and co-crystallised 
MubR5 data sets was surprising, as it is typically found in complex N-glycans, which 
are less abundant in mucin glycoproteins (see 1.2). However, the location of Man 
between two adjacent MubR5 molecules seems to indicate that Man does not interact 
with a distinct carbohydrate binding site, but rather suggests a role of MUB in 
promoting interaction between MUB molecules on the same bacterial cell or from 
different cells. 
4.2 Structure determination of a Mub type 1 repeat protein 
While the Mub type 2 repeats (R1 to R8) of MUB show high sequence identity (84% to 
100%), the Mub type 1 repeats (RI to RVI) are more diverse with sequence similarities 
of 29% to 88% [282].In order to investigate, whether Mub type 1 repeats possess 
A 
β4 
β3 βA 
βB 
βC 
β2 
β1' 
β1' 
β3' β4' 
βaC 
B 
Lys91 
Thr90 Ser86 
Lys137 
Asn139 
C 
Lys91 
Thr90 Ser86 
Lys137 
Asn139 
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a similar protein fold compared to the type 2 MubR5 repeat, crystallisation experiments 
were performed using the recombinant type 1 repeats MubRI and MubRV, which share 
32.4% and 42.4% sequence identity with MubR5, respectively. 
4.2.1 Crystallisation experiments of MubRI 
For crystallisation growth condition screens, the recombinant MubRI protein 
(194 residues) was purified by IEC and SEC, dialysed into sodium phosphate or 
alternatively in Tris-HCl buffer and concentrated to about 18 mg/mL (see 3.1.1). Crystal 
structure screens were set up at 4° and 16°C, but did not result in the growth of single 
crystals of good quality (see 2.5.1.1). Crystal optimisation for various growth conditions 
including the variation of pH, reservoir solution, salt concentration and precipitation 
solution was performed. Finally, single, diamond shaped crystals grew in the following 
precipitation solution: 0.1 M HEPES (pH 7.5), 10% (v/v) 2-propanol/ 20% (w/v) PEG 
4000 at 4°C after crystal seeding (Figure 4.3).  
 
 
 
 
 
 
 
 
Figure 4.3 MubRI crystals in harvesting loop 
(A+B) Orthogonal views on a diamond shaped MubRI crystal of 210 μm  50 μm in size 
grown in 0.1 M HEPES (pH 7.5), 10% (v/v) 2-propanol/ 20% (w/v) PEG 4000 at 4°C in 
a crystal harvest loop flash-cooled to 100 K in a stream of gaseous nitrogen before 
exposure to X-ray beams.  
Native crystals as well as crystals soaked with ytterbium and mercury chloride were 
tested for their X-ray diffraction ability. Ytterbium and mercury chloride were used as 
anomalous scatters to accomplish phasing of crystal diffraction data. Alternatively, MR 
with various MubR5 models derived from the coordinate file (PDB entry 3I57) was 
performed. Four SAD data sets were collected for MubRI, two for native crystals and 
two for halide and heavy atom soaked crystals at resolutions between 2.0 and 2.6 Å 
(see Appendix VIII).  
A B 
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The solvent content analysis of crystal forms giving all 4 collected data sets suggested 
the presence of two protein molecules per asymmetric unit cell (ASU) with an 
estimated solvent content of 50% (v/v). The inspection of the anomalous probability 
plot produced by SCALA suggested the absence of an anomalous signal for the 
soaked crystals after image data integration and data processing via MOSFLM and 
SCALA [333-334] in space group P222. Attempts to obtain initial phase information by 
MR with different MubR5 models using MOLREP and PHASER failed. Data quality 
analysis by XTRIAGE suggested weak translational pseudosymmetry for all MubRI 
data files (see Appendix VIII). Pseudosymmetry can occur when more than one 
molecule is present in the ASU and the non-crystallographic translational symmetry 
operator relating these molecules is close to a true crystallographic symmetry operator. 
This can lead to an incorrect unit cell and false space group assignment after 
autoindexing, making a structure solution difficult or even impossible to obtain [375].  
Pseudosymmetry is a crystal property and may be avoided if an alternative crystal form 
is available. Unfortunately, only a single crystal form was observed for MubRI after 
crystal growth optimisation (as described above). Hence, attempts to solve the 
structure of MubRI were abandoned and the recombinant MubRV protein was 
alternatively used in further crystallisation experiments. 
4.2.2 Structure determination of MubRV 
In parallel to MubRI crystallisation experiments (see 4.2.1), crystal screens were set up 
for the recombinant type 1 MubRV (184 residues) purified via IEC and SEC, after 
dialysis into sodium phosphate buffer and concentration to 12 mg/mL (see 3.1.1).  
Crystals grew as long rods from a single nucleation point for a variety of crystallisation 
conditions (Figure 4.4), but were readily separated allowing crystal harvest for 
diffraction analysis. Diffraction data sets were collected for a number of growth 
conditions. The best X-ray data set was collected to a resolution of 2.6 Å for a crystal 
grown in 0.2 M ammonium acetate and 24% (w/v) PEG 3,350 at 16°C and used for 
further data processing.  
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Figure 4.4 MubRV crystal 
Representative image of MubRV crystals grown from a single nucleation point. 
The initial indexing of the MubRV data set via XDS [376] suggested two potential space 
groups, C2221 and P2221. For correct space group assignment, the diffraction data 
were analysed using ZANUDA and LABELIT [346], revealing a higher probability for 
the space group C2221. A similar outcome was achieved by POINTLESS [334]. The 
data were therefore indexed in a C-centred orthorhombic lattice with cell parameters of 
a=31.4, b=271.7 and c=142.9 (Table 4.2). Data integration and reduction was 
performed by the Xia2 automated data reduction system [335]. The data did not show 
any signs of pseudosymmetry or twinning when analysed by XTRIAGE in PHENIX 
[337]. The solvent content of the crystal was estimated with 50% (v/v) for three 
molecules in the ASU, however we found only two molecules with a solvent content 
67% (v/v). 
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 MubRV  
(PDB entry 4MT5) 
 Data collection  
Beamline Diamond i04 
Space group C 2221 
Cell parameters: a, b , c (Å), (°) 31.4, 271.7, 142.9; α=β=γ=90 
Wavelength (Å) 0.9205 
Resolution (Å) 49.2-2.6 (11.6-2.6) 
Rsym (%) 8 (36) 
I/σI 16.6 (5.5) 
Unique reflections 19614 (1413) 
Completeness (%) 99.9 (99.9) 
Multiplicity 6.0 (6.2) 
Overall B-factor (Å2) 48.0 
Refinement statistics  
Molecules per AU 2 
Total atoms 3010 
Water molecules 162 
Rcryst (%) 21.1 (31.9) 
Rfree (%) 26.9 (35.3) 
Ramachandran analysis  
Most favoured 95.9 
Allowed 3.9 
Outliers 0.3 
r.m.s.d.  
Bonds (Å) 0.008 
Angles (°) 1.083 
Planes (Å2) 0.005 
Mean atomic B-factor (Å2) 36.1 
Table 4.2 Data collection and refinement statistics for MubRV  
 
In an attempt to obtain initial phases by MR, a structural alignment model for MubRV 
was generated by CHAINSAW [342] after sequence alignment of MubR5 and MubRV 
using ClustalW (see 2.6.2). However, MR using PHASER [341] did not produce 
a convincing solution, as good coverage of Cɑ-atoms with electron density was only 
observed for the N-terminal B1 domain. The C-terminal domain of MubRV showed 14% 
sequence identity to the MucBP domain of the adhesion protein PEPE_0118 (PDB 
entry 3LYY) of Pedicoccus pentosaceus compared to 13% to the B2 domain of MubR5. 
Hence, the MucBP of PEPE_0118 and the C-terminal MubR5 B1 domain (residues 
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1-75) were used as models in MR by PHASER resulting in a convincing solution. The 
inter domain region was built both automated using AUTOBUILD and manually in 
COOT with reference to the σ-weighted 2mFobs-DFcalc and mFobs-DFcalc Fourier 
electron density maps, and refined in REFMAC [343-344, 348]. 
The final crystal structure of MubRV was refined at a resolution of 2.6 Å in space group 
C2221 with an Rcryst of 21.1% and an Rfree of 26.9%. The two MubRV molecules present 
in the ASU comprise 184 residues including the N-terminal methionine (Met). They are 
highly similar showing a Z-score of 20.1 (r.m.s.d. 0.9 Å) over the Cα-atoms when 
aligned by DaliLite (see 2.6.2).  
MubRV folds to form an elongated structure 110 Å in length and 24 Å in diameter. 
It shows the same domain organisation as MubR5, comprising an N-terminal B1 
domain and a C-terminal B2 domain with an inter domain region (IR domain) 
(Figure 4.5 A). The Mub type 1 and Mub type 2 structures share high structural 
similarity with a Z-score of 15.1 over 176 aligned residues (r.m.s.d. 4.1 Å). Like MubR5, 
the MubRV B1 domain has an ubiquitin-like β-grasp fold containing two pairs of 
antiparallel β-strands in a 4-stranded sheet connected by an α-helix, which is similar to 
that found in members of the immunoglobulin (Ig)-binding superfamily [377]. However, 
in contrast to MubR5, there was no evidence for a Ca2+-ion coordinated by residues of 
the loop connecting strands β3 and β4 in the electron density map of MubRV 
(Figure 4.5 B). The MubRV repeat lacks the three residues (Asp60, Asp62 and Asn65) 
present in the loop region of MubR5 which mediate binding of the Ca2+-ion. The B2 
domain of MubRV is classed as a mucin-binding domain (MucBP) as annotated in the 
Pfam database (PF06458) [374], with a modified ubiquitin-like β-grasp fold, in which 
the outer strands of the 4-stranded β-sheet are connected by a β-strand (β3’) instead of 
an α-helix as in the B1 domain. This connecting strand together with an additional 
β-strand (β5’), that is located between β4’ and β6’, forms a third antiparallel β-sheet 
and is referred as the IR domain. The ubiquitin-like β-grasp fold is involved in diverse 
functions with variations in the core protein fold [378]. Interestingly, the β-grasp fold 
also shares similarities with β-grasp domains and β-sheet clefts, commonly involved in 
the binding of sialic acid containing carbohydrate ligands [318]. 
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Figure 4.5 X-ray crystal structure of the Mub type 1 repeat MubRV 
(A) Protein fold of MubRV with α-helix and β-sheets coloured red and yellow, respectively. 
The N- and C-termini of the protein and the main structural elements are labelled. (B) 
Superposition of type 1 MubRV (yellow, red) and type 2 MubR5 (grey, PDB entry 35I7) by 
DaliLite with the Ca2+-ion presented as a grey sphere. 
When performing a comparison of MubRV with structures in the protein databank 
(PDB) using DALI [358], the B1 domain of MubRV shows structural similarity to the 
immunoglobulin (Ig)-binding protein L (PpL) of Peptostreptococcus magnus (Z-score 
5.4, 15% sequence identity, r.m.s.d. 2.9 Å), as reported earlier for MubR5 (see 1.5) 
[316]. However, a closer structural homologue in the PDB, characterised by an Ig-like 
fold, is the B-repeat of the Listeria invasion protein internalin B (InlB) (PDB entry 2KVZ) 
(Z-score 5.9, r.m.s.d 2.6 Å, 13% sequence identity) with unknown receptor specificity. 
In addition, MubRV shows high structural homology to the cell-surface adhesin 
Spr1345 of Streptococcocus pneumoniae, a structure solved by MR using the MubR5 
B2 coordinates [240]. The structural alignment of the B2 domain of MubRV with the 
MucBP domain of Spr1345 (PDB entry 3NZ3) shows an r.m.s.d. of 1.4 Å and a Z-score 
of 11.6 at 37% sequence identity. MucBP of Strep. pneumoniae has been 
demonstrated to bind to mucins and polysaccharides [239]. 
More striking, however, is the structural similarity of the B2 domain of MubRV to 
a number of extended modular adhesins from Gram-positive pathogens. These include 
pilin proteins such as GBS52 of Strept. agalactiae (PDB entry 3PHS) (Z-score 5.4), 
BcpA of Bacillus cereus (PDB entry 3KPT) (Z-score 4.7), RrgB of Strep. pneumoniae 
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(PDB entry 3RPK) (Z-score 4.6), Spy0128 of Strep. pyrogenes (PDB entry 3B2M) 
(Z-score 4.2) and SpaA of Corynebacterium diphteriae (PDB entry 3HR6) (Z-score 4.0) 
as well as the MSCRAMM (microbial surface components recognizing adhesive matrix 
molecule) CnaB of Staphylococcus aureus (PDB entry 1D2P) (Z-score 2.5) [261, 379-
383]. These proteins all contain a similar domain organisation of two to 4 Ig-like 
domains with maximum dimensions between 85 Å and 134 Å as observed by 
X-crystallography. The Ig-like fold is a β-sandwich fold of at least 7 predominantly 
anti-parallel β-strands grouped into two β-sheets. Several distinct topology variants of 
the Ig-like fold can be distinguished [320, 384-385].  
 
 
Figure 4.6 Overlay of the B2 domain of MubRV with the N2 domain of GBS52 pilin 
Superposition of the B2 domain (inclusive the IR domain) of MubRV (blue) and the N2 
domain of the GBS52 pilin of Strep. agalactiae (grey) (PDB entry 3PHS) using DaliLite. 
Β-strand in the B2 domain (red) and N-and C-termini are labelled. 
The pilin GBS52 is the closest structural homologue of MubRV and folds in two Ig-like 
domains, N1 and N2. The latter shows a structural alignment Z-score with the B2 
domain of Mub-RV of 5.4 and an r.m.s.d. of 2.4 Å over 64 aligned Cɑ-atoms 
(Figure 4.6) [261]. Both N domains show a typical Ig-fold of 7 β-strands, but display an 
alternative arrangement in the order of their β-strands related to a CnaB topology. 
Interestingly, Ig-like domains of GBS52, BcpA, RrgB, Spy0128 and SpaA all describe 
a CnaB topology, which was first identified in the collagen binding protein Cna B-region 
of Staph. aureus, to which MubRV shows some level of structural similarity 
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(Z-score 2.5, r.m.s.d. 4.5 Å , 45 aligned Cɑ atoms). The CnaB topology, albeit 
reminiscent of the Ig-like fold type C or IgG fold (with ABED/CFG topology), displays an 
inverse relation of β-strands in a four-(DAGF) and a three-(CBE) β-sandwich 
arrangement, and is hence designated as an IgG-rev (Ig-like) fold [320, 379]. The 
β-sandwich in the B2 domain of MubRV (exclusive of the IR domain), comprising the 
4-stranded β-sheet (β2’, β1’, β6’ and β4’) and 2 β-strands (β3’ and β5’), shows 
a different BAFD/EC topology (Figure 4.6). 
In summary, the MubRV type 2 and MubR5 type 1 proteins show a conserved protein 
fold, suggesting a similar physiological function on the bacterial cell-surface. They 
possess structural homology to the Ig-binding protein L and the MucBP domain 
Spr1345 of Strep. pneumoniae indicating their involvement in Ig-binding and potential 
interaction with mucins and glycans. Additionally, MubRV shows structural similarity to 
cell surface adhesins, pili and MSCRAMM, present in Gram-positive GI pathogens, 
perhaps suggesting a common niche at the mucosal surface. 
4.2.3 Functional annotation analysis of MubRV and MubR5 
In order to further investigate the structure-function relationship of Mub repeats, the 
crystal structures of MubRV and MubR5 were analysed using the MarkUS function 
annotation server [386]. The MarkUS server identifies structural neighbours that share 
a minimum of three secondary structure elements for annotation of common molecular 
function.  
The PredUS analysis tool predicted potential protein-protein interaction sites for MubR5 
and MubRV that are exclusively located in the N-terminal B1 domain of both molecules 
including residues of the ɑ-helix and mainly of the β-strand β2 and β4 of MubR5, and   
β3 and β4 of MubRV (Figure 4.7 A and B) [387]. The predicted site is partially identical 
to the possible interaction site of MubR5 with Igs based on structural alignment and 
binding modelling with the Ig-binding protein L [282].  
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Figure 4.7 PredUS and SCREEN analysis of MubR5 and MubRV 
(A) MubR5  and (B) MubRV structures with protein-protein interaction sites predicted by 
PredUS (magenta) and solvent accessible cavities predicted by SCREEN shown as 
surfaces (1 blue, 2 yellow, 3 green) (in A). 
Interestingly, three solvent accessible cavities of 7 (cavity 1) and 6 (cavity 1 and 2) 
residues (Figure 4.7) that may function as non-protein ligand interaction sites were 
identified for MubR5 but not for MubRV by SCREEN [388]. Cavity (1) is located in the 
B1 domain of MubR5 and comprises residues preceding the ɑ-helix and in the loop 
connecting strands β2 and β3 (Figure 4.7 A). It shows a diameter of 7.2 Å, a maximum 
depth of 3.1 Å and a surface area of 27.8 Å2. The other two adjacent cavities (2 and 3) 
show diameters of 6.1 and 5.1 Å, maximum depth of 3.6 and 3.3 Å, and areas of 
24.0 Å2 and 20.5 Å2, respectively. They are located in the IR domain and the B2 
domain, where interaction of MubR5 with Man was detected by X-ray crystallography 
(see 4.2.1). However, they do not comprise the residues that were involved in the 
interaction with Man. These findings may indicate a functional difference between both 
Mub type repeats in ligand recognition and the potential interaction of Mub repeats with 
different types of ligands. 
4.3 Solution structure determination and domain organisation of MUB 
The determination of crystal structures of both Mub type repeats provided valuable 
information on protein architecture at high resolution but is limited to the low energy 
state of these proteins in a rigid crystal lattice. In order to obtain information on the 
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properties of individual Mub repeats freely moving in solution, and of their intra- and 
inter-domain organisation and flexibility, low resolution SAXS experiments were 
conducted. In addition, since no structural information is currently available on multiple 
Mub-repeat proteins, repeat assembly and on the N-terminal region of the native MUB, 
tandem repeats and the Nterm protein were also analysed by SAXS.  
For SAXS analysis, the single Mub repeats, MubR5, -RV and -RI, the type 1 and mixed 
type double repeats, MubRV-VI and Mub8-V, the triple repeat MubRI-II-III and the 
Nterm protein, were purified to homogeneity by IEC or IMAC followed by SEC (see 
3.1.1 and 3.1.2). The single and double repeats as well as the Nterm domain were 
dialysed into Tris-HCl and MubRI-II-III was exchanged into 4 different buffers, Tris-HCl, 
Tris-NaCl (150 mM NaCl), sodium phosphate and PBS. All proteins were concentrated 
to 10 mg/mL (18 mg/mL for MubRI). The single and double repeat proteins were 
snap-frozen, and the Nterm protein and MubRI-II-III were stored at 4°C. 
Analysis of purified Mub proteins by dynamic light scattering (DLS) (see 2.4.4) revealed 
the presence of a single protein species for all tested proteins and buffers accounting 
for 99.9 to 100% of the total mass of the sample and a polydispersity of 13.1 to 23.4%. 
The presence of other protein species, amounting to only 0.1% of total mass, was low 
and may indicate a very small amount of protein aggregation. The DLS data 
demonstrated high homogeneity, low polydispersity and high stability of all tested MUB 
proteins in the sample buffers. 
Scattering curves for MubR5, MubRV, MubRI, MubR8-V, MubRV-VI and Nterm in 
Tris-HCl were recorded in a concentration range of 0.6 to 9.0 mg/mL. Three data sets 
were collected for MubRI-II-III in Tris-HCl, sodium phosphate buffer and PBS, the latter 
two supplemented with 2 mM DTT to reduce the effects of low levels of radiation 
damage, in a protein concentration range of 0.6 to 0.9 mg/mL (in Tris-HCl) or 0.5 to 
5 mg/mL (in sodium phosphate or PBS) (see 2.5.2.1). The scattering data for the triple 
Mub domain in PBS (2 mM DTT) showed the highest quality of all three collected data 
sets and was used for further data processing. The scattering profiles of all Mub 
proteins and the Nterm protein were analysed using PRIMUS and a final scattering 
curve merged from three individual curves covering concentrations of 1.3 to 4.3 mg/mL 
(see Appendix IX) (see 2.5.2.2). 
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The Kratky analysis of the merged scattering curves of the Mub repeats, where s2I(s) is 
plotted against s, revealed a shape characteristic for extended or partially flexible 
molecules with an increasing tail in the larger s-range (see Appendix X). In contrast, for 
the Nterm protein, a bell-shape curve with a plateau in the larger s-range was observed 
in the Kratky plot, indicating a different protein shape in solution compared to the Mub 
repeats (see Appendix X). Using the online tool PONDR for structural disorder 
prediction in the sequence of Mub-repeat proteins, less ordered stretches of residues 
were identified for all repeats (data not shown) [389]. 
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Figure 4.8 SAXS data analysis and shape reconstruction of single and double Mub repeats 
Experimental scattering curves for (A) the Mub type 1 repeats Mub-RV (light blue) and 
Mub-RI (red), the Mub type 2 repeat Mub-R5 (light green) and (C) the tandem Mub repeats 
MubR8-V (dark green) and MubRV-VI (dark blue) shown as the logarithm of the scattering 
intensity I (black dots) as a function of the reverse momentum transfer s and presented 
offset for better visualisation. Overlaying the scattering profiles, are fits of the reconstructed 
averaged models for Mub proteins. (B+D) Pair distribution functions P(r) generated from the 
experimental scattering. Low resolution shape reconstructions of MubRV (E), MubRI (F), 
Mub-R5 (G). MubR8-V (H) and MubRV-VI (I) with manually docked high resolution 
structures of MubRV (blue), MubR5 (green). 
119 
 
Solution envelopes of single and tandem Mub repeats were reconstructed from P(r) 
functions using GASPOR (Figure 4.8 E-I), whereas DAMMIF was used for MubRI-II-III 
shape reconstructions (Figure 4.9 C), revealing an extended boomerang-like solution 
structure of Mub proteins (see 2.5.2.2). The experimental scattering profiles of MubR5 
and MubRV were in good agreement with the computed solution scatterings curves 
from their crystal structures using CRYSOL, showing X values of 1.06 and 1.02 
(see Appendix XI) [355]. The MubRV and –R5 crystal structures were docked manually 
into the reconstructed shapes and docking solutions were refined using SITUS 
(see Appendix IX) [354]. A good fit of low resolution solution envelopes and high 
resolution structures was observed for the singe and tandem repeat proteins (Figure 
4.8 E-I), while the docking of three MubRV structures into the MubRI-II-III shape 
reconstruction proved more challenging (Figure 4.9 C), likely due to the use of rigid 
structural models. Alternatively, it may indicate that the actual, maximal dimensions of 
MubRI-II-III in solution are higher than those determined from the collected SAXS data 
maybe due to sample properties or quality. 
The maximal particle diameters for MubRV, -RI and –RV were found to be 110 Å, 
106 Å and 105 Å (Figure 4.8 E-G), while the Dmax values for MubR8-V and MubRV-VI 
were calculated to be 205 Å and 206 Å (Figure 4.8 H-I). Finally, the triple repeat 
MubRI-II-III showed a maximal particle diameter of 292 Å indicating an elongated 
conformation of single and multiple Mub-repeat proteins in solution (Figure 4.9 C). In 
contrast, the Dmax for the Nterm protein was found to be 159 Å and hence significantly 
lower than that of MubRI-II-III, a protein of similar molecular weight, suggesting 
a different solution structure of the Nterm domain to the Mub repeats (Figure 4.9 D). 
The solution envelope of Nterm, reconstructed from its P(r) function using GASPOR, 
demonstrated a more globular protein shape with an elongated tail and provided the 
first structural information, albeit at low resolution, for the N-terminal domain of MUB 
(Figure 4.9 B and D). To date, no high resolution structural information is available on 
the Nterm protein of MUB or any homologous proteins.  
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Figure 4.9 SAXS data analysis and shape reconstruction of MubRI-II-III and the N-terminal 
domain of MUB 
(A) Experimental scattering curves for the triple MubRI-II-III (light blue) and the N-terminal 
domain (red) are shown as the logarithm of the scattering intensity I (black dots) as 
a function of the reverse momentum transfer s and presented offset for better visualisation. 
Overlaying the scattering profiles, are fits of the reconstructed averaged models for 
MubRI-II-III and Nterm. (B) Pair distribution functions P(r) were generated from the 
experimental scattering. Low resolution shape reconstructions of (C) MubRI-II-III with 
manually docked high resolution structures of MubRV (blue) and (D) Nterm.  
In summary, the results of these SAXS studies indicate the arrangement of Mub 
repeats as ‘beads on a string’ within the full-length MUB surface protein, with an 
alternatively-shaped Nterm domain at the protein tip.  
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4.4 Discussion 
Adhesion to host tissues is a necessary first step of bacterial colonisation and is 
thought to be mediated by cell surface adhesion proteins. Considerable progress has 
been made in the last decade in the structural characterisation of pathogenic 
Gram-positive adhesins such as MSCRAMM or pili, revealing many interesting and 
unique features that may explain their adhesion mechanism to host cell receptors [384, 
390-391]. In sharp contrast, there is currently a lack of structural information on 
Gram-positive adhesins, which are suggested to be involved in commensal or probiotic 
adhesion to mucus.  
The cell surface adhesin MUB of L. reuteri ATCC 53608 is one of the few adhesins for 
which the contribution to the overall bacterial adhesion to mucus has been 
demonstrated [283, 302]. As commonly observed in Gram-positive adhesion 
molecules, MUB is a LPXTG-anchored cell wall protein with a modular domain 
organisation. It contains 14 tandemly arranged Mub repeat domains of two types, 
Mub 1 and Mub 2 (see 1.4.2). The crystal structure of the Mub type 2 repeat MubR5, 
resembling an elongated structure with two distinct domains, B1 and B2, previously 
reported in our lab, provided first structural insight into commensal Mub domains [282]. 
Besides MUB, Mub domain containing proteins have been identified in different 
lactobacilli species by in silico analysis, and are implicated in mucin binding (see 1.4.2) 
[304]. Additionally, the SpaCBA pili present in L. rhamnosus GG exerts mucus-binding 
ability, more specifically its SpaC subunit, potentially resulting in prolonged residency of 
L. rhamnosus GG in the GI tract [288]. However, their functional characterisation is 
fragmentary, no structural information is available, and the mechanism of adhesion and 
the specific ligands recognised remain to be determined. The current hypothesis is that 
glycan structures found in large numbers on mucin proteins are the preferential binding 
sites for mucus binding protein but this has yet to be proven. 
The potential sugar recognition by MUB was investigated by X-ray crystallography 
through co-crystallisation and crystal soaking studies with the single Mub repeat 
MubR5 and various mono- and disaccharides (see 4.1). The only sugar molecule 
identified bound by MubR5 was Man, mediating the cross-linking of two adjacent 
MubR5 repeats in the inter domain region of the protein. This finding may suggest 
a role of carbohydrate-ligand binding by the cell surface MUB protein in bacterial cell 
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interaction and aggregation. Indeed, MUB-positive L. reuteri strains L. reuteri ATCC 
55739 and 53608 demonstrated auto-aggregation properties, which have been 
associated with the presence of MUB on the bacterial cell surface [302]. In contrast, the 
mutant strain 1063N of L. reuteri ATCC 53608, expressing a truncated MUB protein, 
showed significantly less auto-aggregation. The aggregation capability is, besides 
specific mucosal receptor recognition, an important host colonisation factor of 
commensal lactic acid bacteria. For example, the aggregating strain L. crispatus M247 
shows prolonged persistence in the GI tract of mice compared to an 
aggregation-deficient strain [392]. L. acidophilus M29 has been demonstrated to 
autoaggregate and adhere to intestinal epithelial cells, demonstrating a correlation 
between aggregation and adhesion [393]. The interaction between sugars and 
adhesins has recently been suggested to play a role in Lactobacillus aggregation [394]. 
The role of Man as a potential sugar ligand and mediator of bacterial auto-aggregation 
and the characterisation of its interaction with Mub repeats, however, needs to be 
further investigated. Isothermal titration calorimetry (IT) experiments of MubR5 with 
Man sugars were performed to determine their binding affinity (see 5.2.1). 
In order to gain additional functional insight into the structure and function of Mub 
repeats, the crystal structure of the Mub type 1 repeat MubRV was determined 
at 2.6 Å. MubRV shows high structural similarity to MubR5 with the same overall 
organisation of two domains, B1 and B2, and an elongated shape 110 Å in length 
(see 4.2.2). Additionally, MubRV shows structural similarity to a number of pilins and 
MSCRAMM. Those structures include the CnaB structures of Strep. aureus, the 
N2 domain of GBS52 from Strep. agalactiae, that contains the pulmonary binding site, 
the C-terminal D4-domain of RrgB of Strep. penumoniae, the major Spy0128 pilin of 
Strep. aureus and the SpaA shaft pilin of C. diphtheriae [261, 382-383, 395] . Hence, 
MubRV shows structural similarity to members of the 4 major groups of invasive 
Gram-positive pathogens: C. diphtheriae, group A Streptococcus (that is Strep. 
pyogenes), group B Streptococcus (that is Strep. agalactiae) and Strep. pneumoniae.  
Pili, long protein filaments, which are composed of major and minor pilin subunits, and 
MSCRAMM are Gram-positive cell-surface adhesins of pathogenic bacteria. They 
share a similar modular protein organisation and common structural motifs including an 
N-terminal Sec-dependent secretion signal for protein transport to the cell wall, 
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a variable number of modular domains, and a C-terminal cell wall anchor including 
a canonical LPXTG-motif for sortase-dependent covalent attachment to the cell wall 
component peptidoglycan. Individual, modular protein repeats in MSCRAMM and minor 
or ancillary pilins are functional domains that play an important role in host adhesion 
and biofilm formation and are thus key elements of bacterial pathogenicity [263, 309, 
396]. While the interaction of MSCRAMM with extracellular matrix components, such 
as fibronectin, fibrinogen and collagen is well described, less is known about the 
specific target receptors and the binding mode of pilins [226, 385, 397-400].  
To date, crystal structures are available for a number of MSCRAMM domains or 
individual pilins revealing a common structural module based on the IgG-constant 
(IgG-C) domain, designated as an Ig-like fold. The IgG-fold is a β-sandwich 
characterized by a four-stranded β-sheet (ABED) and a three-stranded β-sheet (CFG), 
which is different from other Ig-superfamily folds, i.e. V, H and I [320]. Two variants of 
the Ig-like fold, based on IgG-C have been identified, IgG-rev and DEv-IgG. While the 
latter shows the same topology as the IgG-C but possess additionally strands, the 
IgG-rev is characterized by a reverse strand arrangement in two alternative topologies 
CBE DAGF and CBEF DAG. The IgG-rev fold was first observed in the MSCRAMM 
Cna B-region of Staph. aureus, while the DEv-IgG fold was found in the Cna A-region 
in the same molecule [379, 400-401]. MubRV shows structural homology to pili and 
MSCRAMMs, whose folds are particularly similar to the CnaB Ig-like fold or IgG-rev 
fold. 
However, despite the high similarity of the B2 domain of MubRV to these Ig-like fold 
domains, the β-sandwich in the B2 domain only contains a 4-stranded β-sheet (BAFD) 
and two β-strands (EC) of different topology. MubRV possesses three additional 
β-strands forming a β-sheet in the inter domain region between the B1 domain and the 
C-terminal part of the B2 domain (see 4.2.2). 
AUC experiments of full-length native MUB suggested its appearance as an elongated 
protein in solution (see 3.3.2). SAXS experiment were conducted to investigate the 
properties of single Mub repeats in solution and to obtain information on shape and 
organisation of multiple Mub repeat proteins (see 4.3). Single Mub repeats describe 
boomerang-like solution envelopes 105 to 110 Å (~10 nm) in length, which showed 
a good fit with the elongated X-ray structures of the Mub type 1 MubRV and the type 2 
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MubR5 structures 110 Å in length. In addition, the low resolution structure 
reconstruction of double and triple Mub repeats of about 200 and 300 Å (~20 and 
30 nm) in length demonstrated an elongated protein shape of multiple Mub repeats. 
Additionally, the first structural information on the N-terminal domain of MUB was 
obtained, which demonstrated a less extended, more globular 3D reconstruction 
compared to Mub repeats. These findings thus suggest a potential ‘beads on a string’ 
arrangement of 14 Mub repeats together with a less extended N-terminal domain 
(see Figure 4.10).  
 
 
Figure 4.10 Schematic representation of MUB on the bacterial cell surface  
Mub type 1 and type 2 repeats are coloured blue and green, respectively, as are MubRV 
and MubR5 crystal structures. SAXS shape reconstructions are shown next to 
corresponding Mub repeats and MubRV crystal structurs is fitted into envelopes of 
MubRV, -R8-V and –RV-VI.  
Filamentous pili structures are fairly abundant and better studied in pathogenic 
Gram positive bacteria rather than commensals, and can reach a length of 70-200 nm 
or 0.3-3 μm depending on pili type [402]. For example, the serine-rich pili of 
Strep. parasanguinis has been visualised by electron microscopy (EM) with an 
estimated length of several 100 nm [391]. Commensal pili genes have to date only 
been reported in L. johnsonii NCC533, L. lactis TIL448, two L. ruminis strains and the 
L. rhamnosus strains GG and LC705 (see 1.4.2) [288, 291, 307-308]. The SpaCBA pili 
of L. rhamnosus GG was the first to be visualised on commensal bacterial cells as 
a long extended fiber [288].  
A similar protein shape as shown for Mub repeats was observed for Gram-positive 
pathogenic pilin subunits. A pilin subunit of a serine rich fimbriae of Strep. pneumoniae 
demonstrated a kidney-shaped SAXS solution structure of about 12 nm in length [391]. 
Another example is the Spy0128 backbone pili of Strep. pyogenes, that is, such as 
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a single Mub repeat, composed of two domains and shows both a crystal and a SAXS 
solution structure of about 10 nm in length [381, 403]. In addition, the native pili of 
Strep. pneumoniae describes a rod-like structure as observed in its EM density map 
fitting twice the crystal structure of a RrgB pili subunit [404]. These studies provide the 
first low and high resolution structure information on a commensal mucus-binding 
adhesin, indicating high structural similarity with pathogenic fimbrial proteins, such as 
pilins and MSCRAMM, involved in adhesion and infection.  
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CHAPTER 5 FUNCTIONAL CHARACTERISATION OF MUB 
ADHESION PROPERTIES TO MUCUS 
The cell-surface protein MUB of the pig isolate strain L. reuteri ATCC 53608 is 
a modular adhesion molecule comprised of 14 Mub repeats, of type 1 and type 2, and 
an N-terminal domain (Nterm). The role of MUB as an effector molecule in the 
adhesion of bacterial cells to mucus has been demonstrated in our lab [302]. In 
addition, studies by Roos and Johnsson showed the interaction of L. reuteri ATCC 
53608 cells as well as recombinant Mub-repeat proteins, fused to a maltose binding 
protein, to porcine and hen mucus, and to porcine mucin [283]. However, the distinct 
mucus or mucin components recognised by MUB proteins and the biochemical 
mechanism of interaction remain unkown. The current working hypothesis is that 
cell-surface adhesins mediate bacterial binding to mucosal surfaces by interaction with 
mucin glycans. In order to investigate and dissect the binding ability of MUB proteins to 
different types of mucin, and investigate the potential recognition of mucin glycans, the 
adhesion properties of Mub repeats, MubR5, -RV, -RI, -R8-V, -RV-VI, -RI-II-III and the 
Nterm domain proteins, Nterm and NtermMubRI, as well as the native full-length MUB 
were tested in a variety of different mucin and glycan binding studies. 
5.1 Binding of MUB proteins to mucus and mucin  
5.1.1 MUB protein binding to porcine and human mucin in membrane-adhesion 
assays 
The binding of the recombinant Mub repeats MubR5, -RV, -RI, -R8-V, -RV-VI 
and -RI-II-III, the Nterm protein, as well as native MUB, to isolated pig small intestinal 
mucus (PSIM) and purified commercial porcine gastric mucin (pPGM) was first 
investigated in a slot-blot binding assay (see 2.1.2 and 2.3.6.4). Briefly, recombinant 
Mub-repeat proteins and the Nterm protein were purified by IEC and IMAC followed by 
SEC (see 3.1), and native MUB was purified from a L. reuteri ATCC 53608 cell culture 
via SEC (see 3.3.1). The recombinant MUB proteins (0-64 μg) and native MUB (0-8 μg) 
were immobilised onto nitrocellulose membranes and probed with PSIM and pPGM in 
excess. Bound mucin was detected via FITC labelled RCA (f-RCA), which specifically 
interacts with Gal residues (see 2.3.5), a frequently encountered sugar molecule in 
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mucin O-glycans (see 1.2). The reactivity of PSIM and pPGM with f-RCA was 
separately verified in a test assay (data not shown).  
Native MUB, comprising all 14 Mub repeats and the N-terminal domain, binds to PSIM 
and pPGM when compared to the PBS negative control (Figure 5.1 A). In contrast, no 
binding was observed for any of the single, tandem and triple Mub-repeat proteins or 
the Nterm protein under the current assay conditions, maybe indicating the requirement 
of several Mub repeats for mucin binding. The presence of immobilised adhesion 
proteins was verified by detection via specific anti-MubRI and anti-MubR5 for MUB and 
Mub repeats and anti-His5 for Nterm (Figure 5.1 B). Recombinant MUB proteins as well 
as the native MUB did not show reactivity with f-RCA, suggesting specificity of the 
observed interaction of MUB with mucin samples (Figure 5.1 B). 
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Figure 5.1 Binding of MUB proteins to pPSM and PSIM in a slot-blot assay 
(A) Slot-blot of recombinant MUB proteins MubR5, -RV, -RI, -R8-V, -RV-VI, -RI-II-III and 
Nterm, and the native full-length MUB probed with pPSM and PSIM. Bound mucin was 
detected by f-RCA. (B) Control slot-blot of MUB proteins detected with f-RCA or primary 
anti-MubR5, anti-MubRI or anti-His5 followed by secondary anti-rabbit or anti-mouse-HRP.  
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In addition, the binding of the selected recombinant Mub repeats, MubRI-II-III and 
MubR5, and native MUB to MUC2 isolated from human biopsy samples of the sigmoid 
and ascending colon was investigated after agarose polyacrylamide gel electrophoresis 
(AgPAGE) in collaboration with Gunnar Hansson (and Jessica Holmen-Larsson) at the 
University of Gothenburg (Sweden). Reduced crude MUC2 samples from three 
different patients were separated by AgPAGE, blotted onto a PVDF membrane and 
stained by alcian blue, a cationic dye reacting with acidic mucosal polysaccharides and 
glycosaminoglycans (see 2.3.4.2 and 2.3.4.4) [405]. Membranes were incubated with 
MubR5 (50-70 μg/mL), MubRI-II-III (50-70 μ/mL) and MUB (10 μg/mL) and bound 
proteins detected via primary anti-MubRI and anti-MubR5, and secondary 
anti-rabbit-HRP (see 2.3.5).  
MubRI-II-III showed binding to MUC2 sample components of low and high MW, which 
stained positive with alcian blue, from the ascending and sigmoid colon of two (Pt 584 
and Pt 387) out of three tested patient samples (Figure 5.2), which may indicate 
a differential glycosylation of MUC2 in patient Pt 589. It is known that glycosylation 
profiles differ between individuals, however the relative variability is considered to be 
low (see 1.2.2) [113]. Observed differences in electrophoretic mobility and MW of 
MUC2 material may be due to differences in sample composition, degree of 
glycosylation and possibly degradation. The single repeat protein MubR5 did not show 
binding to MUC2 isolated from any of the patients. Interestingly, Coic and co-workers 
reported the colocalisation of the synthetic MUB70 peptide, which comprises the first 70 
residues of MubR5, with MUC2 on human colonic tissue samples and suggested its 
potential use as a human colonic mucus marker [303]. These observations indicate 
differences between assay types and stress the importance of the careful investigation 
of MUB protein binding to mucins, e.g. using different assay set ups and sufficient 
binding controls. Binding experiments with MUB were not conclusive due to ambiguous 
signals after antibody detection (data not shown). 
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Figure 5.2 Binding of MubR5 and MubRI-II-III to colonic MUC2 from human biopsy samples 
Western-blot of MUC2 isolated from human biopsy samples of the ascending (A) and/or 
sigmoid (S) colon of three different patients (Pt 584, 387, 589) after AgPAGE probed with 
MubR5 and MubRI-II-III. Bound protein detected via primary anti-MubR5 and anti-MubRI, 
and secondary anti-rabbit-HRP and Western-blot stained with alcian blue. 
The observation that the triple repeat MubRI-II-III but not the single repeat MubR5 
showed binding to colonic MUC2 material may again suggest the presence of several 
Mub repeats to be necessary for mucin binding. In addition, the binding of MubRI-II-III 
to MUC2 after AgPAGE but not to PSIM or pPGM after slot-blotting may indicate 
a potential role of mucin type and presentation for ligand recognition (as described 
above).  
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5.1.2 Assessment of MUB and MUB repeat binding to mucin glycans 
The binding of native MUB and the recombinant Mub repeats, MubR5 and MubRI-II-III, 
to human and porcine mucin was further investigated using two different microtitre 
plate assay set-ups modified from those described in literature for adhesin-mucin 
interaction or previously used in our lab for bacteria-mucus adhesion [249, 283, 302]. 
Firstly, purified native MUB (0.6 μg) and BSA (0.6 μg) as a control were coated on 
microtitre plates and then incubated with PSIM (1.6 μg), pPGM (0.4 ng) and purified 
human MUC2 (0.6 μg) kindly provided by Michael McGuckin (Mater Medical Research 
Institute, South Brisbane, Australia) (see 2.1.2). Bound mucin was detected via primary 
anti-Muc2.3 for PSIM and pPGM or anti-MUC2C3 for human MUC2, and secondary 
anti-rabbit-HRP (see 2.3.5). The binding epitope of anti-MUC2C3 is a 16 amino acid 
epitope at the C-terminus of human MUC2 (see 2.1.3). Anti-Muc2.3 is specific for a 14 
amino acid peptide of murine Muc2, but also reacted with PSIM and pPGM (see 2.1.3). 
The reactivity and sufficient signal intensity of PSIM, pPGM and human MUC2 
detection with the used anti-Muc2.3 and anti-MUC2C3 antibodies was confirmed for 
mucins immobilised onto microtitre plates (Figure 5.3 A and C). The presence of 
coated MUB at saturated concentration was confirmed by incubation with primary 
anti-MubRI and anti-MubR5 (data not shown). 
MUB did not show increased binding to PSIM and pPGM when compared to the BSA 
control (Figure 5.3 B), whereas higher signals were detected against MUC2 
(Figure 5.3 D). However, comparable signals were observed in control experiments, 
where primary and secondary antibodies were incubated on MUB and BSA in the 
absence of mucin ligands (Figure 5.3 B and D). The secondary anti-rabbit-HRP alone 
showed reduced signal intensities (Figure 5.3 D), suggesting that the unspecific 
interaction is mainly due to the reaction of the primary antibodies with the coated 
proteins. 
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Figure 5.3 Binding of MUB to porcine and human mucin 
Control assays with (A) immobilised PSIM (1.6 μg) (blue stripes) and pPGM (0.4 ng) (blue 
dots) detected via primary anti-Muc2.3 or (C) human MUC2 (0.6 μg) (blue) detected via 
primary anti-MUC2C3 followed by secondary anti-rabbit-HRP. (A+C) Anti-rabbit-HRP added 
to mucin coated wells as a secondary antibody control in the absence of primary antibodies 
(grey). (B) PSIM (blue stripes) and pPGM (blue dots) incubated on MUB and BSA with 
bound mucin detected by anti-Muc2.3 and anti-rabbit-HRP. (D) Human MUC2 incubated on 
MUB and BSA with bound mucin detected by anti-MUC2C3 and anti-rabbit-HRP. (B+D) 
MUB and BSA incubated with primary anti-Muc2.3 or anti-MUC2C3 followed by secondary 
anti-rabbit-HRP (grey), or anti-rabbit-HRP alone (white) as antibody controls. Error bars 
represented standard deviation from mean calculated from triplicate. 
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Secondly, PSIM, pPGM and BSA as a control were coated onto microtitre plates in 
excess and probed with increasing amounts of native MUB (0-1 μg) or recombinant 
MubR5 (0-20 μg) and MubRI-II-III (0-20 μg) (see 2.3.6.5). Bound MUB proteins were 
detected via protein specific primary anti-MubR5 and anti-MubRI, and secondary 
anti-rabbit-AP (see 2.1.3). The presence of PSIM and pPGM was verified by incubation 
with biotinlylated WGA (b-WGA) and ExtrAvidin-peroxidase. The presence of coated 
mucins was confirmed by detection with b-WGA and ExtrAvidin-peroxidase (data not 
shown). 
MUB showed concentration-dependent binding to PSIM and pPGM, as observed in 
slot-blot assays (see 5.1.1) (Figure 5.4 A). However, signals for MUB probed on BSA 
as a control showed slightly higher signal intensities than on coated mucins. MubR5 
and MubRI-II-III also showed interaction with PSIM and pPGM in a concentration 
dependent-manner, which was increased compared to the BSA control (Figure 5.4 B). 
Binding of the triple domain MubRI-II-III was higher at all tested concentrations 
compared to the single repeat MubR5, again indicating a correlation between the 
number of Mub repeats and binding capability (see 5.1.1).  
The high signals for all tested MUB proteins when probed on BSA may indicate 
unspecific interaction of the adhesins and the need to investigate alternative controls. 
Studies assessing the binding of lectins to coated mucin glycoproteins performed in 
a microtitre plate assay, suggested that BSA used as a blocking agent may interfere 
with binding when studying carbohydrate-protein interactions [406]. A protein free 
blocking solution was thus alternatively applied, which was also used for the above 
described binding experiments of MUB proteins to mucins (see 2.1.1). 
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Figure 5.4 Binding of MUB, MubRI-II-III and MubR5 to porcine mucin 
(A) MUB (0-1 μg) incubated on pPSM (blue dots) and PSIM (blue stripes), and (B) 
MubRI-II-III (blue dots) and MubR5 (green dots) incubated on pPSM (B) as well as BSA as 
a control (grey, grey-blue line, grey-green line). Bound proteins detected via primary 
anti-MubR5 and anti-MubRI, and secondary anti-rabbit-HRP. Error bars represent standard 
deviation of the mean calculated from triplicate.  
In order to further investigate the nature of the interaction of full-length MUB with 
pPGM, soluble sugars, 6’sialyllactose (6’SL, Neu5Acα2-6Galβ1-4Glc), Neu5Ac and 
lactose (Lac, Galβ1-4Glc), were used as inhibitors. Sialylation is commonly found in GI 
mucin O-glycans and has been identified in PGM O- and N-glycans together with high 
amounts of Gal and GlcNAc, the building blocks of Lac (see 1.1.2) [407]. Inhibition 
studies were performed in line to the above described microtitre plate assay, but after 
incubation of MUB (0.6 μg) on pPGM, binding was competed with sugars (0-200 mM), 
and bound MUB was detected via protein specific anti-MubRI and anti-MubR5 followed 
A 
B 
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by anti-rabbit-HRP (see 2.3.6.5). Data are presented as a percentage of binding 
relative to MUB binding in the absence of soluble sugar inhibitor. 
 
 
Figure 5.5 Competition of MUB binding to pPGM with soluble sugars 
Competition of MUB (0.6 μg) binding to pPGM using increasing concentrations of 
6’sialyllactose (6’SL) (blue), Neu5Ac (blue dots) and lactose (Lac) (blue stripes). Bound 
MUB was detected via primary anti-MubR5 and anti-MubRI, and secondary anti-rabbit-HRP. 
Absorbance measured at 405 nm and absorbance values presented as percentage binding 
relative to signal intensity at zero inhibitor concentration. Error bars represent standard 
deviation from the mean of a triplicate. 
 
 
MUB binding to pPGM was reduced by increasing concentrations of 6’SL, Neu5Ac and 
Lac up to 200 mM to about 55-60% compared to MUB adhesion in the absence of 
sugars (Figure 5.5). These data suggest the involvement of different sugar molecules 
in the binding of MUB to mucin, which offers numerous diverse glycan bindings sites 
(see 1.2).  
The potential role of sialic acid in the binding of mucin by MUB was further investigated 
using MUC1-glycopeptides carrying the specific non-sialylated and sialylated glycan 
epitopes: TF (Galβ1-3GalNAcα), STF (Siaα2-3Galβ1-3GalNAcα), Tn (GalNAcα) and 
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Gothenburg, Sweden) (see 2.1.2). Briefly, MUC1-glycopeptides were separated via 
SDS-PAGE and Western-blotted onto a nitrocellulose membrane, before incubation 
with native MUB (10 μg/mL) (see 2.3.6.1). Bound MUB was detected via anti-MubR5 
and anti-MubRI followed by anti-mouse-HRP, and the presence of 
MUC1-glycopeptides was verified using f-RCA and f-WGA. These lectins commonly 
recognise Gal and Neu5Ac residues (see 3.3.2, Table 3.3) and show additional 
reactivity with GalNAc [408]. Since the MUC1-glycopeptides are produced as fusion 
proteins with a mouse IgG Fc fragment (IgGFc), the interaction of MUB to mouse 
IgGFc was examined in a control slot-blot assay as described before, and IgGFc 
detected via anti-mouse-HRP (see 5.1.1). 
SDS-PAGE analysis of the MUC1-glycopeptides showed the presence of predominant 
protein bands for the peptides carrying the STF, Tn and STn antigens at about 150 to 
175 kDa, which is in line with earlier observations and in agreement with their 
theoretical MW (Figure 5.6 A) [327-328]. For MUC1-STF and -STn additional bands at 
lower MW were observed, which may be caused by protein contamination or 
degradation. Two strong bands were observed at about 30 kDa for the MUC1-TF 
peptide, suggesting its degradation in multiple fragments. Our collaborators at the 
University of Gothenburg demonstrated the reactivity of all visible bands for the 
4 tested MUC1-glycoproteins by anti-MUC1 detection after Western-blotting confirming 
their integrity (data not shown). Additionally, all MUC1-glycopeptides samples showed 
reactivity with f-RCA and f-WGA (Figure 5.6 D). 
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Figure 5.6 Binding of MUB to MUC1 glycopeptides 
(A) Coomassie-stained SDS-PAGE gel of MUC1-IgGFc-glycopeptides with protein 
standards (1 and 2). (B) Western-blotted MUC1-IgGFc-glycopeptides probed with MUB, and 
bound MUB detected via primary anti-R5 and anti-RI, and anti-rabbit-HRP. (C) Control 
slot-blot assay of MUB probed with mouse IgGFc detected via anti-mouse-HRP. Slot-blotted 
MUB detected via anti-MubRI and anti-MubRI followed by anti-mouse-HRP, or incubated 
with anti-mouse-HRP alone as a control. (D) Slot-blot of MUC1-IgGFc-glyopeptides probed 
with f-RCA and f-WGA. 
When probed against the MUC1-TF, -STF, -Tn, and -STn peptides after 
Western-blotting, MUB showed binding to MUC1-Tn and the high MW species of 
MUC1-STF and -STn, as well as lower MW fragments of MUC1-STn, while no signals 
could be observed for MUC1-TF (Figure 5.6 B). However, MUB also showed 
interaction with mouse IgGFc as demonstrated in a control slot-blot assay, which may 
contribute to the observed binding of MUB to the MUC1-IgGFc-glycopeptides (Figure 
5.6 C). The binding of recombinant Mub-repeat proteins to Igs, including human IgG 
and IgGFab but not human IgGFc, has been demonstrated in our lab before [282]. 
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5.1.3 MUB binding studies using mucin and neoglycoconjugate arrays  
In order to screen a number of GI mucins for binding by native MUB, mucin microarray 
experiments were performed in collaboration with Lokesh Joshi (and Michelle Kilcoyne) 
at the University of Ireland (Galway, Ireland). The arrays contained mucins isolated 
from the GI tracts of different animal species (deer, equine, bovine, ovine, chicken, 
porcine, mouse and rat) and from two mucus-producing intestinal epithelial cell lines 
(LS174T and HT29-MTX-E12) as well as several binding controls all printed in replicas 
of 6. Covalent conjugation of the mucin probes to the microarray polymer surface was 
achieved via accessible amino groups in the terminal regions of the protein backbone. 
Mucin array printing and binding experiments were performed as described by Kilcoyne 
and co-workers [409]. Briefly, MUB was probed on the array in PBST (0.01% 
Tween-20) at 23°C for one hour, followed by detection via primary anti-MubRI and 
secondary anti-rabbit-AlexaFluor555 with wash steps in between using PBST (0.005% 
Tween-20).  
Under these conditions, MUB (17 μg/mL) was shown to bind a number of mucins from 
different species including deer, equine, ovine, chicken, porcine, rat and predominantly 
mouse, with no obvious preference for mucins isolated from various parts of the 
GI tract (Figure 5.7). Low binding of MUB to commercial PGM was observed in line 
with the microtitre plate and slot-blot assays described earlier (see 5.1.1 and 5.1.2). 
Additionally, MUB bound to mucin originated from mucus-producing intestinal cell lines, 
especially LS174T over HT29-MTX-E12 (Figure 5.7). No binding signals were 
observed for the control proteins, asialofetuin, fetuin, RNase B, transferrin and the egg 
white ovomucin, or in the absence of printed probes. However signals were also 
observed for primary and secondary antibodies in the absence of MUB, which suggests 
some level of unspecific interaction of the antibodies used for adhesin detection with 
the printed probes. However, MUB (5-20 μg/mL) showed concentration-dependent 
binding to different mucins in control arrays, where constant primary and secondary 
antibody concentrations were used indicating binding specificity of MUB to mucin 
probes (Figure  5.8). Nevertheless, further optimisation of the mucin array experiments 
are desirable to reduce unspecific antibody interaction, for example by using 
fluorescently labelled MUB protein. 
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Figure 5.7 Mucin binding of MUB assessed using a GI mucin array 
MUB (17 μg/mL) probed on a GI mucin array containing mucin probes from intestinal epithelial cell lines and different sections of deer, equine, bovine, 
ovine, chicken, porcine, mouse and rat gut as well as binding controls. Bound MUB detected by primary anti-MubRI (1:2,000) and secondary 
anti-rabbit-AlexaFluor555 (1:1,000) (blue). Control array probed with anti-MubRI (1:2,000) and anti-rabbit-AlexaFluor555 (1:1,000) in the absence of MUB 
(grey). Data presented as average of three independent experiments with 6 probe replicas per array with error shown as standard deviaton of the mean. 
Signals above threshold of about 1,700 RFU repesent binding to probes (red line). 
Cell lines 
Deer Equine Bovine Ovine 
Chicken 
Porcine Mouse Rat Controls 
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Figure 5.8 Concentration-dependent binding of MUB to GI mucins 
MUB probed at different concentrations 18 μg/mL (blue), 15 μg/mL (yellow), 10 μg/mL (green) and 5 μg/mL (red)) on a GI mucin array containing mucins 
from intestinal epithelial cell lines and different animal species as well as binding controls. Bound MUB detected via primary anti-MubR1 (1:1,000) and 
secondary anti-rabbit-Alexa Fluor555 (1:1,000). Signals above threshold of about 2,000 RFU represent binding to probes (red line).  
Cell lines 
Deer Equine Bovine Ovine 
Chicken 
Porcine Mouse Rat Controls 
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In parallel, a glycoconjugate array experiment was performed using the same array 
platform as for the GI mucin arrays, in order to identify glycan epitopes that potentially 
mediate MUB binding to mucins and thus can be tested as sugar inhibitors in the 
mucin array [410]. The glycoconjugate array contained different glycan structures 
including blood group epitopes conjugated with bovine or human serum albumin (BSA 
or HSA), which were immobilised via protein amino groups as for mucin arrays 
(described above). Bound MUB was detected via primary anti-MubRI and secondary 
anti-rabbit-AlexaFluor555.  
MUB (10 μg/mL, 15 μg/mL, 18 μg/mL) showed concentration-dependent binding to 
6 glycan strucures with highest signals for GlcNAc and fucosylated LacNAc (Fucα
1-2Galβ1-4GlcNAc-), while no binding was observed for LacNAc alone (Table 5.1, see 
Appendix XII). All bound glycoconjugates contained Fuc, Gal or GlcNAc residues and 
nearly all of them were composed of LacNAc type 1 (Galβ1-3GlcNAc) or type 2 (Galβ
1-4GlcNAc) and Lac (Galβ1-4Glc) disaccharides, which can be found in mucin glycan 
structures (see 1.2). 
 
Name Structure 
GlcNAc- GlcNAc 
 
H2- Fucα1-2Galβ1-4GlcNAc  
LNFPII- Fucα1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc- 
LNFPIII- Galβ1-4[Fucα1-3]GlcNAcβ1-3Galβ1-4Glc- 
3SuLex (SO4)Galα1-3[Fucα1-3]GlcNAc- 
GlobT Galα1-4Galβ1-4Glc- 
Table 5.1 Glycoconjugates recognised by MUB 
 
Interestingly, no binding of MUB to sialylated structures linked α2-6 or α2-3 to Gal was 
observed, which is in contrast to the results from microtitre plate competition studies 
showing that Neu5Ac and 6’SL were able to reduce MUB binding to pPGM (see 5.1.2). 
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Figure 5.9 MUB binding to GI mucins in the presence of sugar molecules 
MUB (17 μg/mL) probed on a mucin array with GI mucins from intestinal epithelial cell lines and different animal species as well as binding controls in the 
absence (blue) or presence of soluble sugars (100 mM), Fuc (yellow), Gal (red), GlcNAc (green) and Lac (white). Bound MUB detected primary anti-MubRI 
(1:2,000) and secondary anti-rabbit-Alexa Flour555 (1:1,000). Data presented as average of three independent experiments with 6 probe replicas per array 
with error presented as standard deviaton of the mean. Signals above threshold of about 1,700 RFU represent binding to probes (red line).  
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After identification of these potential sugar ligands, inhibition studies were performed 
with MUB incubated in the presence of Fuc, Gal, GlcNAc and Lac (100 mM) using the 
mucin arrays as described above. MUB co-incubated with Fuc or Gal showed the 
same level of binding compared to MUB in the absence of soluble sugar molecules, 
while increased binding was observed for GlcNAc and Lac (Figure 5.9). These data 
indicate that Fuc and Gal may not be involved in the binding of MUB to mucins used in 
this array and that MUB however interacts with GlcNAc and Lac residues promoting 
binding to mucin. This enhanced binding may be due to cross-linking of MUB 
molecules by these sugar molecules causing MUB oligomerisation or even 
aggregation. Indeed, the ability of MUB to oligomerise in solution has been 
demonstrated by AUC, albeit in the absence of soluble sugars, and native PAGE 
experiments, and co-crystallisation studies showed the cross-linking of two MubR5 
molecules by Man (see 3.3.2 and 4.1).  
In addition to the mucin and neoglycoconjugate microarray experiments (as above), 
the full-length MUB protein was screened against the mammalian printed glycan array 
(version 5.0) by the Consortium for Functional Glycomics (CFG) [411]. However, no 
binding of MUB to mammalian glycans was observed (see Appendix XIII). 
5.2 Binding of MUB proteins to glycans 
After demonstrating the binding of MUB proteins to different mucins, the involvement 
of glycans in this interaction and identification of potential sugar ligands in an initial 
screening, further studies were performed to investigate the sugar specificity of MUB 
proteins and characterise their sugar binding ability. 
5.2.1 Assessment of MubR5 binding to mannose ligands using ITC 
Co-crystallisation studies of MubR5 with soluble mono- and disaccharides commonly 
encountered in mucin glycans revealed two adjacent MubR5 molecules in contact with 
a single Man molecule (see 4.1). In order to further investigate the binding ability of 
MubR5 to Man ligands, isothermal titration calorimetry (ITC) experiments were 
performed in collaboration with David Bolam (Newcastle University, UK) (see 2.4.1). 
The tri-, di- and monosaccharides, Mannoseα1-3(Mannoseα1-6)mannose 
(Manα1-3(Manα1-6)Man), Mannoseα1-6mannose (Manα1-6man) and Man were 
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titrated into MubR5 (95 μM) as well as into a matching sample buffer control 
(see 2.4.1).  
 
 
Figure 5.10 Binding of MubR5 to mannosides investigated by ITC 
Titration of mannose ligands (10 mM) (A) Mannose-α1-3(Mannoseα1-6)mannose (Manα
1-3(Manα1-6)Man) (C) Mannose-α1-6-mannose (Manα1-6man) and (D) Man, or (B) PBS 
buffer control against MubR5 (95 μM). Upper panel showing injection heats (raw data) and 
lower panel integrated data fitted to a single site binding model. 
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MubR5 did not bind to Manα1-6man or Man at 10 mM, as no change in heat was 
detected with increasing molar ratio of ligand to receptor (Figure 5.10 C and D). 
A decrease in heat was observed for (Manα1-3(Manα1-6)Man), however similar heat 
changes showed for the control titration of the trisaccharide into the sample buffer 
(Figure 5.10 A and B). Hence, MubR5 did not seem to bind to Man saccharides under 
the tested condition despite previous observations in X-crystallography 
co-crystallisation studies (see 4.1). 
5.2.2 Screening of mono- and oligosaccharides for MUB protein binding by 
glycan arrays 
In order to dissect the binding ability and specificity of MUB and Mub repeats, 
additional glycan binding studies were performed using a nitrocelluslose glycan array. 
The array contained immobilised plant derived glycans conjugated or non-conjugated 
to BSA, and BSA as a control, and was kindly provided by William Willats (University 
of Copenhagen, Denmark) (see 2.3.6.2) [412]. Purified MubR5 (0.3 mg/mL), MubRI 
(0.3 mg/mL), NtermMubRI (0.45 mg/mL) and native MUB proteins (60 μg/mL) were 
incubated on the nitrocellulose arrays and bound proteins detected via primary 
anti-MubR5, anti-MubRI and anti-His5 followed by secondary anti-mouse-AP or 
anti-rabbit-AP (see 3.1.1, 3.1.2, 3.3.1 and 2.3.5). 
Only a few very faint binding signals were detected for the single Mub repeats, MubR5 
and MubRI, which were however similar to those observed in the control experiments 
using primary and secondary antibodies in the absence of adhesins (Figure 5.11 A 
and B). An increase in positive spot number was observed for NtermMubRI, while no 
signal was detected for the primary and secondary antibodies in a control experiment 
(Figure 5.11 A and B). Among those, strongest signals were observed for Man 
glycans, Glc structures with β1-4 and β1-3 linkages as well as for arabinose and 
xylose glycans. No signal was detected for the BSA control suggesting that adhesin 
binding to spotted BSA-glycans is mediated by the carbohydrate structures conjugated 
to BSA and not to the carrier protein itself. In addition, a high number of positive spots 
corresponding to carrageenan molecules were observed. These carbohydrates are 
linear, helical polysaccharides isolated from seaweed and composed of repeating α1-3 
and β1-4Gal units with varying levels of sulphation. This may indicate interaction of 
these glycans due to their net negative charge. 
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Figure 5.11 Glycan binding ability of MubR5, MubRI, NtermMubRI and MUB assessed 
using a glycan array 
(A) Nitrocellulose glycan array spotted with plant derived glycans partially BSA-conjugated 
incubated with MubR5 (0.3 mg/mL), MubRI (0.3 mg/mL), MUB (60 μg/mL) and NtermMubRI 
(0.45 mg/ml). Bound protein detected via primary anti-MubR5, anti-MubRI or anti-His5, and 
secondary anti-rabbit-AP or anti-mouse-AP. (B) Control membrane glycan array probed 
with primary and secondary antibodies in the absence of adhesins. 
For the full-length MUB additional strong signals were detected corresponding to 
carrageenan, β-glucan, pectin, gum and mannan containing Gal, Man, Glc and 
B 
A 
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galacturonic acid (GalA) residues (for further information see Appendix XIV). 
Furthermore, signals were detected for the monosaccharides Man, Glc and Gal as well 
as for the Lac disaccharide. 
Taken together, these preliminary data suggest a possible interaction of MUB proteins 
with glycan structures. However, the potential sugar binding ability of MUB proteins 
needs to be further investigated in alternative glycan assays. It is particularly important 
to address, whether the binding to carbohydrate structures depends on specific sugar 
recognition or is the sum of unspecific, weak ionic interactions, for example by 
competition studies with soluble sugar ligands or direct protein detection assays. As 
reported earlier, a correlation between the number of functional domains and the 
interaction capacity of MUB proteins was observed (see 5.1.1 and 5.1.2).  
Moreover, since we showed that antibodies may in some ways interfere with the 
specificity of the interaction, a gold (Au)-array with mucin-like sugar molecules was 
used allowing an alternative detection method of bound adhesins based on MS, in 
collaboration with Sabine Flitsch (and Mirja Hartmann) (University of Manchester, UK). 
Briefly, the Au-arrays were functionalised with the monosaccharides Fuc, Gal, GlcNAc 
and Man, the disaccharide Lac, which was further modified via enzymatic synthesis to 
form 6’SL and 3’SL structures (see 2.3.6.3.1). Functionalised glycan arrays or 
Au-chips with self-assembled monolayers of linker and spacer molecules before 
functionalisation with sugar molecules were probed with MUB, MubRI-II-III, MubRV-VI, 
MubR8-V, MubR5, MubRV and Nterm, to assess binding and unspecific interaction of 
MUB proteins with linker molecules (see 2.3.6.3.2), respectively.  
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Figure 5.12 Sugar binding of MubRI-II-III assessed using a sugar Au-array 
MubRI-II-III probed on a sugar Au-array with Fuc (dark blue), Gal (orange), GlcNAc (green), 
Man (yellow), Lac (light blue), 3’SL (grey) and 6’SL (red) and on non-functionalised 
Au-surface (black). MS spectra shown as average intensity (a.i.) plotted against 
mass-to-charge-ratio in a mass range of 6,500 to 160,000 m/z and presented offset for 
better visualisation.  
MS spectra were obtained for all tested adhesins except for the native MUB after 
incubation of proteins on untreated Au-surfaces, allowing the detection of any bound 
protein molecules via MS on sugar-functionalised surfaces. (The presence of 
characteristic protein peaks but not signal intensity defines the binding event). Only 
MubRI-II-III showed reproducible binding to the sugar Au-array to Fuc, Gal, GlcNAc, 
Lac, and both sialylated Lac structures, but not to Man (Figure 5.12). No unspecific 
interaction for MubRI-II-III probed on non-functionalised linker monolayers was 
observed (data not shown). These data suggest the recognition of certain sugar 
molecules by MubRI-II-III and is in line with previous observations, that several 
Mub repeats may be necessary for receptor recognition. Furthermore, it is in 
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agreement with the results for MUB binding to glycans on a glycoconjugate array, 
where MUB bound to Fuc, Gal, GlcNAc and Lac containing glycan structures (see 
5.1.3). In addition, previous findings were confirmed, which demonstrated that MubR5 
does not recognise Man ligands in ITC experiments (see 5.2.1). 
These different screening approaches also highlight the difficulty in assessing 
glycan-protein interaction and the necessity to carry out biomolecular interaction 
assays, such as ITC, SPR or bio-layer interferometry (BLI), to confirm or infirm the 
specificity of the interaction.  
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5.3 Discussion 
The mucus layer is the first point of contact for intestinal bacteria with the host and 
serves as a habitat for the gut microbiota [25]. Bacterial adhesion to mucus is thought 
to be mediated via the interaction of mucin glycoproteins, the main structural 
components of mucus, with bacterial cell-surface adhesins [22, 179, 275]. A number of 
different mucus adhesins have been identified in lactobacilli and implicated in bacterial 
adhesion to mucus (see 1.4.2.). A correlation between the presence of mucus binding 
(Mub) or mucin-binding protein (MucBP) domains (Pfam database PF06458) in 
cell-surface proteins from Lactobacillus strains and their mucus binding ability has 
been reported (see 1.4.2) [8, 304]. The presence of the mucus-binding protein MUB of 
L. reuteri ATCC 53608, comprised of 14 Mub repeats of type 1 and type 2, is important 
for bacterial adhesion to mucus, as previously demonstrated in our lab (see 1.4.2) 
[302]. Reduced mucus adhesion was observed for the mutant strain 1063N of 
L. reuteri ATCC 53608, expressing a truncated MUB protein [302]. Besides the 
reported binding of recombinant Mub-repeat proteins in fusion with a maltose-binding 
protein (MBP) to chicken and porcine mucin in a microtitre plate assay, no further 
characterisation of the interaction of individual Mub repeats or of the native full-length 
MUB has been reported [283]. The current working hypothesis is that bacterial 
adhesins, such as MUB, mediate mucus interaction via the recognition of mucin 
glycans. 
In order to test this hypothesis, we investigated the binding ability of recombinant 
single and tandem Mub-repeat proteins, N-terminal domain proteins and the native 
full-length MUB to different mucins and mucin glycans in vitro. The full-length native 
MUB, demonstrated binding to PSIM and pPGM after slot-blotting onto nitrocellulose 
membrane, while no binding was observed for Mub-repeat proteins or the Nterm 
region (see 5.1.1). However, MUB as well as MubR5 and MubRI-II-III showed 
concentration-dependent binding to PSIM and pPGM when incubated on immobilised 
mucin. In contrast, no MUB binding to PSIM, pPGM or human MUC2 was observed 
when mucins were probed on immobilised MUB protein in a microtitre plate assay 
(see 5.1.2), indicating the potential importance of correct ligand presentation. 
Additionally, MubRI-II-III but not MubR5 bound to colonic MUC2 from human biopsy 
samples after AgPAGE and Western-blotting (see 5.1.1). Furthermore, when 
screening a number of mucins for binding by native MUB using a GI mucin array, 
151 
 
binding was detected to mucins from various animal species, especially mouse, rat, 
pig, sheep and deer. MUB also bound to mucins isolated from the intestinal epithelial 
cell lines LS174T and HT29, which express the gel-forming mucins MUC2, MUC6, 
MUC5AC and MUC5B (see 5.1.3) [413-414]. Taken together these results 
demonstrate the binding of native MUB and recombinant Mub repeats but not the 
Nterm protein to different mucins and indicate a correlation between the number of 
Mub repeats and protein binding capability.  
The binding ability of commensal adhesins to mucus and mucins has been 
demonstrated for a few lactobacilli. For example, the MapA protein of L. reuteri 104R 
showed binding to porcine small intestinal mucin and PGM in dot-blot assay similar to 
that one used for MUB-protein binding studies (see 5.1.1) [285]. Additionally, 
interaction with mucins isolated from colonic HT29-MTX epithelial cells was observed 
for the recombinant GroEL and EF-Tu proteins from L. johnsonii NCC 533 in 
a microtitre plate assay [297-298]. Another example are the fiber-like pilin structures, 
SpaCBA and SpaFED, identified in L. rhamnosus GG, which are similarly found in 
other Lactobacillus strains (see 1.4.2). The recombinant, labelled pilin proteins SpaB, 
C and F bound to human colonic mucus coated onto microtitre plates and binding was 
competed adding unlabeled protein. In addition, binding of bacterial cells expressing 
SpaC, F and B to human mucus was inhibited by SpaC and SpaF, but not by SpaB 
antiserum [288-289]. The positively charged Spa B (pI 8) seems to adhere to mucus, 
which has a net negative charge, via non-specific electrostatic interactions under the 
used assay conditions [289]. In contrast, native MUB and Mub-repeat proteins have 
low pI values of about 4.5 to 5.0 pI, as calculated from their amino acid sequence 
(see 2.6.2) and demonstrated via IEF (see 3.2). They thus have a neutral or negative 
net charge in the GI tract or under the used assay condition, indicating the specificity 
of the interaction with mucins. However, adhesion of MUB proteins to highly sialylated 
and sulphated mucins (see 1.2.2) due to electric charge cannot be completely 
excluded, and thus further investigation of the nature of MUB-mucin adhesion is 
needed.  
From the observations made in this study, it seems that the number of Mub repeats is 
important for their ability to bind mucin and multivalent interactions are generally 
common in biology and considered to be necessary to achieve high avidity binding 
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[415]. For some L. plantarum strains, expressing the mannose-specific adhesin Msa, 
a partial correlation between Man-dependent yeast agglutination and varying numbers 
of MucBP domains in Msa proteins can be observed (see 1.4.2) [312]. Studies with 
Staph. aureus showed that at least three out of 11 fibronectin-binding repeats (FnBRs) 
of the cell-surface fibronectin binding protein (FnBP), which possess different binding 
affinities for fibronectin, are necessary for target cell adhesion and invasion [416-417]. 
In addition, the MSCRAMM LigB from pathogenic Leptospira species contains Ig-like 
domains, as found in other MSCRAMM (see 4.4), and shows an increase in ligand 
binding affinity with increasing number of Ig-like domains [418]. 
In addition, mucin binding control experiments revealed some level of MUB protein 
binding to BSA and IgGFc fragments (see 5.1.2). This suggests that MUB may interact 
with mucin proteins via the recognition of the protein backbone or with other protein 
ligands found in mucus (see 1.1.2). Indeed, the binding ability of Mub repeats to IgA 
and other Igs has been demonstrated in our lab [282]. Igs, especially IgA, are found in 
large amounts in mucus [25, 27]. Proteomic analysis of mucus from stomach, small 
intestine and colon of mice also revealed a high abundance of albumin, however it is 
unclear whether this is due to contamination during sample extraction [28]. The ability 
of a mucus-adhesin to bind mucin and another protein in human colonic mucus was 
reported for 32-MmubP from L. fermentum (see 1.4.2) [419]. Further experiments, are 
warranted to investigate the potential binding of MUB proteins to the mucin protein 
backbone using for example glycosylated and de-glycosylated mucins after enzymatic 
or chemical treatment, or by performing sugar inhibition studies [420-422]. 
The role of mucin glycans in the interaction of MUB proteins was further assessed in 
sugar competition studies. MUB showed reduced binding to pPGM in the presence of 
Neu5Ac, Lac and 6’SL in microtitre plate assays (see 5.1.2). In contrast, increased 
MUB binding was observed for Lac and GlcNAc, while Gal and Fuc did not have an 
effect on MUB binding to GI mucins in a mucin array (see 5.1.3). This may indicate the 
cross-linkage of MUB molecules by sugar residues. The tendency of MUB to form 
oligomers has been demonstrated by native PAGE and AUC experiments albeit 
without further addition of sugars (see 3.3.2). Furthermore, L. reuteri ATCC 53608 but 
not the mutant strain 1063N, expressing a truncated MUB protein on the cell surface, 
shows auto-aggregation ability (see 4.4) [302]. Co-crystallisation studies of MubR5 
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demonstrated the cross-linking of two MubR5 molecules by Man (see 4.1). However, 
ITC experiments with MubR5 and Man ligands did not confirm the binding of Man by 
MubR5 (see 5.2.1). Man is part of the core N-glycan structure and thus less abundant 
in mucin glycans, which are mainly O-linked (see 1.2). However, MucBP domain 
containing Msa proteins from L. plantarum strains seem to be involved in 
Man-dependent binding to epithelial cells (see 1.4) [293, 312]. In addition, the binding 
of Man by the FimH adhesin present in uropathogenic E. coli (UPEC), which colonise 
the urinay bladder mucosa and whose reservoir is thought to be the GI tract, is well 
established (see 1.4.1) [234, 423]. Even though, interaction of FimH with mucins has 
not yet been reported, the bladder is interestingly lined by a ‘bladder mucus layer’ 
composed of glycosaminoglycans (GAGs) also known as mucopolysaccharides. 
GAGs are long polysaccharide chains which can be O- or N-linked to proteins and the 
GAG keratan sulphate is linked to the N-glycan core structure [424-427]. It is thus 
possible that commensal bacteria adhere to mucins via recognition of less abundant 
Man sugars by cell-surface adhesins. 
Further screening for specific glycan ligands with native MUB was performed using 
different glycan array platforms. This analysis revealed binding to glycan structures in 
a neoglycoconjugate array, which were composed of LacNAc and Lac units including 
terminal blood group epitopes, H2 (Fucα1-2Galβ1-4GlcNAc) or sulphated Lex 
(see 5.1.3). Additionally, membrane glycan arrays revealed binding of MUB to Man, 
Gal, Glc and Lac-containing sugar molecules as well as to a number of highly 
sulphated polysaccharides (see 5.2.2), again indicating a potential role for unspecific 
electrostatic interactions in MUB binding to glycans as discussed earlier. In an 
Au-glycan array the recombinant triple domain MubRI-II-III showed binding to Fuc, Gal 
and GlcNAc monosaccharides, as well as the disaccharide Lac and sialylated Lac 
structures with α2-3 and α2-6 linkages. As reported earlier, no binding was observed 
for single or double Mub-repeat proteins, and the Nterm protein, indicating that MUB 
sugar binding is mediated by the presence of several Mub repeats (see 5.2.2). 
Additionally, no difference can be observed between the mucin or sugar binding ability 
of Mub type 1 or type 2 repeats (see 5.1.1 and 5.2.2). Very few studies have 
investigated the nature of mucin ligands recognised by mucus adhesins. The adhesin 
GAPDH from L. plantarum LA 318 binds to human colonic mucin, and recent 
characterisation studies using SPR showed its specificity for ABO blood antigens 
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H (Fucα1-2Gal-), A (GalNAcα1-3[Fucα1-2]Gal) and B (Galα1-3[Fucα1-2]Gal), whereas 
comparably weaker binding to Neu5Ac was observed [294]. Similary, the BabA and 
SabA protein of H. pylori, binds to gastric mucins via recognition of ABO blood group 
antigens, Lea or sialyl-Lea and sialyl-Lex, respectively, which contain Gal, GlcNAc, Fuc 
and Neu5Ac residues (see 1.4.1) [207, 242]. SPR experiments with the pathogenic 
E coli F17 G pili protein demonstrated binding to GlcNAc but not to Gal, GalNAc or Glc 
sugar molecules [237]. The enteric parasite E. histolytica, which expresses a cell-
surface Gal/GalNAc lectin, binds to human and rat colonic mucin and binding can be 
inhibited by Gal and GalNAc [246-247]. These data suggest that pathogenic and 
commensal adhesins may share the same molecular targets at the mucosal surface, 
although more work is required to further biochemically assess the exact sugar affinity 
and specificity of MUB proteins. 
Ligand recognition of fimbrial adhesins is often mediated via their N-terminal protein 
domain, while additional domains act as a scaffold to present the ligand binding 
domain and enhance ligand accessibility. For example the PapG, F17-G and FimH 
adhesins present in E. coli pili are located at the N-terminal pili tip, where they mediate 
binding to Gal, GlcNAc and Man ligands, respectively (see 1.5) [235, 237, 428-431]. 
Another example are siglecs, which are composed of variable numbers of C-domains 
and an N-terminal V-domain (V-set Ig-like domain) which mediates sialic acid binding 
[432]. X-ray crystal structures are available for the V-domain of Siglec-1 (sialoadhesin) 
and Siglec-7 in complex with Neu5Acα2-3Gal and Neu5Ac, respectively [433-434]. 
However, while the first, N-terminal domain is sufficient for sialic acid recognition in 
Siglec-1, Siglec-2 (CD22) requires the first two N-terminal domains for ligand binding 
[435-437]. In the SpaCBA pili present on the cell-surface of L. rhamnosus GG, the 
SpaC adhesin, mediating binding to human intestinal mucus, has been located at the 
pilus tip as well as along the pilus fiber [288, 438]. In contrast, the N-terminal domain 
of MUB did not demonstrate any binding to mucin or mucin glycans under the used 
assay conditions in vitro, but binding was observed for MubRI-II-III comprising the first 
three N-terminal Mub repeats of MUB. These observations may indicate an alternative 
molecular mechanism of ligand interaction of MUB compared to other elongated 
adhesion molecules.  
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This study additionally highlighted potential pitfalls of in vitro screening approaches 
when studying protein-glycan interaction, including for example adequate ligand 
presentation, appropriate detection methods, blocking agents or suitable binding 
controls [439]. Significant advances have been made to improve and develop glycan 
array platforms that account for the complex glycan landscape found in natural 
systems. These include the natural ligand presentation using glycan material isolated 
from natural sources and direct immobilisation methods without the use of chemical 
linkers or use of carrier proteins such as albumin [409, 412, 440-443]. Alternative 
strategies to obtain glycan material for linker based surface-conjugation are chemical, 
chemoenzymatic or enzymatic syntheses, which avoid microheterogeneity present in 
naturally sourced glycans and aim for a natural mimetic surface presentation [444-
447]. Although, fluorescent-labelling is one of the most frequently used detection 
methods for protein-carbohydrate interactions, label-free technologies such as SPR or 
MS can be combined with glycan-arrays. A recent comparison between two 
sialoglycan microarrays, differing in the number of diverse sialic acid structures, using 
fluorescently labelled antibodies for detection, revealed their potential to provide 
complementary information, however also highlighted possible factors leading to 
differential glycan recognition, such as glycan immobilisation [448]. These 
observations stress the need of using additional techniques such as SPR or ITC to 
biochemically evaluate the interaction of potential sugar ligands identified by glycan 
array screening.  
In summary, we demonstrated the binding of native MUB and recombinant 
Mub repeats to mucins and different mucin glycans as indicated by sugar inhibition 
assays and sugar screens (see 5.1 and 5.2). In particular, we showed binding to blood 
group antigens, Lac, sialylated Lac as well as to Gal, GlcNAc and Fuc 
monosaccharides or glycan structures containing those sugars using different glycan 
arrays (see 5.2.2). However, the interaction of potential sugar ligands with MUB 
proteins requires further characterisation. Inhibitions studies with soluble sugar 
molecules using Au-arrays are ongoing. In order to validate carbohydrate-adhesin 
interactions, SPR, ITC and BLI experiments need to performed, which have the 
additional benefit of label-free detection. Additionally, co-crystallisation experiments of 
multiple Mub-repeat proteins with sialylated Lac or blood group antigens will provide 
functional basis for the glycan recognition by MUB proteins. 
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CHAPTER 6 STRUCTURAL AND FUNCTIONAL 
CHARACTERISATION OF LAR0958 
Lar0958 is a recently identified cell-surface adhesion protein present in the human 
isolate strains L. reuteri MM4-1a, DSM 20016T and JCM 112T [302, 324]. It is 
a modular protein with an N-terminal signal peptide and a C-terminal LPXTG-motif 
facilitating covalent attachment to the bacterial cell wall.  
 
 
Figure 6.1 Schematic representation of Lar0958 
Domain organisation of the Lar0958 cell-surface protein of DSM 20016T with five virtually 
identical repeats (1-5, green), one repeat of lower homology (6, blue) and the N-terminal 
domain (Nterm, grey). The LPXTG-motif for covalent attachment to cell wall peptidoglycan 
is presented as a black line. 
The full length Lar0958 contains 4 identical repeats of 96 residues, a virtually identical 
fifth repeat of 97 residues, and a final 94 amino acid repeat of lower homology (46% 
identity) (Figure 6.1). L. reuteri DSM 20016T and MM4-1a bind to mouse colonic 
mucus (MCM), whereas the MM4-1a Lar0958 knock out (KO) strain MM4KO shows 
reduced binding ability to mucin [302, 324]. The specific ligands involved and the 
biochemical mechanism of adhesion remains, however, elusive. In order to structurally 
and functionally characterise Lar0958, we cloned and heterologously expressed 
a recombinant single Lar0958 repeat in E. coli. 
6.1 Cloning, expression, purification and biophysical characterisation of 
Lar0958 
For the cloning of a single lar0958 gene, primers were designed to anneal to the 
border regions of the identical repeats of the full length lar0958 gene of L. reuteri 
DSM20016T (BioProject accession numbers PRJNA15766 and PRJNA58471). The 
PCR-amplified lar0958 repeat (see 2.2.1) was cloned into the pETBlue-1 AccepTor 
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vector (see 2.2.4), the sequence integrity verified by automated DNA sequencing 
(see 2.2.6) and the pETBlue-1 AccepTor_lar0958 vector construct transformed into 
E. coli Tuner(DE3)pLacI2 cells (see 2.2.5). The single Lar0958 repeat protein was 
expressed in the periplasm of the expression host in a soluble form at 37°C after 
induction with 1 mM IPTG (see 2.3.1.1), but some recombinant protein was also 
present in the insoluble bacterial pellet fraction (Figure 6.2 B). Lar0958 was extracted 
from bacterial cells via a freeze-thaw method, thus avoiding cell disruption and 
contamination with host cell proteins in the cell extract (see 2.3.1.2). The clarified 
crude extract was applied to an IEC column and Lar0958 eluted in a distinct peak 
(Figure 6.2 A). 
 
 
Figure 6.2 Lar0958 protein purification via IEC 
(A) IEC profile of Lar0958 (red) and (B) SDS-PAGE gel analysis of IEC elution fractions (as 
indicated in A) (1 pellet, 2 crude extract, 3-5 elution fractions). 
The IEC elution fractions were analysed by SDS-PAGE and only a single protein band 
with an apparent MW of 11.6 kDa was observed, which is in good agreement with the 
10.4 kDa theoretical MW of Lar0958 (see 2.6.2). The absence of contaminating bands 
upon SDS-PAGE analysis revealed the sample homogeneity to be sufficient for further 
functional and structural studies (Figure 6.2 B).  
In order to determine the pI value of Lar0958, to examine proper protein folding and to 
obtain initial information on secondary structural elements of the recombinant Lar0958 
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protein, IEF and CD experiments were conducted (see 2.4.1 and 2.4.2). IEF was 
performed via gel electrophoresis in a pH range of 3 to 7 and a voltage gradient 
(see 2.3.4.3). The pI value of Lar0958 was determined as 6.23 compared to the IEF 
standard (Figure 6.3 A) in reasonable agreement with the theoretical pI value of 6.09 
(see 2.6.2).  
 
 
 
 
 
 
 
 
 
 
 
sample ɑ-helix [%] β-sheets [%] β-turns [%] 
β-sheets and β-
turns [%] unordered 
Lar0958 12.2 (10.3)a 28.7 (27.8)a 18.2 46.9 40.9 
 
Figure 6.3 IEF and CD of Lar0958 
(A) IEF of Lar0958 by PAGE for pI determination in comparison to a pI standard. (B) Far 
UV CD spectra of purified Lar0958 over a scan range of 180-260 nm and (C) secondary 
structure analysis using the DichroWeb online tool (and based on X-ray crystal structure)a. 
A far UV CD spectra was recorded for the Lar0958 protein in ultrapure water over 
a scan range of 180-260 nm and further analysed by the DichroWeb online using the 
CONTIN analysis program (Figure 6.3 B) (see 2.4.2). Secondary structural elements 
give distinct spectra characteristics and secondary structure determination of Lar0958 
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revealed an ɑ-helix content of 12.2% and a combined β-sheet and β-turn composition 
of 46.9% (Figure 6.3 C). These data suggest a difference in protein fold between 
Lar0958 and Mub repeats, as CD analysis of recombinant Mub proteins showed an 
ɑ-helix content of 1% (see 3.2). 
6.2 Structure determination of a single Lar0958 repeat 
X-ray crystallography of a purified single Lar0958 repeat protein was used to obtain 
high-resolution structure information for the Lar0958 cell-surface protein repeat and to 
gain structural insight into recognition of mucins (see 6.1).  
For crystallisation experiments, recombinant purified Lar0958 was dialysed against 
10 mM sodium phosphate buffer and concentrated to 12 mg/mL. Initial crystallisation 
condition screens were performed and single prismatic crystals of high quality were 
observed for the precipitation solution containing 0.2 M ammonium sulphate, 0.1 M 
sodium acetate (pH 4.5) and either 25% (w/v) PEG 4,000 or 30% (v/v) PEG 2,000 
MME (monomethylester) (see 2.5.1). Higher quality diffraction was observed for 
crystals grown in 25% (w/v) PEG 4,000 compared to 30% (v/v) PEG 2,000 MME after 
adding 20% ethylene glycol to the crystallisation mother liquor, and this condition was 
thus used for further crystallisation experiments. 
Due to the lack of structural information on Lar0958 proteins or protein homologues to 
provide a search model for MR, phasing was attempted by derivatisation of crystals 
with different anomalous scatters, including KBr. Following a short soak of a crystal in 
cryoprotectant solution (as described) containing 0.5 M KBr, an X-ray fluorescence 
scan at the bromide K-edge was performed, where the inflection and peak energies 
were calculated to be 13,472.5 eV and 13,475.5 eV, respectively. Subsequently, 
a single wavelength anomalous dispersion (SAD) data set was collected at 13,472 eV 
(0.9203 Å) showing measureable diffraction to a resolution of 2.0 Å. After integration 
and reduction of the SAD diffraction data (see 2.5.1.3), 30 bromide ion sites were 
located and initial phases estimated using AutoSol [449]. The highest occupancy of 
a bromide ion located on the surface of a Lar0958 molecule was found to be 0.48 
(Table 6.1). A first molecular model of Lar0958 was built by AUTOBUILD and a final 
model refined with an Rcryst of 17.6% and an Rfree of 21.4% with RESOLVE [345, 348] 
(Table 6.2) (see 2.5.1.3). 
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Bromide atom Occupancy B-factor (Å2) 
1 0.48 17.8 
2 0.36 17.2 
4 0.35 12.7 
3 0.33 20.7 
9 0.32 16.3 
Table 6.1 Bromide sites with five highest occupancies found 
by AutoSol 
 
A native Lar0958 crystal diffraction data set was then collected at an X-ray wavelength 
of 0.9795 Å (12658 eV) to a resolution of 1.5 Å. The corresponding X-ray data 
collection and reduction parameters are listed in Table 6.2. The solvent content of the 
crystal was estimated to be 50% for three Lar0958 molecules in the ASU (see 2.5.1.3). 
The diffraction data were indexed in a primitive monoclinic lattice and processed by 
MOSFLM and SCALA in the P 21 space group (Table 6.2) [333]. The Lar0958 model 
determined from a KBr derivatised crystal (as decribed above) was used for MR. After 
several rounds of manual model building in COOT [343] and refinement, the final 
crystal structure (PDB entry 4NG0) was refined at a resolution of 1.5 Å with Rcryst of 
15.8% and Rfree of 18.7%.  
Three Lar0958 molecules were present in the ASU, as indicated by solvent content 
analysis of the crystal (see 2.5.1.3), each consisting of 96 residues comprising Lys2 to 
Asp97, thus only lacking the N-terminal Met. The three Lar0958 molecules showed 
only minor structural difference when compared by DaliLite (see 2.6.3) [450] with 
Z-scores of 18.9-19.1 and r.m.s.d. values of 0.3-0.5 Å. 
 
 
 
 
 
 
 
161 
 
 Lar0958  
(KBr SAD data set) 
Native Lar0958 
repeat  
(PDB entry 4NG0) 
Data collection   
Beamline  Diamond i02 
Space group P 1 21 1 P 1 21 1 
Cell parameters: a, b , c (Å), (°) 
52.8, 36.8, 75.3; 
α= γ=90, β=100.4 
52.8, 37.0, 75.6; 
α= γ=90, β=100.6 
Wavelength (Å) 0.920 0.9795 
Resolution (Å) 37-2.0 (2.1-2.0) 46.8-1.5 (1.6-1.5) 
Rsym (%) 3.6 (51.0) 2.8 (14.2) 
I/σI 30.7 (1.7) 30.1 (9.2) 
Unique reflections 30893 (2235) 45978 (3327) 
Completeness (%) 99.6 (98.4) 99.4 (97.8) 
Multiplicity 6.6 (2.5) 4.0 (3.9) 
Anomalous completeness (%) 66.3 (40.0)  
Anomalous multiplicity 3.7 (1.9)  
Overall B-factor (Å2) 17.2 13.6 
FOM (SAD phasing) 0.364  
Refinement statistics   
Molecules per AU  3 
Total atoms  2912 
Water molecules  690 
Rcryst (%)  15.8 (18.5) 
Rfree (%)  18.7 (23.9) 
Ramachandran analysis   
Most favoured  98.9 
Allowed (%)  1.0 
Outliers (%)  0 
r.m.s.d.   
Bonds (Å)  0.006 
Angles (°)  0.988 
Planes (Å2)  0.004 
Mean atomic B-factor (Å2)  11.7 
Table 6.2 Data collection and refinement statistics of Lar0958 diffraction data sets 
 
The Lar0958 structure displayed an ubiquitin-like β-grasp fold (Figure 6.4 A and B). 
This fold contains a pair of parallel β-strands (β1, β4) and a pair of antiparallel 
β-strands (β2, β3), forming a four stranded mixed β-sheet of the order 1432 connected 
by an α-helix.  
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Figure 6.4 Representations of the Lar0958 repeat X-ray crystal structure 
(A) Crystal structure of Lar0958 at 1.5 Å resolution with helices in red and β-sheets in 
yellow. Secondary structural elements and, N- and C-termini labeled. (B) Representation of 
the Lar0958 structure as sticks overlaid with 2mFobs-DFcalc electron density map contoured 
at 1.0 σlevel. 
Additionally, Lar0958 possesses a third pair of anti-parallel β-strands (β1’, β2’). 
An ubiquitin-like β-grasp fold is also present in the N-terminal B1 domain of MubR5 
and MubRV (see 4.2.2). Pair wise structural alignment using DaliLite revealed low 
similarity of Lar0958 to the B1 domain of MubR5 (Z-score of 1.9, 49 aligned residues, 
r.m.s.d. 5.9 Å) (Figure 6.5 A). Interestingly, Lar0958 showed a higher structural 
similarity to the B2 domain of MubRV with a Z-score of 2.0 (61 aligned residues, 
r.m.s.d. 8.2 Å) than to its B1 domain (Z-score 1.8, 49 aligned residues, r.m.s.d. 6.7 Å) 
(Figure 6.5 B). The B2 domain of MubR5 and MubRV also forms a modified β-grasp 
fold, where the connecting helix of the 4 stranded β-sheet is replaced by 
α1 
β2 
β3 
β4 
β1 
β2' 
β1' N 
C 
55 Å 
B 
A 
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a two-stranded β-sheet. This domain is annotated as a mucus binding protein (MucBP) 
domain in the Pfam database (PF06458) [451]. 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Structural overlay of Lar0958 with MubR5 and MubRV 
Structural alignment of Lar0958 (grey) with (A) the B1 domain of MubR5 (green) and (B) 
the B2 domain of MubRV (blue) by DaliLite. 
When comparing Lar0958 with structures in the protein database (PDB) using DALI 
[358], structural similarity was observed for InlC and other members of the internalin 
protein family, i.e. InlA (PDB entry 1O6T) and InlB (PDB entry 2WQW). Superposition 
of Lar0958 and InlC (PDB entry 1XEU) gave a Z-score of 3.8 and an r.m.s.d. of 2.8 Å 
for 69 aligned residues (Figure 6.6 A) despite a sequence identity of only 7%. 
Internalins are bacterial cell-surface proteins of L. monocytogenes, an intracellular 
food-borne pathogen that crosses the intestinal barrier and causes severe infections 
[270, 452]. The structure of internalin proteins comprises an N-terminal cap followed 
by a concave shaped leucin rich repeat (LRR) domain and C-terminal Ig-like domains 
including the inter-repeat (IR) and additionally the B-repeat domain [321]. Lar0958 
shows highest structural homology to the C-terminal IR-domain of InlC, which lacks 
the helix bridging the two pairs of β-sheets in an ubiquitin β-grasp fold (Figure 6.6 B). 
The B1 domain of MubR5 has been identified as structural homologue of the B-repeat 
of InlB having an r.m.s.d. of 2.4 Å for 61 aligned residues (Z-score of 5.2) (see 4.2.2) 
[453]. In contrast, Lar0958 does not show structural similarity to the InlB B-repeat as 
revealed by its low Z-score of 1.3 (r.m.s.d. 6.2 Å over 44 aligned residues). 
A B 
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Figure 6.6 InlC crystal structure and overlay with Lar0958 
(A) Representation of InlC (PDB entry 1XEU) showing the internalin Leucine rich repeat 
(LRR) domain (grey) and the IR domain (blue). (B) Overlay of Lar0958 (red, yellow, green) 
and the IR domain (blue). The alignment has a Z-score of 3.1 over 68 aligned residues and 
an r.m.s.d. value of 2.8 Å.  
The structural similarity of Lar0958 and Mub repeats from Lactobacillus to the 
internalin Ig-like domains, IR and B-repeat, of Listeria, may indicate a similar role of 
these cell-surface protein repeats in adhesion to structural components in the 
intestine. However, there is a current lack of knowledge on the nature of the ligands 
and the mechanism of interaction. 
The MarkUs function annotation server was used to identify structural similarities and 
surface properties of functional relevance between Lar0958 and structures in the PDB 
[386]. Four solvent accessible cavities were identified by SCREEN for Lar0958 with 
surface areas between 66.1 and 25.2 Å2 and diameters of 8.2 to 5.9 Å, which may 
function as potential ligand interaction sites [388]. The program VASP used for cavity 
comparison of Lar0958 with those of known structures did not provide further insight 
into potential ligands or the mode of interaction [454]. Additionally, Lar0958 contains 
A 
B 
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a potential interface for protein-protein interaction (as predicted by PredUs) formed by 
residues of the sheet β3 and the loop connecting β2 and β3 (Figure 6.4) [387]. 
6.3 Expression and purification of internalin proteins 
The X-ray crystal structure of Lar0958 revealed structural similarity to the IR domain of 
internalin cell-surface proteins of L. monocytogenes, especially InlA and InlB (see 6.2). 
InlA and InlB are the best functionally characterised internalins to date and have been 
demonstrated to bind to the human host cell receptors E-cadherin and the Met 
receptor tyrosine kinase, respectively, via the LRR domain to facilitate bacterial cell 
entry [455-457]. Interestingly, the internalin proteins, InlB, InlC, InlJ and InlJ-LRR-IR, 
only comprising the LRR domain and the IR domain, bind with different affinities to 
human intestinal mucin MUC2 in vitro by a yet unknown mechanism [249]. In order to 
investigate the binding of Lar0958 to human MUC2 as compared to internalins, InlJ 
and InlJ-LRR-IR were heterologouesly expressed in E. coli and purified. 
The E. coli BL21StarTM (DE3) strains harbouring the pET101-InJ or 
pET101-InlJ-LRR-IR vectors (courtesy of P. Cossart, Institute Pasteur, Bacteria-cell 
interactions Unit, Paris, France), encode the inlJ gene, also designated as lmo2821, or 
the inlJLRRIR gene fragment of L. monocytogenes EGD-e (GenBank accession 
number CAD01034) [458]. The N-terminal His-tagged proteins InlJ and InlJ-LRR-IR 
were expressed in E .coli at 37°C after induction with 1 mM IPTG (see 2.3.1.1).  
The recombinant internalin proteins were extracted from bacterial cell pellets by 
ultrasonication and the clarified protein extract applied to an IMAC resin column 
(see 2.3.1.2 and 2.3.1.2). IMAC wash and elution fractions were analysed by 
SDS-PAGE and showed a heterogeneous sample composition with predominant 
protein bands at an apparent MW of about 106 kDa and 65 kDa for InlJ and 
InlJ-LRR-IR, respectively (Figure 6.7). These apparent MW are higher than the 
theoretical MW of both proteins calculated as 87.5 kDa and 56 kDa by based on their 
amino acid sequence (see 2.6.2). Both protein bands reacted with anti-His5 after 
Western-blotting (data not shown). 
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Figure 6.7 Purification of InlJ and InlJ-LRR-IR by IMAC  
(A) SDS-PAGE analysis of IMAC purification fractions of InlJ (1-6) and InlJ-LRR-IR (7-11) 
(flow through 1+7, wash 2, eluates 3-6 (InlJ) and 8-11 (InlJ-LRR-IR).  
In order to achieve higher purity, IMAC elution fractions of InlJ and InlJ-LRR-IR were 
pooled, dialysed into PBS and further purified by SEC (see 2.3.1.3). Major elution 
peaks showed at elution volumes of 56.1 mL and 60.3 mL corresponding to an 
apparent MW of about 261 and 192 kDa for InlJ and InlJ-LRR-IR, respectively 
(Figure 6.8 A and B). The observed MW of recombinant InlJ and InlJ-LRR-IR is about 
3-old or 4-fold higher than the theoretical MW, respectively, perhaps indicating 
oligomerisation in PBS buffer. SDS-PAGE analysis of SEC elution fractions showed 
sufficient sample homogeneity for use in binding studies (Figure 6.8 C). 
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Figure 6.8 Purification of InlJ and InlJ-LRR-IR by SEC  
SEC elution profiles of (A) InlJ and (B) InlJ-LRR-IR. (C) SDS-PAGE analysis of SEC elution 
fractions (as indicated in A and B, main target protein elution peak indicated by red box) 
(InlJ-LRR-IR: 1 IMAC eluate, 2-5 elution fractions; InlJ: 6 IMAC eluate, 7-12 elution 
fractions). 
6.4 Assessment of Lar0958 and internalin binding to mucin  
In order to investigate the binding of Lar0958 to mucus and mucin in vitro compared to 
InlJ and InlJ-LRR-IR, slot-blot and microtitre plate assays were performed. 
Human MUC2 of the same source as used for the binding studies mentioned above 
(kindly provided by Michael McGuckin, Mater Medical Research Institute, South 
Brisbane, Australia), pPGM and PSIM (see 2.1.2) were used as a source of mucin in 
the performed binding experiments (see 6.3). 
For slot-blot assays, purified Lar0958 (0-64 μg) was immobilised onto a nitrocellulose 
membrane and then probed with pPSM and PSIM in excess (see 2.3.6.4). Bound 
mucin was detected via f-RCA, which recognises Gal residues, commonly found in 
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mucin O-glycans (see 2.3.5) [114, 459]. The reactivity of pPSM and PSIM with f-RCA 
was confirmed in a membrane test assay (data not shown).  
Lar0958 did not bind to pPSM and PSIM when compared to the negative PBS control 
or to the f-RCA control in the absence of mucin, suggesting that the adhesin does not 
recognise porcine mucins under the applied assay conditions (Figure 6.9). The 
presence of Lar0958 was confirmed by primary anti-Lar0958 and secondary 
anti-rabbit-AP. 
 
 
 
 
 
 
 
Figure 6.9 Binding of Lar0958 to pPSM and PSIM assessed in a slot blot assay 
Slot-blot assay of Lar0958 probed with pPSM and PSIM and bound mucin detected by 
f-RCA. Slot-blot membrane probed with f-RCA in absence of mucin and with by 
anti-Lar0958 and secondary anti-rabbit-HRP as controls.  
In order to investigate the binding of Lar0958, InlJ and InlJ-LRR-IR to human MUC2, 
PSIM and pPSM, a microtitre plate assay was performed following that described by 
Linden and co-workers, with modifications, used to demonstrate binding of internalins 
to MUC2 [460].  
Briefly, adhesins (0.4 μg) were coated on microtitre plates and the presence of 
Lar0958 or His-tagged InlJ and InlJ-LRR-IR was verified using primary anti-Lar0958 or 
anti-His5 and secondary anti-rabbit-HRP or anti-mouse-HRP, respectively 
(Figure 6.10 A). Biotinylated WGA (b-WGA) and ExtrAvidin-peroxidase proved to be 
most suitable for the detection of MUC2, pPGM and PSIM. An anti-MUC2C3 
(kindly provided by Gunnar Hansson, University of Gothenburg, Sweden), anti-Muc2.3 
f-RCA  
4 16 
pPSM  
8 32 64 0 
PSIM  
Lar0958  
[μg] 
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(kindly provided by Michael McGuckin, Mater Medical Research Institute, South 
Brisbane, Australia), as well as two commercially available anti-Muc2 antibodies, used 
with secondary HRP-conjugated antibodies, showed no reactivity with human MUC2 
or demonstrated high background binding to target adhesins (see 2.1.3) (data not 
shown). To determine the optimum mucin concentration, microtitre plates were coated 
with varying amounts of PSIM (1.6-8 μg), pPGM (0.4 ng-1 μg) and human MUC2 
(0.3-0.6 μg) (data not shown). Sufficient signal intensities were observed for 1.6 μg 
PSIM, 0.4 ng pPGM and 0.6 μg human MUC2 (Figure 6.10 B). 
 
 
 
 
 
 
 
 
Figure 6.10 Detection of Lar0958, InlJ and InlJ-LRR-IR via antibodies and of mucin via 
WGA 
(A) Immobilised Lar0958, InlJ and InlJ-LRR-IR incubated with via specific primary 
antibodies and secondary HRP antibody conjugates (blue). (B) Immobilised PSIM (1.6 μg), 
pPGM (0.4 ng) and human MUC2 (0.6 μg) (blue) probed with b-WGA and 
ExtrAvidin-peroxidase. (A+B) Adhesins or mucins incubated with secondary antibodies or 
ExtrAvidin-peroxidase as control (grey). Error bars represent standard deviation from mean. 
In summary, in order to assess the binding of Lar0958, InlJ and InlJ-LRR-IR to mucin, 
adhesins were coated onto micro titre plates along with BSA as a control, probed with 
PSIM, pPGM and MUC2, and bound mucin detected via b-WGA and 
ExtrAvidin-peroxidase. 
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Figure 6.11 Binding of Lar0958, InlJ and InlJ-LRR-IR to mucin or mucus 
Immobilsed PSIM (blue stripes), pPGM (blue dots) and human MUC2 (blue) incubated on 
Lar0958, InlJ and InlJ-LRR-IR and BSA with bound mucin detected by b-WGA and 
ExtrAvidin-peroxidase. Adhsins incubated witth B-WGA and ExtrAvidin-peroxidase (grey), 
or ExtrAvidin-peroxidase alone (white) as controls. Error bars represent standard deviation 
from mean.  
Lar0958, InlJ and InlJ-LRR-IR did not show increased binding to PSIM, pPGM or 
MUC2 compared to the BSA control (Figure 6.11). As described before, BSA may 
interfere with binding when studying carbohydrate-protein interactions (see 5.1.1) 
[406]. In addition, signal intensities for mucins incubated on the immobilised adhesins 
and BSA were similar for those of b-WGA and ExtrAvidin-peroxidase alone in the 
absence of mucin. The interaction of b-WGA seems to vary slightly between Lar0958, 
InlJ, InlJ-LRR-IR and BSA, whereas the background signal for ExtrAvidin-peroxidase 
was comparably low for all tested proteins.  
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6.5 Discussion 
The Lar0958 protein of the human isolate strains L. reuteri MM4-1a, DSM 20016T and 
JCM 112T is a newly-identified cell-surface adhesion molecule, that shares a similar 
domain organisation with other Gram-positive cell surface adhesins (see 1.4.2). It is 
a modular protein covalently attached to the bacterial cell wall via an LPXTG-anchor, 
but it is additionally found in the bacterial culture supernatant [324]. The Lar0958 
protein of L. reuteri MM4-1a and DMS 20016T seems to be involved in the adhesion of 
bacterial cells to mucus [302, 324], but no structural or functional characterisation of 
the Lar0958 protein has been conducted so far. 
In order to obtain structural information on the novel Lar0958 cell-surface adhesin and 
to identify potential ligands, a single Lar0958 protein repeat was cloned, 
heterologously expressed and purified (see 6.1). The purified Lar0958 repeat protein 
forms a fully-folded, independent protein domain with a higher α-helix content than the 
Mub-repeat proteins as demonstrated by CD (see 3.2 and 6.1). Like recombinant 
Mub repeats, recombinant Lar0958 has a negative overall charge at neutral pH in 
standard PBS used for functional studies. 
The X-ray crystal structure of the Lar0958 protein was determined at 1.5 Å resolution 
revealing a an ubiquitin-like β-grasp fold, showing some level of similarity to the B1 
and B2 domains of MubR5 and MubRV, respectively (see 6.2). Lar0958 showed 
generally low structural similarity to structures found in the PDB, apart from internalin 
proteins, especially InlC.  
Internalin proteins are cell surface proteins of the Gram-positive food borne pathogen 
L. monocytogenes [461]. To date, 25 members of the internalin protein family have 
been dentified in Listeria, which are either covalently anchored to the cell wall (InlA, 
InlJ), non-covalently attached (InlB) or secreted (InlC) [462-463]. They show modular 
domain organisation consisting of an N-terminal cap structure, an LRR-domain, and 
an Ig-like IR-domain. In addition, some internalins possess additional domains 
containing a β-grasp fold, such as B-repeats (InlA or InlB) or MucBP repeats (InlJ), 
which show structural similarity to MucBP domains as defined in the Pfam database 
(PF06458) [321, 453] (Figure 6.12). The β-grasp fold is a widespread fold involved in 
a variety of physiological functions [378].  
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Lar0958 is structurally similar to the IR domains of InlC, InlA and InlB, but not to the 
B-repeat of InlB. The level of structural homology between Mub repeats, Lar0958 
repeats and Internalin protein domains may indicate a related function of these protein 
domains. 
 
 
Figure 6.12 Domain organisation of members of the internalin protein family 
Internalin protein classification in three families of LPXTG-anchored (I), surface associated 
(via GW- or WxL module) (II) and secreted (III) internalins. Homologous domains are 
presented in the same colour and the number of repeats indicated (taken from [462]).  
Functional characterisation of internalin protein domains has focussed so far on the 
characteristic LRR domains, mainly of InlA and InlB, which interact with the host cell 
receptors E-cadherin and Met, respectively [455, 457]. The IR domain is believed to be 
important for stability of the LRR domain, as the first N-terminal β-strand of the 
IR domain extends into the LRR domain [321]. The recombinant InlB-LRR protein 
lacking the IR domain shows significantly reduced stability compared to the 
InlB-LRR-IR protein [464]. Additionally, there is some evidence in the literature that the 
IR domain as well as the B-repeat fulfil an additional functional role in infection. The 
Ig-like IR domain and the LRR domain of InlA are necessary for host infection [465]. 
The InlB B-repeat seems to recognise another, unidentified host cell receptor different 
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to the one bound by its LRR domain [453, 466]. The GW modules present only in InlB 
interact with GAGs on the host cell surface, which is important for bacterial invasion 
[467]. Interestingly, Linden and co-workers demonstrated binding of several internalins 
including InlB and InlJ to human MUC2 in vitro [460]. However, the functional 
characterisation of the binding of internalins to mucins remains elusive. 
Based on the functional similarities of the recombinant Lar0958 repeat to internalin 
protein domains, the binding ability of Lar0958 to pPGM, PSIM and human MUC2 was 
investigated in comparison to InlJ and InlJ-LRR-IR. No increased binding to mucin was 
observed for neither the recombinant single Lar0958 repeat nor the InlJ and 
InlJ-LRR-IR protein compared to BSA (see 6.4), which may indicate that a single 
repeat is not sufficient for ligand interaction, as previously observed in MUB protein 
binding studies (see 5.1 and 5.2).  
To address the question, whether the presence of multiple Lar0958 repeats may be 
necessary for ligand binding, we purified the full-length native Lar0958 from the culture 
media of L. reuteri MM4-1a [324]. However, the low recovery of the native protein 
prevented its use in binding studies. Alternatively, for future functional characterisation 
of Lar0958, multi-protein repeats will need to be cloned and expressed in recombinant 
form for binding studies including GI mucin and sugar Au-arrays (see 5.1.3 and 5.2.2) 
[409]. 
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CHAPTER 7 GENERAL DISCUSSION AND FUTURE 
PROSPECTIVES 
Despite recent advances in the identification of commensal mucus-adhesins enabled 
by genome sequencing of Lactobacillus species (see 1.4.2) [280], there is a current 
lack of knowledge on the structural and functional characterisation of these adhesins 
thought to mediate adherence of commensal bacteria to mucus and mucin (see 1.4.2). 
Lactobacilli, which are autochthonous members of the microbiota in different 
vertebrate hosts and commonly encountered in food produces, play a critical role in 
maintaining the healthy state in the gut [162, 175].  
This study provides first insights into the low and high resolution structural organisation 
of a commensal mucus-adhesin, the modular-repeat containing MUB protein of 
L. reuteri ATCC 53608, and additionally reveals structural similarities to Gram-positive 
pathogenic adhesins. The Mub type 1 repeat MubRV folds to form an elongated 
structure of two distinct domains, an N-terminal ubiquitin-like β-grasp fold domain (B1) 
and a C-terminal MucBP domain (B2), as determined by X-ray crystallography 
(see 4.2.2). The MubRV structure is highly similar to the rod-like structure of the Mub 
type 2 repeat MubR5, showing only limited flexibility around the inter domain region, 
suggesting a similar protein fold between Mub repeats as relatively rigid building 
blocks of the cell-surface MUB protein (see 4.2.2). However, the MubRV structure 
lacks the Ca2+-ion, which stabilises the loop conformation preceding strand β4 in the 
N-terminal domain of MubR5 (see 4.4.2). Whether calcium is required for the folding of 
some Mub repeats or is also important for ligand binding, as for example observed in 
C-type lectins, needs to be further investigated [468-469]. Extensive structural 
similarities of MubRV to a number of pilins and MSCRAMM including GBS52 of 
Strep. agalactiae, BcpA of B. cereus, RrgB of Strep. pneumoniae, Spy0128 of 
Strep. pyogenes and SpaA of C. diphtheriae has been demonstrated (see 4.2.2). They 
share a common Ig-like fold designated as an IgG-rev and frequently encountered in 
pili and MSCRAMM. The IgG-rev fold is reminiscent of the Ig-superfamily IgG fold (or 
Ig-like fold type C) with an ABED/CFG topology, however it shows a reverse strand 
arrangement in two alternative topologies (CBE/DAGF and CBEFT/DAG) (see 4.4). 
Despite the structural similarity of the B2 domain of MubRV to Ig-like pilin domains, it 
shows a different BAFD/EC topology (see 4.2.2). Pilins are components of long, 
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filamentous pili structures present on the bacterial cell surface, which are abundant in 
pathogens but rather rare in Lactobacillus species (see 4.4). SAXS experiments with 
single and tandem Mub repeats demonstrated their presence as extended structures 
with limited flexibility in solution, as observed in MubRV and MubR5 crystal structures 
(described above). These findings suggest the arrangement of Mub repeats as 
‘beads on a string’ to form a relatively rigid fibre-like MUB protruding from the bacterial 
cell surface and capped by a differentially shaped Nterm region at the tip (see 4.3). 
An elongated appearance of native MUB was also indicated by sedimentation velocity 
AUC experiments (see 3.3.2). The organisation of Mub repeats along the length of the 
MUB fibre potentially enhances their ability to interact with multiple ligands for higher 
avidity binding. A similar mechanism of mucin binding may be employed by the 
L. rhamnosus GG pili, since the binding receptor SpaC, which contains two copies of 
a CnaB-type domain, is located along the pilus shaft [470]. Whether the Nterm region 
is involved in ligand interaction, remains to be demonstrated, however no mucin 
binding was observed in preliminary binding experiments (see 5.1.1). This is in 
contrast with the mode of interaction employed by bacterial flagella and pili, as well as 
most siglecs, where binding is mediated by the N-terminal tip domain (see 5.3 and 
1.4.1). In addition to the relatively comprehensive structural information presented 
here on MUB, we provided the first structural information on the newly identified 
modular mucus-adhesin Lar0958 present on the cell-surface of L. reuteri ATCC 53608. 
In line with observations made for MUB, the X-ray crystal structure of a single Lar0958 
repeat shows structural similarity to pathogenic cell-surface proteins from Listeria 
involved in host cell attachment and invasion (see 6.2 and 1.5). These findings further 
highlight structural similarities between L. reuteri adhesins, containing 
tandemly-arranged repeats, and filamentous, pathogenic adhesion molecules with 
similar modular organisation, which may be indicative of a similar mode of ligand 
binding and specificity.  
We investigated the binding ability of recombinant Mub repeats and native MUB to 
mucin and mucin glycans in vitro, and demonstrated that mucin binding seems to be 
mediated via sugar recognition (see 5.1.2 and 5.1.3). Additionally, we showed binding 
of MUB proteins to several glycan structures and blood-group epitopes (see 5.2). More 
work is required to biochemically evaluate and characterise MUB protein interactions 
with potential sugar ligands including Au-array inhibition studies, SPR, ITC and 
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co-crystallisation experiments. Other commensal adhesins that recognise glycans or 
ABO blood group antigens, are Msa of L. acidophilus NCFM, which contains MucBP 
domains, GAPDH of L. plantarum LA 318 and Lam29 of L. mucosae ME-380 
(see 1.4.2). Additionally, sugar binding has been reported for a number of pathogenic 
bacterial adhesins, for example BabA and Sab of H. pylori, the MucBP domain of 
Spr1345 from Strep. pneumoniae as well as E. coli pilins and GspB of Stept. gordonii, 
the last two containing Ig-like protein domains found in Gram-positive adhesins 
(as described above) (see 1.4.1) [384]. The MucBP domain of Spr1345, which has 
additionally been demonstrated to bind different mucins, shows structural similarity to 
the B2 domains of MubR5 and MubRV (see 1.4.1), while their B1 domains are 
structurally similar to the Ig-binding protein L (see 4.1.2) [282]. These findings indicate 
a dual receptor specificity of MUB to glycan and protein ligands (such as IgA) present 
in the mucus layer (see 1.1.2 and 1.2), as suggested by mucin adhesion assays 
(see 5.1.2 and 5.3) and demonstrated earlier in our lab [302]. Mucin binding studies 
further suggested a mulitvalency binding of Mub repeats, as observed in FnBPs from 
Gram-positive bacteria (see 5.3) [416, 471]. Multivalent interactions may potentiate 
MUB-dependent binding of bacteria to mucin glycans or proteins in the GI mucus and 
increase the avidity of the binding enabled by the elongated fiber-like structural 
organisation of MUB, similarily reported for the L. rhamnosus GG pili (as described 
above). Furthermore, the cross-linking of two MubR5 molecules by Man, which we 
showed using X-crystallography, suggests a role of MUB in bacterial aggregation as 
demonstrated in our lab (see 4.1) [302], and may yet be another mechanism by which 
sugar-adhesin interactions facilitate lactobacilli mucus adhesion [394]. These findings 
provide insights into mechanisms by which gut bacteria may achieve pathogen 
exclusion, i.e. via competition for mucosal attachment sites, and facilitate persistence 
in the gut (see 1.3.1). This knowledge may be used to design strategies for the 
targeted selection of suitable commensal lactobacilli to be used as probiotics.  
Here we report the potential glycosylation of native MUB isolated from a L. reuteri 
ATCC 53608 culture (see 3.3.2) as shown via lectin staining (see 3.3.3.2). A few 
glycoproteins have been identified in commensal bacteria including Lactobacillus or 
Bacteroides species (see 3.4) [472], demonstrating that protein glycosylation is not 
restricted to pathogenic organisms such as Pseudomonas, Clostridium, 
Campylobacter and Helicobacter species, where glycosylation is often found in flagella 
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or pili structures [365-366]. For example, the extracellular autolysin protein Acm2 from 
L. plantarum, or the major secreted protein Msp1/p75 from L. rhamnosus, which has 
been suggested to be involved in intestinal epithelial cell signalling, have been 
demonstrated to contain GlcNAc or Man residues, respectively. Lectin staining of MUB 
(with WGA) indicated the presence of GlcNAc molecules (see 3.3.3.2) [367, 473]. 
Further work is required, to determine the glycan profile of MUB by MS glycopeptide 
analysis and metabolic glycoprotein labeling. Probiotic cell-surface molecules may 
contribute to the maturation of the host immune system. For example, L. rhamnosus 
pili have been shown to possess immunomodulating properties in intestinal epithelial 
cells [474]. Glycosylation of lactobacilli cell-surface proteins such as MUB may yet be 
another mechanism contributing to the overall health benefit of commensals on the 
host immune system to establish homeostasis in the gut [138, 475]. However, further 
work is required to investigate potential immunomodulating effects of MUB and the 
role of glycans in this process including the in vitro investigation of the expression 
levels of pro- and anti-inflammatory markers after treatment of intestinal epithelial cells 
with glycosylated and de-glycosylated MUB. This finding indicates a dual function of 
MUB in mediating bacterial adhesion to mucins supporting its role as an important 
probiotic factor for Lactobacillus host colonisation (see 1.3.1). 
Further investigations, as proposed here, as well as in vitro experiments including the 
application of MUB-expressing and –non-expressing L. reuteri cells to intestinal 
epithelial cells with intact or aberrant mucin glycosylation, will help us to identify 
relevant probiotic features important to maintain or promote a beneficial relationship 
with our gut microbiota. 
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APPENDIX  
I. LDMII media composition 
Ingredients Amount per L 
K2HPO4 (anhydrous) 1.5 g 
KH2PO4 (anhydrous) 1.5 g 
Sodium acetate 15 g 
Sodium citrate 0.22 g 
Tryptophan 50 mg 
Asparagine 50 mg 
Cysteine 
Glyc 
50 mg 
Glycine 
Serine 
 
 
 
50 mg 
Serine 50 mg 
Alanine 
 
50 mg 
Phenylalanine 50 mg 
Histidine 50 mg 
Isoleucine 50 mg 
Methionine 50 mg 
Proline 
Thre 
50 mg 
Threonine 50 mg 
Valine 50 mg 
Tyrosine 50 mg 
Leucine 50 mg 
Glutamine 50 mg 
Aspartic acid 50 mg 
Glutamic acid 50 mg 
Thiamine-HCl 0.2 mg 
para-Aminobenzoic acid 0.04 mg 
Calcium pantothenic acid 0.4 mg 
Niacin 1.0 mg 
Pyridoxine-HCl 0.5 mg 
Biotin 0.05 mg 
Folic acid 0.1 mg 
Riboflavin 0.4 mg 
Adenine sulphate 10 mg 
Uracil 20 mg 
Guanine-HCl 10 mg 
Cytidine (acid) 50 mg 
Thymidine 1.6 μg 
Tween-80 1.0 ml 
MgSO4 H2O 0.163 g 
MnSO4 7H2O 23.4 mg 
FeSO4 7H2O 13 mg 
Sucrose 30 g 
Optional aminio acids (arginine 
and lysine 
50 mg (each) 
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II. Primers for amplification and sequencing 
Protein Primer Sequence  
Nucleotide aligment position in 
target genea/b  
Amino acid residue limits 
(size in amino acids) 
MubRV  RV_for 
RV_rev 
5’-ATGCAAACAGCCTACGTCAAG-3’ 
5’-TTAGGGATCACCAACATAAACGA-3’ 
8515-9063 (& 7963-7980) 
9044-9063 
2799-2981 (183) 
MubR8-V RV_for 
RV_rev 
5’-ATGCAAACAGCCTACGTCAAG-3’ 
5’-TTAGGGATCACCAACATAAACGA-3’ 
7963-7980 (& 8515-9063) 
9044-9063 
2615-2798 (367) 
MubRV-VI RV_for 
RVI_rev 
5’-ATGCAAACAGCCTACGTCAAG-3’ 
5’-TTAATCAAGCTTCTTGTAGGT-3’ 
8515-9063 (& 7963-7980) 
9664-9681 
2799-3187 (389) 
MubR5 MucB1-R4F 
MucB2-R4R 
5’-ATGCAAAAGGTTCACGTTCAA-3’ 
5’-TTAGGCATCAGCCGTGTAGA-3’ 
6307-6324 & 6859-6876 
6842-6858 & 7394-7410 
2063-2246 (184) 
MubRI MucB1-RIF 
MucB2-RIR 
5-’ATGCAAGAAGCTGCCATCAG-3’ 
5’-TAACGTGTCAGCGGTATAGT-3’ 
1789-1805 
2351-2367 
557-749 (193) 
MubRI-II-III MucB1-RIF 
MucB2-RIIIR 
5-’ATGCAAGAAGCTGCCATCAG-3’ 
5’-TTAGGCATTCCCAACATAAAC-3’ 
1789-1805 
3505-3522 
557-1134 (578) 
Nterm NtermMUB-
pOPINF-for 
NtermMUB-
pOPINF-rev 
5’-AAGTTCTGTTTCAGGGCCCGGCAACTACTGAATCG-3’ 
 
5’-ATGGTCTAGAAAGCTTTACGTGTCAGCTACATAAAC-3’ 
241-287 
 
1768-1788 
50-556 (507)  
without His6-tag 
NtermRI NtermMUB-
pOPINF-for 
5’-AAGTTCTGTTTCAGGGCCCGGCAACTACTGAATCG-3’ 
 
241-287 
 
50-749 (700) 
without His6-tag 
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MubRI-pOPINF-
rev 
5’-ATGGTCTAGAAAGCTTTACGTGTCAGCGGTATAGT-3’ 2351-2347 
 pOPINFrev 
(sequencing) 
5’-TCAGATGCTCAAGGGGCTT-3’   
 midNterm-1 
(sequencing) 
5’-GCTGCTGATGTAGAAACAGT-3’ 592-612  
 midNterm-2 
(sequencing) 
5’-CAAAAAGGTCTGGATGGTCA-3’ 1189-1208  
Lar0958 Lar0958for 
 
Lar0958rev 
5’-ATGAAAGTTACCTATAGTGGTAG-3’ 
 
5’-TTAATCAATCCCTAGTGGATT-3’ 
1729-1748, 2017-2036, 2305-
2324 & 2593-2612 
1998-2016, 2286-2244, 2574-
2592 & 2862-2880 
577-672, 675-768, 769-
864 or 865-960 (95) 
a Nucleotide aligment position in target gene mub based on DNA sequence from GenBank accession number AF120104 
b Nucleotide aligment position in target gene lar_0958 based on DNA sequence from GenBank accession number BAG25474 
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III. In-Fusion cloning system  
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IV. Alignment of Mub repeat sequences using ClustaWl 
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 Alignment score  
Mub 
repeat 
sequence R1 R2 R3 R4 R5 R6 R7 R8 RI RII RIII RIV RV RVI 
R1 100 85.3 87.5 85.3 87.5 85.3 84.8 83.7 32.1 38.1 31.5 30.4 35.0 23.9 
R2 85.3 100 97.8 100 97.8 100 99.5 93.5 33.7 31.5 25.0 32.6 42.6 26.6 
R3 87.5 97.8 100 97.8 100 97.8 97.3 91.3 32.6 30.4 25.0 31.5 42.1 23.9 
R4 85.3 100 97.8 100 97.8 100 99.5 93.5 33.7 31.5 25.0 32.6 42.6 26.6 
R5 87.5 97.8 100 97.8 100 97.8 97.3 91.3 32.6 30.4 25.0 31.5 42.1 23.9 
R6 85.3 100 97.8 100 97.8 100 99.5 93.5 33.7 31.5 25.0 32.6 42.6 26.6 
R7 84.8 99.5 97.3 99.5 97.3 99.5 100 94.0 33.7 32.1 25.0 32.6 42.6 26.6 
R8 83.7 93.5 91.3 93.5 91.3 93.5 94.0 100 36.4 32.1 28.3 35.9 48.6 29.9 
RI 32.1 33.7 32.6 33.7 32.6 33.7 33.7 36.4 100 87.6 59.6 39.6 49.2 32.6 
RII 38.1 31.5 30.4 31.5 30.4 31.5 32.1 32.1 87.6 100 67.6 40.1 42.6 32.0 
RIII 31.5 25.0 25.0 25.0 25.0 25.0 25.0 28.3 59.6 67.6 100 38.8 54.1 31.4 
RIV 30.4 32.6 31.5 32.6 31.5 32.6 32.6 35.9 39.6 40.1 38.8 100 29.0 55.7 
RV 35.0 42.6 42.1 42.6 42.1 42.6 42.6 48.6 49.2 42.6 54.1 29.0 100 31.2 
RVI 23.9 26.6 23.9 26.6 23.9 26.6 26.6 29.9 32.6 32.0 31.4 55.7 31.2 100 
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V. Crystal structure screen conditions 
Structure Screen 1 (Molecular Dimensions, Newmarket, UK; April 2010) 
ID  Salt  Buffer  pH  Precipitant  
1  0.02 M calcium chloride  0.1 M sodium acetate  4.6  30 % v/v MPD  
2  0.2 M ammonium acetate  0.1 M sodium acetate  4.6  30 % w/v PEG 4K  
3  0.2 M ammonium sulfate  0.1 M sodium acetate  4.6  25 % w/v PEG 4K  
4  None  0.1 M sodium acetate  4.6  2.0 M sodium formate  
5  None  0.1 M sodium acetate  4.6  2.0 M ammonium sulfate  
6  None  0.1 M sodium acetate  4.6  8 % w/v PEG 4K  
7  0.2 M ammonium acetate  0.1 M tri-sodium citrate  5.6  30 % w/v PEG 4K  
8  0.2 M ammonium acetate  0.1 M tri-sodium citrate  5.6  30 % v/v MPD  
9  None  0.1 M tri-sodium citrate  5.6  20 % v/v 2-propanol, 20%w/v PEG 
4K  
10  None  0.1 M tri-sodium citrate  5.6  1.0 M ammonium dihydrogen  
phosphate 
11  0.2 M calcium chloride  0.1 M sodium acetate  4.6  20 % v/v 2-propanol  
12  None  0.1 M sodium cacodylate  6.5  1.4 M sodium acetate  
13  0.2 M tri-sodium citrate  0.1 M sodium cacodylate  6.5  30 % v/v 2-propanol  
14  0.2 M ammonium sulfate  0.1 M sodium cacodylate  6.5  30 % w/v PEG 8K  
15  0.2 M magnesium acetate  0.1 M sodium cacodylate  6.5  20 % w/v PEG 8K  
16  0.2 M magnesium acetate  0.1 M sodium cacodylate  6.5  30 % v/v MPD  
17  None  0.1 M imidazole  6.5  1.0 M sodium acetate  
18  0.2 M sodium acetate  0.1 M sodium cacodylate  6.5  30 % w/v PEG 8K  
19  0.2 M zinc acetate  0.1 M sodium cacodylate  6.5  18 % w/v PEG 8K  
20  0.2 M calcium acetate  0.1 M sodium cacodylate  6.5  18 % w/v PEG 8K  
21  0.2 M tri-sodium citrate  0.1 M Na HEPES  7.5  30 % v/v MPD  
22  0.2 M magnesium chloride  0.1 M Na HEPES  7.5  30 % v/ v 2-propanol  
23  0.2 M calcium chloride  0.1 M Na HEPES  7.5  28 % v/v PEG 400  
24  0.2 M magnesium chloride  0.1 M Na HEPES  7.5  30 % v/v PEG 400  
25  0.2 M tri-sodium citrate  0.1 M Na HEPES  7.5  20 % v/v 2-propanol  
26  None  0.1 M Na HEPES  7.5  0.8 M K/Na tartrate  
27  None  0.1 M Na HEPES  7.5  1.5 M lithium sulfate  
28  None  0.1 M Na HEPES  7.5  0.8 M sodium dihydrogen 
phosphate/  
0.8 M K dihydrogen phosphate  
29  None  0.1 M Na HEPES  7.5  1.4 M tri-sodium citrate  
30  None  0.1 M Na HEPES  7.5  2 % v/v PEG 400  
, 2.0 M ammonium sulfate  
31  None  0.1 M Na HEPES  7.5  10 % v/v 2-propanol, 20% w/v 
PEG 4K  
32  None  0.1 M Tris  8.5  2.0 M ammonium sulfate  
33  0.2 M magnesium chloride  0.1 M Tris  8.5  30 % w/v PEG 4K  
34  0.2 M tri-sodium citrate  0.1 M Tris  8.5  30 % v/v PEG 400  
35  0.2 M lithium sulfate  0.1 M Tris  8.5  30 % w/v PEG 4K  
36  0.2 M ammonium acetate  0.1 M Tris  8.5  30 % v/v 2-Propanol  
37  0.2 M sodium acetate  0.1 M Tris  8.5  30 % w/v PEG 4K  
38  None  0.1 M Tris  8.5  8 % w/v PEG 8K  
39  None  0.1 M Tris  8.5  2.0 M ammonium dihydrogen  
phosphate 
40  None  None  -  0.4 M K/Na Tartrate  
41  None  None  -  0.4 M ammonium dihydrogen  
phosphate 
42  0.2 M ammonium sulfate  None  -  30 % w/v PEG 8K  
43  0.2 M ammonium sulfate  None  -  30 % w/v PEG 4K  
44  None  None  -  2.0 M ammonium sulfate  
45  None  None  -  4.0 M sodium formate  
46  0.05 M potassium 
dihydrogen phosphate 
None  -  20 % w/v PEG 8K  
47  None  None  -  30 % w/v PEG 1.5K  
48  None  None  -  0.2 M magnesium formate  
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Structure Screen 2 (Molecular Dimensions, Newmarket, UK; April 2010) 
ID Salt  Buffer  pH  Precipitant  
1 0.1 M sodium chloride 0.1 M Bicine 9.0 30 % v/v PEG 550 MME 
2 None 0.1 M Bicine 9.0 2.0 M magnesium chloride 
3 None 0.1 M Bicine 9.0 2 % v/v 1,4-Dioxane/10 % w/v 
PEG 20,000 
4 0.2 M magnesium chloride 0.1 M Tris 8.5 3.4 M 1,6-hexanediol 
5 None 0.1 M Tris 8.5 25 % v/v tert-butanol 
6 0.01 M nickel chloride 0.1 M Tris 8.5 1.0 M lithium sulfate 
7 1.5 M ammonium sulfate 0.1 M Tris 8.5 12 % v/v glycerol 
8 0.2 M ammonium 
dihydrogen phosphate 
0.1 M Tris 8.5 50 % v/v MPD 
9 None 0.1 M Tris 8.5 20 % v/v ethanol 
10 0.01 M nickel chloride 0.1 M Tris 8.5 20 % w/v PEG 2000 MME 
11 0.5 M ammonium sulfate 0.1 M Na HEPES 7.5 30 % v/v MPD 
12 None 0.1 M Na HEPES 7.5 10 % w/v PEG 6000, 5% v/v MPD 
13 None 0.1 M Na HEPES 7.5 20 % v/v Jeffamine M-600 
14 0.1 M sodium chloride 0.1 M Na HEPES 7.5 1.6 M ammonium sulfate 
15 None 0.1 M Na HEPES 7.5 2.0 M ammonium formate 
16 0.05 M cadmium sulfate 0.1 M Na HEPES 7.5 1.0 M sodium acetate 
17 None 0.1 M Na HEPES 7.5 70 % v/v MPD 
18 None 0.1 M Na HEPES 7.5 4.3 M sodium chloride 
19 None 0.1 M Na HEPES 7.5 10 % w/v PEG 8000, 8 % v/v 
ethylene glycol 
20 None 0.1 M MES 6.5 1.6 M magnesium sulfate 
21 0.1 M potassium phosphate 
+ 0.1 M sodium phosphate 
0.1 M MES 6.5 2.0 M sodium chloride 
22 None 0.1 M MES 6.5 12 % w/v PEG 20,000 
23 1.6 M ammonium sulfate 0.1 M MES 6.5 10 % v/v Dioxane 
24 0.05 M caesium chloride 0.1 M MES 6.5 30 % v/v Jeffamine M-600 
25 0.01 M cobalt chloride 0.1 M MES 6.5 1.8 M ammonium sulfate 
26 0.2 M ammonium sulfate 0.1 M MES 6.5 30 % w/v PEG 5000 MME 
27 0.01 M zinc sulfate 0.1 M MES 6.5 25 % v/v PEG 550 MME 
28 None 0.1 M Na HEPES 7.5 20 % w/v PEG 10,000 
29 0.2 M potassium sodium 
tartrate 
0.1 M Na citrate 5.6 2.0 M ammonium sulfate 
30 0.5 M ammonium sulfate 0.1 M Na citrate 5.6 1.0 M lithium sulfate 
31 0.5 M sodium chloride 0.1 M Na citrate 5.6 4 % v/v polyethyleneimine 
32 None 0.1 M Na citrate 5.6 35 % v/v tert-butanol 
33 0.01 M ferric chloride 0.1 M Na citrate 5.6 10 % v/v Jeffamine M-600 
34 0.01 M manganese chloride 0.1 M Na citrate 5.6 2.5 M 1,6-hexanediol 
35 None 0.1 M Na acetate 4.6 2.0 M sodium chloride 
36 0.2 M sodium chloride 0.1 M Na acetate 4.6 30 % v/v MPD 
37 0.01 M cobalt chloride 0.1 M Na acetate 4.6 1.0 M 1,6-hexanediol 
38 0.1 M cadmium chloride 0.1 M Na acetate 4.6 30 % v/v PEG 400 
39 0.2 M ammonium sulfate 0.1 M Na acetate 4.6 30 % w/v PEG 2000 MME 
40 2.0 M sodium chloride None None 10 % w/v PEG 6000 
41 0.01 M CTAB None None 0.5 M sodium chloride, 0.1 M 
magnesium chloride 
42 None None None 25 % v/v ethylene glycol 
43 None None None 35 % v/v dioxane 
44 2.0 M ammonium sulfate None None 5 % v/v 2-propanol 
45 None None None 1.0 M imidazole pH 7.0 
46 None None None 10 % w/v PEG 1000, 10 % w/v 
PEG 8000 
47 1.5 M sodium chloride None None 10 % v/v ethanol 
48 None None None 1.6 M sodium citrate pH 6.5 
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JCSG-plus Screen 1 (Molecular Dimensions, Newmarket, UK; April 2010) 
ID Salt  Buffer  pH  Precipitant  
1  0.2 M lithium sulfate  0.1 M sodium acetate  4.5  50 % v/v PEG 400  
2  None  0.1 M sodium citrate  5.5  20 % w/v PEG 3000  
3  0.2 M di-ammonium 
hydrogen  
citrate  
None  -  20 % w/v PEG 3350  
4  0.02 M calcium chloride  0.1 M sodium acetate  4.6  30 % v/v MPD  
5  0.2 M magnesium formate  None  -  20 % w/v PEG 3350  
6  0.2 M lithium sulfate  0.1 M phosphate/citrate  4.2  20 % w/v PEG 1000  
7  None  0.1 M CHES  9.5  20 % w/v PEG 8000  
8  0.2 M ammonium formate  None  -  20 % w/v PEG 3350  
9  0.2 M ammonium chloride  None  -  20 % w/v PEG 3350  
10  0.2 M potassium formate  None  -  20 % w/v PEG 3350  
11  0.2 M ammonium 
dihydrogen  
phosphate  
0.1 M Tris  8.5  50 % v/v MPD  
12  0.2 M potassium nitrate  None  -  20 % w/v PEG 3350  
13  None  0.1 M citrate  4.0  0.8 M ammonium sulfate  
14  0.2 M sodium thiocyanate  None  -  20 % w/v PEG 3350  
15  None  0.1 M Bicine  9.0  20 % w/v PEG 6000  
16  None  0.1 M HEPES  7.5  10 % w/v PEG 8000/  
8 % v/v Ethylene glycol  
17  None  0.1 M sodium 
cacodylate  
6.5  40 % v/v MPD/ 5 % w/v PEG 
8000  
18  None  0.1 M phosphate/citrate  4.2  40 % v/v Ethanol/ 5 % w/v PEG 
1000  
19  None  0.1 M sodium acetate  4.6  8 % w/v PEG 4000  
20  0.2 M magnesium chloride  0.1 M Tris  7.0  10 % w/v PEG 8000  
21  None  0.1 M citrate  5.0  20 % w/v PEG 6000  
22  0.2 M magnesium chloride  0.1 M sodium 
cacodylate  
6.5  50 % v/v PEG 200  
23  None  None  6.5  1.6 M tri-sodium citrate  
24  0.2 M tri-potassium citrate  None  -  20 % w/v PEG 3350  
25  0.2 M sodium chloride  0.1 M phosphate/citrate  4.2  20 % w/v PEG 8000  
26  1.0 M lithium chloride  0.1 M Na citrate  4.0  20 % w/v PEG 6000  
27  0.2 M ammonium nitrate  None  -  20 % w/v PEG 3350  
28  None  0.1 M Na HEPES  7.0  10 % w/v PEG 6000  
29  None  0.1 M Na HEPES  7.5  0.8 M sodium dihydrogen  
phosphate  
0.8 M potassium dihydrogen  
phosphate  
30  None  0.1 M phosphate/citrate  4.2  40 % v/v PEG 300  
31  0.2 M zinc acetate  0.1 M sodium acetate  4.5  10 % w/v PEG 3000  
32  None  0.1 M Tris  8.5  20 % v/v Ethanol  
33  None  0.1 M Na/K phosphate  6.2  25 % v/v 1,2-propanediol  
10 % v/v Glycerol  
34  None  0.1 M Bicine  9.0  10 % w/v PEG 20,000/  
2% v/v Dioxane  
35  None  0.1 M sodium acetate  4.6  2.0 M ammonium sulfate  
36  None  None  -  10 % w/v PEG 1000/  
10 % w/v PEG 8000  
37  None  None  -  24 % w/v PEG 1500/  
20 % v/v Glycerol  
38  0.2 M magnesium chloride  0.1 M Na HEPES  7.5  30 % v/v PEG 400  
39  0.2 M sodium chloride  0.1 M Na/K phosphate  6.2  50 % v/v PEG 200  
40  0.2 M lithium sulfate  0.1 M sodium acetate  4.5  30 % w/v PEG 8000  
41  None  0.1 M HEPES  7.5  70 % v/v MPD  
42  0.2 M magnesium chloride  0.1 M Tris  8.5  20 % w/v PEG 8000  
43  0.2 M lithium sulfate  0.1 M Tris  8.5  40 % v/v PEG 400  
44  None  0.1 M Tris  8.0  40 % v/v MPD  
45  0.17 M ammonium sulfate  None  -  25.5 % w/v PEG 4000/  
15 % v/v Glycerol  
46  0.2 M calcium acetate  0.1 M sodium 
cacodylate  
6.5  40 % v/v PEG 300  
47  0.14 M calcium chloride  0.07 M sodium acetate  4.6  14 % v/v 2-propanol/  
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30 % v/v Glycerol  
48  0.04 M potassium 
dihydrogen  
phosphate  
None  -  16 % w/v PEG 8000/ 20 % v/v  
 
JCSG-plus Screen 2 (Molecular Dimensions, Newmarket, UK; April 2010) 
 
ID  Salt  Buffer  pH  Precipitant  
1  None  0.1 M sodium 
cacodylate  
6.5  1.0 M tri-sodium citrate  
2  0.2 M sodium chloride  0.1 M sodium 
cacodylate  
6.5  2.0 M ammonium sulfate  
3  0.2 M sodium chloride  0.1 M HEPES  7.5  10 % v/v 2-propanol  
4  0.2 M lithium sulfate  0.1 M Tris  8.5  1.26 M ammonium sulfate  
5  None  0.1 M CAPS  10.5  40 % v/v MPD  
6  0.2 M zinc acetate  0.1 M imidazole  8.0  20 % w/v PEG 3000  
7  0.2 M zinc acetate  0.1 M sodium 
cacodylate  
6.5  10 % v/v 2-propanol  
8  None  0.1 M sodium acetate  4.5  1.0 M di-ammonium hydrogen  
phosphate  
9  None  0.1 M MES  6.5  1.6 M magnesium sulfate  
10  None  0.1 M Bicine  9.0  10 % w/v PEG 6000  
11  0.16 M calcium acetate  0.08 M sodium 
cacodylate  
6.5  14.4 % w/v PEG 8000/  
20 % v/v glycerol  
12  None  0.1 M imidazole  8.0  10 % w/v PEG 8000  
13  0.05 M caesium chloride  0.1 M MES  6.5  30 % v/v Jeffamine M-600  
14  None  0.1 M Na Citrate  5.0  3.2 M ammonium sulfate  
15  None  0.1 M Tris  8.0  20 % v/v MPD  
16  None  0.1 M HEPES  7.5  20 % v/v Jeffamine M-600  
17  0.2 M magnesium chloride  0.1 M Tris  8.5  50 % v/v ethylene glycol  
18  None  0.1 M Bicine  9.0  10 % v/v MPD  
19  None  None  7.0  0.8 M succinic acid  
20  None  None  7.0  2.1 M DL-malic acid  
21  None  None  7.0  2.4 M sodium malonate  
22  1.1 M sodium malonate  0.1 M HEPES  7.0  0.5 % v/v Jeffamine ED-2001  
23  1.0 M succinic acid  0.1 M HEPES  7.0  1 % w/v PEG 2000 MME  
24  None  0.1 M HEPES  7.0  30 % v/v Jeffamine M-600  
25  None  0.1 M HEPES  7.0  30 % v/v Jeffamine ED-2001  
26  0.02 M magnesium chloride  0.1 M HEPES  7.5  22 % w/v polyacrylic acid 5100  
sodium salt  
27  0.01 M cobalt chloride  0.1 M Tris  8.5  20 % w/v polyvinylpyrrolidone K15  
28  0.2 M tri-methylamine N-
oxide  
0.1 M Tris  8.5  20 % w/v PEG 2000 MME  
29  0.005 M cobalt chloride  
0.005 M cadmium chloride  
0.005 M magnesium chloride  
0.005 M nickel chloride  
0.1 M HEPES  7.5  12 % w/v PEG 3350  
30  0.2 M sodium malonate  None  7.0  20 % w/v PEG 3350  
31  0.1 M succinic acid  None  7.0  15 % w/v PEG 3350  
32  0.15 M DL - malic acid  None  7.0  20 % w/v PEG 3350  
33  0.1 M potassium thiocyanate  None  -  30 % w/v PEG 2000 MME  
34  0.15 M potassium bromide  None  -  30 % w/v PEG 2000 MME  
35  None  0.1 M Bis Tris  5.5  2.0 M ammonium sulfate  
36  None  0.1 M Bis Tris  5.5  3.0 M sodium chloride  
37  None  0.1 M Bis Tris  5.5  0.3 M magnesium formate  
38  1.0 M ammonium sulfate  0.1 M Bis Tris  5.5  1 % w/v PEG 3350  
39  None  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
40  0.2 M calcium chloride  0.1 M Bis Tris  5.5  45 % v/v MPD  
41  0.2 M ammonium acetate  0.1 M Bis Tris  5.5  45 % v/v MPD  
42  0.1 M ammonium acetate  0.1 M Bis Tris  5.5  17 % w/v PEG 10000  
43  0.2 M ammonium sulfate  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
44  0.2 M sodium chloride  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
45  0.2 M lithium sulfate  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
46  0.2 M ammonium acetate  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
47  0.2 M magnesium chloride  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
48  0.2 M ammonium acetate  0.1 M HEPES  7.5  45 % v/v MPD  
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PEG/Ion Screen 1 (Hampton Research, Aliso Viejo, USA; May 2011) 
ID Salt Buffer pH Precipitant 
1 
 
0.2 M imidazole malate  5.5 15% v/v PEG 600  
2 
 
0.2 M imidazole malate  5.5 24 %v/v PEG 600  
3 
 
0.2 M imidazole malate  5.5 33 % v/v PEG 600  
4 
 
0.2 M imidazole malate  5.5 42 % v/v PEG 600  
5 
 
0.2 M imidazole malate  7 10 % w/v PEG 4000  
6 
 
0.2 M imidazole malate  7 15 % w/v PEG 4000  
7 
 
0.2 M imidazole malate  7 20 % w/v PEG 4000  
8 
 
0.2 M imidazole malate  7 25 % PEG w/v 4000  
9 
 
0.2 M imidazole malate  8.5 7.5 % w/v PEG 10,000  
10 
 
0.2 M imidazole malate  8.5 12.5 % w/v PEG 10,000  
11 
 
0.2 M imidazole malate  8.5 17.5 % w/v PEG 10,000  
12 
 
0.2 M imidazole malate  8.5 22.5 % w/v PEG 10,000  
13 
 
0.15 M sodium citrate  5.5 0.75 M ammonium sulfate  
14 
 
0.15 M sodium citrate  5.5 1.0 M ammonium sulfate  
15 
 
0.15 M sodium citrate  5.5 1.5 M ammonium sulfate  
16 
 
0.15 M sodium citrate  5.5 2.0 M ammonium sulfate  
17 
 
0.8 M NaH2PO4/K2HPO4 7 -  
18 
 
1.32 M NaH2PO4/K2HPO4 7 -  
19 
 
1.6 M NaH2PO4/K2HPO4 7 -  
20 
 
2.0 M NaH2PO4/K2HPO4 7 -  
21 
 
0.01 M sodium borate  8.5 0.75 M sodium citrate  
22 
 
0.01 M sodium borate  8.5 1.0 M sodium citrate  
23 
 
0.01 M sodium borate  8.5 1.2 M sodium citrate  
24 
 
0.01 M sodium borate  8.5 1.5 M sodium citrate  
25 
 
0.1 M Na HEPES  8.2 30 % v/v PEG 550 MME  
26 
 
0.1 M Na HEPES  8.2 40 % v/v PEG 550 MME  
27 
 
0.1 M Na HEPES  8.2 50 % v/v PEG 550 MME  
28 
 
0.1 M Na HEPES  8.2 60 % v/v PEG 550 MME  
29 
 
0.1 M Na HEPES  7.5 18 % v/v PEG 600  
30 
 
0.1 M Na HEPES  7.5 27 % v/v PEG 600  
31 
 
0.1 M Na HEPES  7.5 36 % v/v PEG 600  
32 
 
0.1 M Na HEPES  7.5 45 % v/v PEG 600  
33 
 
0.1 M sodium cacodylate  6.5 18 % w/v PEG 2000 MME  
34 
 
0.1 M sodium cacodylate  6.5 27 % w/v PEG 2000 MME  
35 
 
0.1 M sodium cacodylate  6.5 36 % w/v PEG 2000 MME  
36 
 
0.1 M sodium cacodylate  6.5 45 % w/v PEG 2000 MME  
37 
 
0.2 M imidazole malate  6 8 % w/v PEG 4000  
38 
 
0.2 M imidazole malate  6 15 % w/v PEG 4000  
39 
 
0.2 M imidazole malate  6 20 % w/v PEG 4000  
40 
 
0.2 M imidazole malate  6 30 % w/v PEG 4000  
41 
 
0.1 M sodium acetate  5.5 12% PEG w/v 5000 MME  
42 
 
0.1 M sodium acetate  5.5 18% PEG w/v 5000 MME  
43 
 
0.1 M sodium acetate  5.5 24% PEG w/v 5000 MME  
44 
 
0.1 M sodium acetate  5.5 36% PEG w/v 5000 MME  
45 
 
0.1 M ammonium acetate  4.5 9 % w/v PEG 10,000  
46 
 
0.1 M ammonium acetate  4.5 15 % w/v PEG 10,000  
47 
 
0.1 M ammonium acetate  4.5 22.5 % w/v PEG 10,000  
48 
 
0.1 M ammonium acetate  4.5 27 % w/v PEG 10,000  
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PEG/Ion Screen 2 (Hampton Research, Aliso Viejo, USA; May 2011) 
 ID  Salt Buffer Precipitant 
1 0.2 M  Sodium fluoride 
 
20% (w/v) Polyethylene glycol 3,350 
2 0.2 M  Potassium fluoride 
 
20% (w/v) Polyethylene glycol 3,350 
3 0.2 M  Ammonium fluoride 
 
20% (w/v) Polyethylene glycol 3,350 
4 0.2 M  Lithium chloride 
 
20% (w/v) Polyethylene glycol 3,350 
5 0.2 M  
Magnesium chloride 
hexahydrate 
 
20% (w/v) Polyethylene glycol 3,350 
6 0.2 M  Sodium chloride 
 
20% (w/v) Polyethylene glycol 3,350 
7 0.2 M  Calcium chloride dihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
8 0.2 M  Potassium chloride 
 
20% (w/v) Polyethylene glycol 3,350 
9 0.2 M  Ammonium chloride 
 
20% (w/v) Polyethylene glycol 3,350 
10 0.2 M  Sodium iodide 
 
20% (w/v) Polyethylene glycol 3,350 
11 0.2 M  Potassium iodide 
 
20% (w/v) Polyethylene glycol 3,350 
12 0.2 M  Ammonium iodide 
 
20% (w/v) Polyethylene glycol 3,350 
13 0.2 M  Sodium thiocyanate 
 
20% (w/v) Polyethylene glycol 3,350 
14 0.2 M  Potassium thiocyanate 
 
20% (w/v) Polyethylene glycol 3,350 
15 0.2 M  Lithium nitrate 
 
20% (w/v) Polyethylene glycol 3,350 
16 0.2 M  Magnesium nitrate hexahydrate 
 
20% (w/v) Polyethylene glycol 3,350 
17 0.2 M  Sodium nitrate 
 
20% (w/v) Polyethylene glycol 3,350 
18 0.2 M  Potassium nitrate 
 
20% (w/v) Polyethylene glycol 3,350 
19 0.2 M  Ammonium nitrate 
 
20% (w/v) Polyethylene glycol 3,350 
20 0.2 M  Magnesium formate dihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
21 0.2 M  Sodium formate 
 
20% (w/v) Polyethylene glycol 3,350 
22 0.2 M  Potassium formate 
 
20% (w/v) Polyethylene glycol 3,350 
23 0.2 M  Ammonium formate 
 
20% (w/v) Polyethylene glycol 3,350 
24 0.2 M  Lithium acetate dihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
25 0.2 M  Magnesium acetate tetrahydrate 
 
20% (w/v) Polyethylene glycol 3,350 
26 0.2 M  Zinc acetate dihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
27 0.2 M  Sodium acetate trihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
28 0.2 M  Calcium acetate hydrate 
 
20% (w/v) Polyethylene glycol 3,350 
29 0.2 M  Potassium acetate 
 
20% (w/v) Polyethylene glycol 3,350 
30 0.2 M  Ammonium acetate 
 
20% (w/v) Polyethylene glycol 3,350 
31 0.2 M  Lithium sulfate monohydrate 
 
20% (w/v) Polyethylene glycol 3,350 
32 0.2 M  Magnesium sulfate heptahydrate 
 
20% (w/v) Polyethylene glycol 3,350 
33 0.2 M  Sodium sulfate decahydrate 
 
20% (w/v) Polyethylene glycol 3,350 
34 0.2 M  Potassium sulfate 
 
20% (w/v) Polyethylene glycol 3,350 
35 0.2 M  Ammonium sulfate 
 
20% (w/v) Polyethylene glycol 3,350 
36 0.2 M  Sodium tartrate dibasic dihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
37 0.2 M  Potassium sodium tartrate tetrahydrate 20% (w/v) Polyethylene glycol 3,350 
38 0.2 M  Ammonium tartrate dibasic 
 
20% (w/v) Polyethylene glycol 3,350 
39 0.2 M  Sodium phosphate monobasic monohydrate  20% (w/v) Polyethylene glycol 3,350 
40 0.2 M  Sodium phosphate dibasic dihydrate 20% (w/v) Polyethylene glycol 3,350 
41 0.2 M  Potassium phosphate monobasic 20% (w/v) Polyethylene glycol 3,350 
42 0.2 M  Potassium phosphate dibasic 
 
20% (w/v) Polyethylene glycol 3,350 
43 0.2 M  Ammonium phosphate monobasic 20% (w/v) Polyethylene glycol 3,350 
44 0.2 M  Ammonium phosphate dibasic 
 
20% (w/v) Polyethylene glycol 3,350 
45 0.2 M  Lithium citrate tribasic tetrahydrate 20% (w/v) Polyethylene glycol 3,350 
46 0.2 M  Sodium citrate tribasic dihydrate 
 
20% (w/v) Polyethylene glycol 3,350 
47 0.2 M  Potassium citrate tribasic monohydrate 20% (w/v) Polyethylene glycol 3,350 
48 0.2 M  Ammonium citrate dibasic 
 
20% (w/v) Polyethylene glycol 3,350 
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VI. AUC sedimentation velocity profile of MUB in PBS 
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VII. MubR5 crystal soaking and co-crystallisation data sets 
 MubR5 data collection  
sugar ligand Fuc Man  GalNAc GlcNAc LacNAc   Neu5Ac 
soak/ co-
crystallisation 
S S C S S S C C C 
Ligand concentration 
(mM) 
200 200 10 200 500 5 50 100 200 
Beamline Diamond 
i02 
Diamond 
i02 
Diamond 
i04 
Diamond 
i02 
Diamond 
i02 
Diamond 
i02 
Diamond 
i04 
Diamond 
i03 
Diamond 
i03 
Wavelength (Å) 0.9795 0.9795 0.9763 0.9795 0.9795 0.9795 0.9763 0.9709 0.9709 
Space group P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 
Cell 
parameters:  
a, b , c (Å) 
45.3, 
45.6, 
197.3 
45.3, 
45.5, 
197.9 
45.2, 
45.7, 
197.2 
46.8, 
47.0, 
194.6 
44.8, 
45.4, 
197.8 
45.3, 
45.6, 
197.8 
45.0, 
45.6, 
197.8 
45.0, 
45.1, 
196.6 
46.0, 
45.0, 
196.4 
Resolution (Å) 45-1.8 45-1.7 37-1.5 45-1.7 45-1.8 45-1.7 49-1.8 39-1.5 41-1.7 
Rsym (%) 8.8 
(32.6) 
6.3  
(21.5) 
3.6 
(11.4) 
5.3 
(18.4) 
6.8 
(31.8) 
9.1 
(41.4) 
6.5 
(26.1) 
6.9 
(37.4) 
7.2 
(22.9) 
I/σI 9.0   
(3.3) 
17.1  
(5.2) 
17.8 
(8.2) 
21.9 
(8.4) 
11.8 
(3.5) 
10.2 
(2.9) 
15.8 
(5.1) 
13.5 
(4.3) 
10.6 
(4.2) 
Unique 
reflections 
37602 47572 67337 45219 40084 46769 39964 56162 53950 
Completeness 
(%) 
97.4 
(99.0) 
99.7 
(99.4) 
97.9 
(98.5) 
95.7 
(98.9) 
98.8 
(97.8) 
99.9 
(99.9) 
99.1 
(98.0) 
90.1 
(91.0) 
99.5 
(99.5) 
Multiplicity 3.4 (3.6) 3.8 (3.8) 2.7 (2.6) 6.1 (6.4) 3.9 (4.0) 3.9 (3.9) 3.8 (3.8) 5.7 (6.1) 3.8 (3.8) 
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VIII. MubRI data processing parameters 
 MubRI data collection 
 Native Native Ytterbium Mercury chloride 
Ligand concentration (mM) - - 10 200 
Beamline Diamond i03 Diamond i04 Diamond i04 Diamond i04 
Wavelength (Å) 0.97090 0.98000 1.38670 1.00780 
Space group P222 P222 P222 P222 
Cell parameters:  
a, b , c (Å) 
44.1, 49.5, 216.5 44.2, 49.3, 217.1 44.3, 49.6, 217.6 44.1, 49.3, 217.3 
Resolution (Å) 49.5-1.9 (2.0-1.9) 49.2-2.0 (2.1-2.0) 54.4-2.4 (2.5-2.4) 49.0-2.6 (2.7-2.6) 
Rsym (%) 21.6 (198.8) 16.7 (124.6) 12.7 (50.9) 9.3 (41.6) 
I/σI 6.2 (1.1) 3.6 (3.5) 6.1 (6.6) 5.6 (5.5) 
Unique reflections 39405 (4948) 34167 (4398) 20040 (3090) 16201 (2621) 
Completeness (%) 99.0 (76.2) 99.6 (71.8) 99.7 (79.9) 99.4 (86.8) 
Multiplicity 7.3 (7.3) 3.6 (3.5) 6.1 (6.6) 5.6 (5.5) 
p-valuea  2.384e-02 2.2520e-03 3.435e-03 3.688e-0.3 
ap-values determined by XTRIAGE for reflection data quality analysis; p-value < 0.05 indicates weak translational pseudosymmetry;   
p-value < 1e-0.3 indicates strong pseudosymmetry 
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IX. SAXS data set statistics 
 
Molecular 
weight 
calculated 
from 
sequence 
[kDa] 
Molecular 
weight 
determined 
from SAXS 
dataa [kDa] 
Rg (Guinier 
analysis) 
[nm] 
Rg (GNOM 
analysis) 
[nm] 
Dmax 
[nm] 
GASPOR 
SITUS/ 
Sculptor CRYSOL 
sample Χb NSDc R Χ 
MubR5 20.5 24.4 3.00 ± 0.05 3.15 ± 0.01  10.5 1.8 0.91 ± 0.04 0.83 1.06 
MubRV 20.3 25.9 3.09 ± 0.05 3.23 ± 0.01 11.0 2.18 0.87 ± 0.01 0.82 1.02 
MubRI 21.3 25.2 3.10 ± 0.04 3.29 ± 0.00 10.6 1.92 0.92 ± 0.02 0.84 - 
MubR8-V 40.6 48.3 5.87 ± 0.10 6.03 ± 0.02 20.5 3.15 1.55 ± 0.08 0.60 - 
MubRV-VI 38.7 48.7 5.79 ± 0.15 5.37 ± 0.02 20.6 3.34 1.48 ± 0.12  0.54 - 
Nterm 56.3 53.3 4.53 ± 0.05 4.47 ± 0.02 15.9 1.40 1.54 ± 0.05 - - 
      DAMMIF   
MubRI-II-III 64.1 71.1 8.66 ± 0.44  8.61 ± 0.50 29.2 1.55 1.02 ± 0.07 0.45 - 
aparticle molecular weight calculated using the formula I(0)÷ I(0)BSA × MWBSA; where MWBSA was 66.5 kDa and I(0)BSA was 65.9 or 66.8 
(Nterm or MubRI-II-III) 
baverage discrepancy of computed scattering curves from 10 ab-inito shape reconstructions compared to experimental scattering curves 
cNSD value between 10 individual shape reconstructions  
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X. Kratky analysis of SAXS scattering data  
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XI. Comparison of experimental and calculated SAXS scattering 
data of MubRV and MubR5 
 
 
 
 
 
 
 
 
 
Comparison of experimental scattering data of (A) MubRV and (B) MubR5 (black dotted 
line) and calculated SAXS scattering profiles (blue for Mub-RV, green for Mub-R5) from 
X-ray crystal structures of Mub-RV and Mub-R5 using CRYSOL. 
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XII. Screening of glycoconjugates for MUB binding  
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XIII. Screening of the mammalian glycan array (CFG) for MUB binding 
 
Chart 
Number 
MUB detected by anti-MubR5 CFG#2311 Slide#:13810 09/12/2011 at 488nm 
Average 
RFU StDev 
% 
CV 
1 Gala-Sp8 17 23 136 
2 Glca-Sp8 12 14 118 
3 Mana-Sp8 14 6 44 
4 GalNAca-Sp8 12 6 54 
5 GalNAca-Sp15 8 8 93 
6 Fuca-Sp8 11 7 59 
7 Fuca-Sp9 5 9 176 
8 Rhaa-Sp8 21 12 58 
9 Neu5Aca-Sp8 17 17 95 
10 Neu5Aca-Sp11 10 4 39 
11 Neu5Acb-Sp8 9 4 48 
12 Galb-Sp8 9 14 150 
13 Glcb-Sp8 8 1 13 
14 Manb-Sp8 7 4 52 
15 GalNAcb-Sp8 15 12 79 
16 GlcNAcb-Sp0 12 9 72 
17 GlcNAcb-Sp8 3 7 219 
18 GlcN(Gc)b-Sp8 11 10 96 
19 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAca-Sp8 11 6 57 
20 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)GalNAc-Sp14 16 10 67 
21 GlcNAcb1-6(GlcNAcb1-4)(GlcNAcb1-3)GlcNAc-Sp8 5 5 104 
22 6S(3S)Galb1-4(6S)GlcNAcb-Sp0 13 4 30 
23 6S(3S)Galb1-4GlcNAcb-Sp0 14 7 52 
24 (3S)Galb1-4(Fuca1-3)(6S)Glc-Sp0 6 6 105 
25 (3S)Galb1-4Glcb-Sp8 10 12 113 
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26 (3S)Galb1-4(6S)Glcb-Sp0 11 5 44 
27 (3S)Galb1-4(6S)Glcb-Sp8 10 10 99 
28 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp8 8 5 61 
29 (3S)Galb1-3GalNAca-Sp8 3 5 139 
30 (3S)Galb1-3GlcNAcb-Sp0 10 7 68 
31 (3S)Galb1-3GlcNAcb-Sp8 4 1 19 
32 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp0  7 7 98 
33 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp8 14 8 59 
34 (3S)Galb1-4(6S)GlcNAcb-Sp0 10 15 153 
35 (3S)Galb1-4(6S)GlcNAcb-Sp8 7 2 30 
36 (3S)Galb1-4GlcNAcb-Sp0 10 5 48 
37 (3S)Galb1-4GlcNAcb-Sp8 6 4 68 
38 (3S)Galb-Sp8 4 3 91 
39 (6S)(4S)Galb1-4GlcNAcb-Sp0 9 16 186 
40 (4S)Galb1-4GlcNAcb-Sp8 10 7 70 
41 (6P)Mana-Sp8 5 5 100 
42 (6S)Galb1-4Glcb-Sp0 9 7 78 
43 (6S)Galb1-4Glcb-Sp8 0 4 -848 
44 (6S)Galb1-4GlcNAcb-Sp8 9 10 119 
45 (6S)Galb1-4(6S)Glcb-Sp8 10 4 39 
46 Neu5Aca2-3(6S)Galb1-4GlcNAcb-Sp8 4 7 181 
47 (6S)GlcNAcb-Sp8 8 6 75 
48 Neu5,9Ac2a-Sp8 6 3 44 
49 Neu5,9Ac2a2-6Galb1-4GlcNAcb-Sp8 3 2 75 
50 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 5 5 120 
51 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 6 4 71 
52 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 15 10 69 
53 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 2 2 84 
54 Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 18 14 79 
55 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 8 5 59 
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56 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp13 6 5 81 
57 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Man-a1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp21 12 10 87 
58 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp24 16 3 19 
59 Fuca1-2Galb1-3GalNAcb1-3Gala-Sp9 1 3 296 
60 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 7 3 49 
61 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 14 6 45 
62 Fuca1-2Galb1-3GalNAca-Sp8 1 3 341 
63 Fuca1-2Galb1-3GalNAca-Sp14 5 4 80 
64 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 6 5 81 
65 Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 10 6 65 
66 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8 1 2 130 
67 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 11 7 64 
68 Fuca1-2Galb1-3GlcNAcb-Sp0 5 5 109 
69 Fuca1-2Galb1-3GlcNAcb-Sp8 9 4 51 
70 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 2 100 
71 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 2 49 
72 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp0 8 4 44 
73 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8 2 2 131 
74 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4 4 101 
75 Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 11 11 105 
76 Fuca1-2Galb1-4GlcNAcb-Sp0 14 8 58 
77 Fuca1-2Galb1-4GlcNAcb-Sp8 11 6 57 
78 Fuca1-2Galb1-4Glcb-Sp0 -1 3 -280 
79 Fuca1-2Galb-Sp8 2 1 60 
80 Fuca1-3GlcNAcb-Sp8 11 8 77 
81 Fuca1-4GlcNAcb-Sp8 8 3 31 
82 Fucb1-3GlcNAcb-Sp8 8 4 49 
83 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 5 4 76 
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84 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 9 9 98 
85 (3S)Galb1-4(Fuca1-3)Glcb-Sp0 4 5 105 
86 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 7 6 90 
87 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 4 5 104 
88 GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 2 4 185 
89 GlcNAcb1-3Galb1-3GalNAca-Sp8 9 6 68 
90 GalNAca1-3(Fuca1-2)Galb-Sp8 5 3 56 
91 GalNAca1-3(Fuca1-2)Galb-Sp18 7 7 91 
92 GalNAca1-3GalNAcb-Sp8 5 2 36 
93 GalNAca1-3Galb-Sp8 1 2 199 
94 GalNAca1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 0 1 316 
95 GalNAcb1-3GalNAca-Sp8 6 4 56 
96 GalNAcb1-3(Fuca1-2)Galb-Sp8 4 2 58 
97 GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 4 4 95 
98 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 12 4 35 
99 GalNAcb1-4GlcNAcb-Sp0 7 4 63 
100 GalNAcb1-4GlcNAcb-Sp8 5 5 84 
101 Gala1-2Galb-Sp8 2 4 228 
102 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 8 6 77 
103 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp8 7 9 131 
104 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 3 105 
105 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb-Sp8 6 8 135 
106 Gala1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 6 7 102 
107 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 3 4 144 
108 Gala1-3(Fuca1-2)Galb-Sp8 7 10 133 
109 Gala1-3(Fuca1-2)Galb-Sp18 12 7 60 
110 Gala1-4(Gala1-3)Galb1-4GlcNAcb-Sp8 10 3 31 
111 Gala1-3GalNAca-Sp8 18 3 14 
112 Gala1-3GalNAca-Sp16 1 6 544 
113 Gala1-3GalNAcb-Sp8 0 6 2084 
114 Gala1-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 6 1 23 
201 
 
115 Gala1-3Galb1-3GlcNAcb-Sp0 5 2 49 
116 Gala1-3Galb1-4GlcNAcb-Sp8 12 4 30 
117 Gala1-3Galb1-4Glcb-Sp0 11 3 23 
118 Gala1-3Galb1-4Glc-Sp10 2 3 164 
119 Gala1-3Galb-Sp8 6 5 84 
120 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 1 4 316 
121 Gala1-4Galb1-4GlcNAcb-Sp0 7 4 53 
122 Gala1-4Galb1-4GlcNAcb-Sp8 17 15 89 
123 Gala1-4Galb1-4Glcb-Sp0 9 10 107 
124 Gala1-4GlcNAcb-Sp8 9 4 45 
125 Gala1-6Glcb-Sp8 13 13 101 
126 Galb1-2Galb-Sp8 9 5 55 
127 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 4 6 150 
128 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 2 5 220 
129 Galb1-3(Fuca1-4)GlcNAc-Sp0  22 10 46 
130 Galb1-3(Fuca1-4)GlcNAc-Sp8  4 4 110 
131 Fuca1-4(Galb1-3)GlcNAcb-Sp8 5 3 50 
132 Galb1-4GlcNAcb1-6GalNAca-Sp8 2 3 157 
133 Galb1-4GlcNAcb1-6GalNAc-Sp14 14 7 47 
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp8  5 6 110 
135 GlcNAcb1-6(Galb1-3)GalNAca-Sp14 3 6 202 
136 Neu5Aca2-6(Galb1-3)GalNAca-Sp8 8 8 105 
137 Neu5Aca2-6(Galb1-3)GalNAca-Sp14 10 6 65 
138 Neu5Acb2-6(Galb1-3)GalNAca-Sp8 5 2 35 
139 Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 10 5 53 
140 Galb1-3GalNAca-Sp8 4 2 58 
141 Galb1-3GalNAca-Sp14 13 10 75 
142 Galb1-3GalNAca-Sp16 4 3 78 
143 Galb1-3GalNAcb-Sp8 4 2 47 
144 Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 10 8 80 
145 Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 4 4 110 
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146 Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 5 4 66 
147 Galb1-3Galb-Sp8 8 8 93 
148 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5 1 26 
149 Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 4 2 60 
150 Galb1-3GlcNAcb-Sp0 8 8 98 
151 Galb1-3GlcNAcb-Sp8 7 5 72 
152 Galb1-4(Fuca1-3)GlcNAcb-Sp0 10 7 66 
153 Galb1-4(Fuca1-3)GlcNAcb-Sp8 11 3 25 
154 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 4 1 16 
155 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 12 6 49 
156 Galb1-4(6S)Glcb-Sp0 8 8 96 
157 Galb1-4(6S)Glcb-Sp8 12 12 99 
158 Galb1-4GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 10 6 65 
159 Galb1-4GalNAcb1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 7 4 59 
160 Galb1-4GlcNAcb1-3GalNAca-Sp8 2 3 146 
161 Galb1-4GlcNAcb1-3GalNAc-Sp14 4 3 60 
162 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 4 135 
163 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 12 9 70 
164 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 1 3 362 
165 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 3 3 133 
166 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp8 6 3 57 
167 Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp8 8 1 13 
168 Galb1-4GlcNAcb1-6(Galb1-3)GalNAc-Sp14 4 4 95 
169 Galb1-4GlcNAcb-Sp0 7 5 67 
170 Galb1-4GlcNAcb-Sp8 6 2 34 
171 Galb1-4GlcNAcb-Sp23 9 5 54 
172 Galb1-4Glcb-Sp0 0 1 -193 
173 Galb1-4Glcb-Sp8 1 2 114 
174 GlcNAca1-3Galb1-4GlcNAcb-Sp8 2 2 133 
175 GlcNAca1-6Galb1-4GlcNAcb-Sp8 9 3 31 
176 GlcNAcb1-2Galb1-3GalNAca-Sp8 4 2 54 
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177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 2 3 108 
178 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 5 6 130 
179 GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAcb-Sp8 7 5 74 
180 GlcNAcb1-3GalNAca-Sp8 8 6 76 
181 GlcNAcb1-3GalNAca-Sp14 2 2 83 
182 GlcNAcb1-3Galb-Sp8 7 5 77 
183 GlcNAcb1-3Galb1-4GlcNAcb-Sp0 12 4 36 
184 GlcNAcb1-3Galb1-4GlcNAcb-Sp8 9 7 85 
185 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2 3 123 
186 GlcNAcb1-3Galb1-4Glcb-Sp0 5 6 125 
187 GlcNAcb1-4-MDPLys 13 13 98 
188 GlcNAcb1-6(GlcNAcb1-4)GalNAca-Sp8 7 3 44 
189 GlcNAcb1-4Galb1-4GlcNAcb-Sp8 12 8 64 
190 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 1 2 236 
191 GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-Sp8 8 5 68 
192 GlcNAcb1-4GlcNAcb1-4GlcNAcb-Sp8 3 3 93 
193 GlcNAcb1-6GalNAca-Sp8 7 3 42 
194 GlcNAcb1-6GalNAca-Sp14 8 7 84 
195 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 16 8 48 
196 Glca1-4Glcb-Sp8 1 2 170 
197 Glca1-4Glca-Sp8 12 7 58 
198 Glca1-6Glca1-6Glcb-Sp8 9 2 22 
199 Glcb1-4Glcb-Sp8 10 10 103 
200 Glcb1-6Glcb-Sp8 5 2 44 
201 G-ol-Sp8 11 7 60 
202 GlcAa-Sp8 5 4 85 
203 GlcAb-Sp8 10 7 69 
204 GlcAb1-3Galb-Sp8 7 4 63 
205 GlcAb1-6Galb-Sp8 4 2 55 
206 KDNa2-3Galb1-3GlcNAcb-Sp0 5 7 148 
207 KDNa2-3Galb1-4GlcNAcb-Sp0 6 8 133 
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208 Mana1-2Mana1-2Mana1-3Mana-Sp9 5 3 56 
209 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana-Sp9 7 5 70 
210 Mana1-2Mana1-3Mana-Sp9 10 9 91 
211 Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 3 2 87 
212 Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 5 4 76 
213 
Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 5 3 59 
214 Mana1-6(Mana1-3)Mana-Sp9 0 2 973 
215 Mana1-2Mana1-2Mana1-6(Mana1-3)Mana-Sp9 12 9 73 
216 Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 18 12 65 
217 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 8 9 113 
218 Manb1-4GlcNAcb-Sp0 4 3 68 
219 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 11 14 122 
220 (3S)Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8  12 8 64 
221 Fuca1-2(6S)Galb1-4GlcNAcb-Sp0 7 5 65 
222 Fuca1-2Galb1-4(6S)GlcNAcb-Sp8 4 3 63 
223 Fuca1-2(6S)Galb1-4(6S)Glcb-Sp0 13 15 115 
224 Neu5Aca2-3Galb1-3GalNAca-Sp8 7 4 54 
225 Neu5Aca2-3Galb1-3GalNAca-Sp14 10 5 51 
226 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 5 4 78 
227 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 5 4 78 
228 Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 10 8 79 
229 GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 9 6 60 
230 Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 5 3 75 
231 Neu5Aca2-3(6S)Galb1-4(Fuca1-3)GlcNAcb-Sp8 12 5 42 
232 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp0 2 2 93 
233 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 11 9 84 
234 GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 5 5 101 
235 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 6 5 73 
236 Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 8 3 34 
237 Neu5Aca2-3GalNAca-Sp8 7 3 39 
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238 Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 12 8 65 
239 Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 5 3 73 
240 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8 7 9 127 
241 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 6 3 54 
242 Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 12 7 60 
243 Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8 7 9 129 
244 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 5 3 63 
245 Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 8 3 41 
246 Neu5Aca2-3Galb-Sp8 14 12 91 
247 Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 10 3 35 
248 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6 4 68 
249 Fuca1-2(6S)Galb1-4Glcb-Sp0 21 6 27 
250 Neu5Aca2-3Galb1-3GlcNAcb-Sp0 9 3 40 
251 Neu5Aca2-3Galb1-3GlcNAcb-Sp8 11 3 24 
252 Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 4 6 146 
253 Neu5Aca2-3Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 -1 2 -356 
254 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 11 7 61 
255 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 6 199 
256 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 5 4 81 
257 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 11 6 58 
258 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 4 4 100 
259 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 2 3 154 
260 Neu5Aca2-3Galb1-4GlcNAcb-Sp0 9 7 81 
261 Neu5Aca2-3Galb1-4GlcNAcb-Sp8 5 7 134 
262 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4 5 133 
263 Fuca1-2Galb1-4(6S)Glcb-Sp0 6 1 11 
264 Neu5Aca2-3Galb1-4Glcb-Sp0 5 7 133 
265 Neu5Aca2-3Galb1-4Glcb-Sp8 4 3 78 
266 Neu5Aca2-6GalNAca-Sp8 11 10 85 
267 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 13 3 22 
268 Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 7 7 90 
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269 Neu5Aca2-6Galb1-4GlcNAcb-Sp0 1 3 181 
270 Neu5Aca2-6Galb1-4GlcNAcb-Sp8 3 5 164 
271 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 2 75 
272 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 9 8 91 
273 Neu5Aca2-6Galb1-4Glcb-Sp0 7 2 31 
274 Neu5Aca2-6Galb1-4Glcb-Sp8 7 5 67 
275 Neu5Aca2-6Galb-Sp8 3 5 149 
276 Neu5Aca2-8Neu5Aca-Sp8 7 5 77 
277 Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 6 1 13 
278 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 16 10 65 
279 Neu5Acb2-6GalNAca-Sp8 9 5 48 
280 Neu5Acb2-6Galb1-4GlcNAcb-Sp8 6 6 93 
281 Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 4 6 133 
282 Neu5Gca2-3Galb1-3GlcNAcb-Sp0 6 3 52 
283 Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 5 8 146 
284 Neu5Gca2-3Galb1-4GlcNAcb-Sp0 9 18 189 
285 Neu5Gca2-3Galb1-4Glcb-Sp0 1 7 1317 
286 Neu5Gca2-6GalNAca-Sp0 2 3 112 
287 Neu5Gca2-6Galb1-4GlcNAcb-Sp0 5 9 161 
288 Neu5Gca-Sp8 10 7 67 
289 Neu5Aca2-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 8 3 41 
290 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 1 2 339 
291 Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp0  6 3 56 
292 Galb1-4(Fuca1-3)(6S)Glcb-Sp0 10 4 43 
293 Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 8 8 98 
294 Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 6 5 82 
295 Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 8 7 84 
296 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 9 2 20 
297 4S(3S)Galb1-4GlcNAcb-Sp0 13 8 62 
298 (6S)Galb1-4(6S)GlcNAcb-Sp0 3 1 42 
299 (6P)Glcb-Sp10 4 2 41 
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300 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3)GalNAca-Sp14 5 4 73 
301 Galb1-3Galb1-4GlcNAcb-Sp8 11 6 50 
302 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 3 2 86 
303 Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 13 14 110 
304 GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4GlcNAc-Sp0 6 6 99 
305 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 2 4 238 
306 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 11 3 25 
307 GalNAcb1-3Galb-Sp8 11 2 17 
308 GlcAb1-3GlcNAcb-Sp8 10 2 17 
309 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 10 12 119 
310 GlcNAcb1-3Man-Sp10 8 7 94 
311 GlcNAcb1-4GlcNAcb-Sp10 5 6 111 
312 GlcNAcb1-4GlcNAcb-Sp12 8 7 85 
313 MurNAcb1-4GlcNAcb-Sp10 5 4 89 
314 Mana1-6Manb-Sp10 14 10 74 
315 Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb-Sp10 13 8 61 
316 Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Mana-Sp9 4 4 105 
317 Mana1-2Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Mana-Sp9 4 6 167 
318 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 7 8 112 
319 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 13 6 49 
320 
Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp12 5 5 98 
321 GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 7 3 50 
322 Neu5Aca2-8Neu5Acb-Sp17 8 4 51 
323 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 4 2 42 
324 Neu5Gcb2-6Galb1-4GlcNAc-Sp8 4 3 59 
325 Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 9 5 60 
326 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 23 9 38 
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327 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 12 9 77 
328 
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp20 11 6 53 
329 Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0 1 5 402 
330 Neu5,9Ac2a2-3Galb1-3GlcNAcb-Sp0 4 7 161 
331 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 -1 5 -517 
332 Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 16 10 61 
333 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4 5 124 
334 Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 2 6 398 
335 GalNAcb1-3Gala1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 6 4 65 
336 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5 3 59 
337 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 6 6 102 
338 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAc-Sp14 5 5 93 
339 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 8 6 74 
340 GlcNAca1-4Galb1-4GlcNAcb-Sp0 6 3 52 
341 GlcNAca1-4Galb1-3GlcNAcb-Sp0 16 10 63 
342 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 9 11 126 
343 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 3 1 41 
344 GlcNAca1-4Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 4 6 142 
345 GlcNAca1-4Galb1-3GalNAc-Sp14 13 6 44 
346 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 4 4 113 
347 Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 5 7 126 
348 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 7 4 56 
349 Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 11 3 23 
350 Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 10 7 67 
351 Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 12 8 67 
352 Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 2 1 44 
353 GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 11 7 60 
354 Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 11 12 110 
355 Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 5 4 69 
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356 (6S)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 3 1 23 
357 KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0 7 6 83 
358 KDNa2-6Galb1-4GlcNAc-Sp0 3 3 115 
359 KDNa2-3Galb1-4Glc-Sp0 5 3 59 
360 KDNa2-3Galb1-3GalNAca-Sp14 2 4 190 
361 
Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp20 5 6 138 
362 
Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp20 4 3 67 
363 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAb-Sp20 7 2 23 
364 
Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp20 7 8 112 
365 Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 9 5 60 
366 
Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-6(Fuca1-4(Galb1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp22 5 1 29 
367 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 4 2 57 
368 Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 7 4 64 
369 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 1 3 204 
370 
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-
4GlcNAc-Sp21 8 7 85 
371 
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 9 7 79 
372 
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 15 8 53 
373 
Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Gala1-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 9 8 89 
374 
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp20 7 3 38 
375 
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp20 3 3 93 
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376 
Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-2Mana1-3(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAcb-Sp19 2 3 179 
377 Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 4 5 107 
378 Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 2 4 204 
379 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 13 4 27 
380 GalNAcb1-4GlcNAcb1-2Mana1-6(GalNAcb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 12 6 51 
381 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glc-Sp0 9 3 32 
382 Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAc-Sp0 7 8 109 
383 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp0 2 5 218 
384 Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21  4 6 166 
385 Galb1-4GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 5 13 275 
386 Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 -1 2 -145 
387 Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21  2 4 189 
388 
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 19 6 32 
389 GlcNAcb1-2Mana1-6(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 4 7 193 
390 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb-Sp0 0 4 -843 
391 Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 3 3 106 
392 Galb1-3GlcNAcb1-3GalNAca-Sp14 4 4 112 
393 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb1-3GalNAca-Sp14 10 5 47 
394 GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 4 2 47 
395 
Gala1-3Galb1-3GlcNAcb1-2Mana1-6(Gala1-3Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp19 13 11 84 
396 
Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Gala1-3Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp19 5 2 41 
397 
Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAc-Sp19 6 3 48 
398 GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 10 8 82 
399 Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 6 6 109 
400 Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 9 12 133 
401 Fuca1-2Galb1-4GlcNAcb1-3GalNAca-Sp14 6 5 78 
402 Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 10 2 18 
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403 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4GlcNAcb-Sp0 1 2 354 
404 
Gala1-4Galb1-3GlcNAcb1-2Mana1-6(Gala1-4Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp19 2 3 178 
405 
Gala1-4Galb1-4GlcNAcb1-2Mana1-6(Gala1-4Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp24 15 8 53 
406 Gala1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 6 5 90 
407 Galb1-3GlcNAcb1-6Galb1-4GlcNAcb-Sp0 5 6 112 
408 Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0 5 1 26 
409 GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8 1 5 626 
410 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21 9 10 116 
411 Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 9 4 50 
412 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 10 10 99 
413 Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 2 3 110 
414 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 7 4 61 
415 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3GalNAca-Sp14 6 4 65 
416 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 5 3 73 
417 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 5 4 91 
418 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 2 4 174 
419 GalNAca1-3(Fuca1-2)Galb1-4(Fuca1-3)GlcNAcb1-3GalNAc-Sp14 8 3 44 
420 
Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp22 6 2 35 
421 
Fuca1-2Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 8 3 45 
422 GlcNAcb1-2(GlcNAcb1-6)Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 4 9 203 
423 Fuca1-2Galb1-3GlcNAcb1-3GalNAc-Sp14 -1 3 -284 
424 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 9 8 80 
425 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3GalNAc-Sp14 4 2 54 
426 Gala1-3Galb1-3GlcNAcb1-3GalNAc-Sp14 5 6 126 
427 
Fuca1-2Galb1-3GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp22 2 3 109 
428 
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 10 6 60 
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429 
Galb1-3GlcNAcb1-6(Galb1-3GlcNAcb1-2)Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp19 15 6 41 
430 Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 3 3 106 
431 Fuca1-3GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc-Sp21 2 4 198 
432 GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 1 1 96 
433 
GlcNAcb1-2Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 9 4 47 
434 
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 2 4 202 
435 
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-
4GlcNAc-Sp21 2 3 113 
436 
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp21 -1 2 -122 
437 
Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 4 5 110 
438 
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4GlcNAc-Sp21 7 2 30 
439 
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 8 6 78 
440 Galb1-4Galb-Sp10 6 7 105 
441 Galb1-6Galb-Sp10 12 4 39 
442 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 2 3 167 
443 GalNAcb1-6GalNAcb-Sp8 6 6 103 
444 (6S)Galb1-3GlcNAcb-Sp0 10 10 92 
445 (6S)Galb1-3(6S)GlcNAc-Sp0 6 3 57 
446 
Fuca1-2Galb1-4 GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2(Fuca1-2Galb1-4GlcNAcb1-4)Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 6 3 39 
447 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-4(Fuca1-2Galb1-
4(Fuca1-3)GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 13 15 116 
448 Galb1-4(Fuca1-3)GlcNAcb1-6GalNAc-Sp14 12 6 44 
449 Galb1-4GlcNAcb1-2Mana-Sp0 10 9 91 
450 Fuca1-2Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)GalNAc-Sp14 7 3 40 
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451 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3)GalNAc-Sp14 8 6 85 
452 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6(GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3)GalNAc-Sp14 3 2 85 
453 Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 4 4 123 
454 GalNAcb1-4Galb1-4Glcb-Sp0 6 5 78 
455 
GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 11 8 74 
456 
Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 6 6 110 
457 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 13 2 13 
458 
GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-6(GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 8 7 88 
459 
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp19 13 3 24 
460 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 4 4 122 
461 
Neu5Aca2-3Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-4(Neu5Aca2-
3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 12 6 52 
462 
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 4 5 151 
463 
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 5 3 68 
464 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 11 4 32 
465 
Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-4(Neu5Aca2-
6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 5 6 120 
466 
Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 1 6 518 
467 
Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-
6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 5 3 62 
468 Gala1-3(Fuca1-2)Galb1-3GalNAca-Sp8 10 11 108 
469 Gala1-3(Fuca1-2)Galb1-3GalNAcb-Sp8 2 4 215 
470 Glca1-6Glca1-6Glca1-6Glcb-Sp10 7 3 52 
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471 Glca1-4Glca1-4Glca1-4Glcb-Sp10 14 7 47 
472 Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 9 8 83 
473 
Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 4 4 96 
474 
Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 8 13 158 
475 
Neu5Aca2-3Galb1-3GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(Neu5Aca2-3Galb1-
3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 21 7 36 
476 GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 7 7 99 
477 
Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-
Sp21 10 14 141 
478 Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp21 7 7 99 
479 Neu5Aca2-3Galb1-4GlcNAcb1-2Mana-Sp0 6 4 64 
480 Neu5Aca2-3Galb1-4GlcNAcb1-6GalNAca-Sp14 9 6 69 
481 Neu5Aca2-6Galb1-4GlcNAcb1-6GalNAca-Sp14 7 2 27 
482 Neu5Aca2-6Galb1-4 GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3)GalNAca-Sp14 5 4 71 
483 
Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp24 13 15 115 
484 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp24 13 8 67 
485 Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 3 5 139 
486 
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp24 9 7 77 
487 
Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 17 6 38 
488 Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 6 4 64 
489 Galb1-3GlcNAcb1-6GalNAca-Sp14 14 12 81 
490 Gala1-3Galb1-3GlcNAcb1-6GalNAca-Sp14 4 2 42 
491 Galb1-3(Fuca1-4)GlcNAcb1-6GalNAca-Sp14 10 10 98 
492 Neu5Aca2-3Galb1-3GlcNAcb1-6GalNAca-Sp14 2 2 79 
493 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp0 1 5 977 
494 Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6(Neu5Aca2-3Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 6 6 104 
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495 Fuca1-2Galb1-4GlcNAcb1-6GalNAca-Sp14 12 1 10 
496 Gala1-3Galb1-4GlcNAcb1-6GalNAca-Sp14 11 9 80 
497 Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 10 2 21 
498 Fuca1-2(6S)Galb1-3GlcNAcb-Sp0 5 3 59 
499 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAca-Sp14 8 4 55 
500 Fuca1-2Galb1-4GlcNAcb1-2Mana-Sp0 1 3 321 
501 Fuca1-2Galb1-3(6S)GlcNAcb-Sp0 5 2 46 
502 Fuca1-2(6S)Galb1-3(6S)GlcNAcb-Sp0 11 10 84 
503 Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 3 4 164 
504 GalNAcb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 14 12 85 
505 (3S)GalNAcb1-4(Fuca1-3)GlcNAcb-Sp8 9 2 18 
506 Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)GalNAca-Sp14 10 7 67 
507 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAca-Sp14 10 3 31 
508 
GlcNAcb1-6(GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAc-Sp21 3 4 113 
509 
Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)Galb1-4GlcNAcb1-4(Gal b1-4GlcNAcb1-
2)Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 13 16 123 
510 Galb1-3GlcNAca1-3Galb1-4GlcNAcb-Sp8  7 6 83 
511 Galb1-3(6S)GlcNAcb-Sp8  11 8 69 
512 (6S)(4S)GalNAcb1-4GlcNAc-Sp8 4 12 294 
513 (6S)GalNAcb1-4GlcNAc-Sp8  4 3 59 
514 (3S)GalNAcb1-4(3S)GlcNAc-Sp8 5 1 27 
515 GalNAcb1-4(6S)GlcNAc-Sp8  8 5 63 
516 (3S)GalNAcb1-4GlcNAc-Sp8  1 4 291 
517 (4S)GalNAcb-Sp10 8 13 161 
518 Galb1-4(6P)GlcNAcb-Sp0  16 8 47 
519 (6P)Galb1-4GlcNAcb-SP0  21 12 58 
520 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-6GalNAc-Sp14 9 9 110 
521 Neu5Aca2-6Galb1-4GlcNAcb1-2Man-Sp0 8 9 118 
522 Gala1-3Galb1-4GlcNAcb1-2Mana-Sp0 6 2 33 
523 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana-Sp0 7 4 54 
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524 GalNAca1-3(Fuca1-2)Galb1-4 GlcNAcb1-2Mana-Sp0 10 16 161 
525  Galb1-3GlcNAcb1-2Mana-Sp0 8 4 53 
526 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAc-Sp14 7 3 45 
527 Neu5Aca2-3Galb1-3GlcNAcb1-2Mana-Sp0 1 3 250 
528 Gala1-3Galb1-3GlcNAcb1-2Mana-Sp0 13 7 59 
529 GalNAcb1-4GlcNAcb1-2Mana-Sp0 8 3 37 
530 Neu5Aca2-3Galb1-3GlcNAcb1-4Galb1-4Glcb-Sp0 5 8 161 
531 GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAc-Sp21 20 21 103 
532 
Galb1-4GlcNAcb1-2 Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAc-Sp21 7 3 46 
533 
Galb1-4GlcNAcb1-2 Mana1-6(Galb1-4GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAc-Sp21 14 6 41 
534 Fuca1-4(Galb1-3)GlcNAcb1-2 Mana-Sp0 4 4 86 
535 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 7 7 109 
536 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3)Galb1-4GlcNAc-Sp0 6 8 131 
537 GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 6 3 50 
538 Gala1-3(Fuca1-2)Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc-Sp21 14 13 88 
539 Galb1-3GalNAcb1-3Gal-Sp21 4 3 71 
540 
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp12 2 2 76 
541 
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp25 4 5 142 
542 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 8 6 71 
543 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 6 4 68 
544 
Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 8 3 34 
545 
Fuca1-2Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 5 2 47 
546 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 18 6 30 
217 
 
547 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 5 5 109 
548 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 13 8 61 
549 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 2 3 146 
550 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 15 6 42 
551 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp25 6 5 80 
552 
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAc-Sp25 4 2 42 
553 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 7 3 42 
554 Neu5Aca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 4 3 89 
555 Neu5Gca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 7 7 94 
556 Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc-Sp0 10 4 37 
557 Neu5Gca2-8Neu5Gca2-6Galb1-4GlcNAc-Sp0 1 4 273 
558 Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 1 2 258 
559 
GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-2Man a1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp24 8 4 51 
560 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2)Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Mana1-4GlcNAcb1-4GlcNAc-Sp24 6 6 93 
561 
Gala1-3Galb1-4GlcNAcb1-2Mana1-6(Gala1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-
Sp24 6 12 191 
562 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-3)GalNAca-Sp14 6 5 78 
563 GalNAcb1-3GlcNAcb-Sp0  9 6 73 
564 GalNAcb1-4GlcNAcb1-3GalNAcb1-4GlcNAcb-Sp0  9 5 53 
565 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 7 3 46 
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566 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 5 2 35 
567 GlcNAb1-3Galb1-3GalNAc-Sp14 11 7 64 
568 Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14 3 7 260 
569 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 9 7 77 
570 (3S)GlcAb1-3Galb1-4GlcNAcb1-3Galb1-4Glc-Sp0 
3 7 221 
571 (3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana-Sp0 4 3 89 
572 
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAb1-2)Mana1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 17 10 58 
573 
Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-
3GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 16 5 30 
574 Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glc-Sp21 3 4 117 
575 
GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp24 12 4 31 
576 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 3 3 117 
577 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 3 3 118 
578 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 8 3 42 
579 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-
Sp24 24 11 46 
580 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4(Fuca1-6)GlcNAcb-Sp24 12 2 20 
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581 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 6 9 141 
582 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 7 9 124 
583 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 8 8 93 
584 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 10 6 59 
585 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 5 3 71 
586 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 10 9 92 
587 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb- 7 7 106 
588 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb 14 6 41 
589 
Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4G 10 7 70 
590 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 4 7 161 
591 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 14 11 74 
592 Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 8 8 99 
593 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 2 5 183 
594 GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 5 2 47 
595 GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 7 4 51 
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596 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 6 3 55 
597 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 7 5 71 
598 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 18 11 64 
599 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 5 4 70 
600 Galb1-4GlcNAcb1-3Galb1-3GalNAca-Sp14 6 6 94 
601 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 7 3 39 
602 Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 7 2 29 
603 Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 5 2 34 
604 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 12 10 89 
605 GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 4 3 71 
606 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3)GalNAca-Sp14 5 5 113 
607 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 17 15 86 
608 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-
4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 8 6 80 
609 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 9 2 24 
610 GlcNAcb1-3Fuca-Sp21 15 7 46 
611 Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp21 5 6 120 
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XIV. MUB binding to plant derived glycans 
non-BSA-conjugated structures 
Name Glycan structure Description 
Sugar beet pectin (α1-4)-galacturonic acid  Possible modifications 
galactose, rhamnose, 
arabinose, fucose 
Lime pectin (α1-4)-galacturonic acid as above 
Arabinan D-arabinose (C5) Component of 
hemicullose or pectin 
Gum arabic (β1-3)(β1-6)-galactose (plus Gal, Rha, 
Ara, GlcA sidechains (β1-6) linked) 
Dietary and functional 
fibre for (thickening 
agent) 
Gum guar Galactomannan, (β1-4)-mannose with 
1,6 linked galacotose (every second 
mannose) 
guar beans, dietary and 
functional fibre  
Carrageenan (α1-3),(β1-4)-galactose, sulfated polysaccharide from red 
seaweeds 
Tomato mannan  (β1-4)-mannose plant polysaccharide 
β-glucan  yeast 
Pachyman (1-3)-β-D-Glucan  
BSA-conjugated structures 
Arabinose (α1-5)-L-arabinobiose(C5), feruloyted 
(feruloyl, phenolic acid)  
hemicellulose or pectin 
 (α1-5)-L-arabinotriose, feruloyted  
Chitin  (β1-4)-chitotobiose to -chitohexaose   
Glucose D-glucose  
Laminarin  (β1-3)-glucotriose to –hexaose () storage glucan of algae 
Cellulose  (β1-4)-glucotriose to glucohexaose  
Maltose  (α1-4)-glucobiose to –decaose  
 (α1-6), (α1-4)-glucotetraose  
Mlg (Glc) (β1-3),(β1-4)-glucotriose to –
glucopentaose (A,B,C) 
 
Xylose (β1-4)-xylotriose to -xylohexaose (C5),  hemicellulose precurser 
XG XG-heptamer XG blood group antigen, 
glycoprotein 
Isoprimeverose xylosyl-β1-6-glucose Hydrolysis product of 
xyloglucan 
Mannose D-mannose to (β1-4)-mannohexaose  
Galactomannan   
Gal2M5 galactosyl-(β1-4)-mannopentaose  
GalM2 galactosyl-(β1-4)-mannobiose  
Galactose β-D-galactose  
 (β1-4)-galactotobiose  
 galactosyl-(β1-4)-galactobiose, 
feruloyted 
 
Lactose galactosyl-(β1-4)-glucose  
Galactouronic acid 
(GalA) 
(α1-4)-hexaglactouronate (and 
derivates) + -octagalacturonate 
Main component of 
pectin 
191 
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